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The resistance-nodulation-division (RND) family efflux systems are ubiquitous transporters that 
have been extensively studied due to their ability to efflux a broad range of xenobiotic substrates. 
There is increasing evidence to suggest that the RND efflux systems have physiological roles 
beyond xenobiotic resistance to include pathogenesis and cellular stress responses. The Vibrio 
cholerae genome encoded six RND efflux systems: VexAB, VexCD, VexEF, VexGH, VexIJK, 
and VexLM. This work sought to characterize the role of these systems in antimicrobial 
resistance, pathogenesis, and environmental stress. 
The V. cholerae RND efflux systems were characterized according to their substrate 
specificity and contribution to antimicrobial resistance. The VexAB, VexCD, VexGH, and 
VexIJK RND efflux systems were shown to contribute to resistance against multiple antibiotics, 
bile salts, and other detergents. In addition to functioning in antimicrobial resistance, the RND 
efflux systems were found to function in the extrusion of metabolic intermediates. In the absence 
of RND efflux, the accumulation of potentially toxic metabolites induced the expression of 
vexRAB, vexGH, and the Cpx membrane stress response system. Subsequent studies showed that 
independent activation of the Cpx system also resulted in the induction of vexRAB and vexGH 
expression, which indicated that the Cpx system and the vexRAB and vexGH RND efflux 
systems were reciprocally regulated. Collectively these results suggested a model whereby the 
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vexRAB and vexGH RND efflux systems function to reduce cellular stress resulting from 
endogenous metabolites, xenobiotics, and factors that induce a membrane stress response.  
The VexAB RND system was also found to be positively regulated by VexR, a TetR-
family regulator that was encoded within the same operon (i.e. vexRAB). VexR activated vexRAB 
expression in response to VexAB efflux substrates and in the absence of RND efflux activity. 
The latter phenotype suggested that the VexR modulated vexRAB expression in response to 
endogenous cues. Overall the data presented in this thesis supported the conclusion that the V. 
cholerae RND efflux systems functioned in responses that were essential for environmental 
adaptation including intestinal colonization, xenobiotic resistance, metabolic imbalance, and 
membrane stress.  
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1.0  INTRODUCTION 
1.1 CHOLERA 
Vibrio cholerae is the causative agent of the diarrheic disease cholera (1). The burden of cholera 
has largely been abolished in developed countries due to the formation of public sanitation works 
(2, 3). However, cholera remains a global health concern as it is now endemic in many regions of 
the world, affecting underdeveloped communities and refugee camps which often lack access to 
clean drinking water, proper sanitation, and medical care (1, 3, 4). In many ways, those most 
affected by the morbidity of cholera are the children who contract cholera during key 
developmental stages (5). The loss of fluids and electrolytes characteristic of the disease are not 
only an immediate threat to their life and health, but can cause lasting developmental retardation 
which may follow the child into adulthood (6). Cholera is estimated to annually afflict ~5 million 
people; as such it remains a significant public health problem (7).  
Cholera-like diseases have been long recorded throughout history (8). The first in modern 
history originated in India in 1817, but it was not until 1883 that bacteria were demonstrated to 
be the cause of cholera (9). Between 1817 and 1923 there were six  recorded cholera pandemics 
(8, 10). The seventh and ongoing pandemic began in 1961, spreading from Indonesia to India 
and the Middle East. In the 1970s, it moved to Africa and reached South America in the 1990s 
(11-14). 
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1.2 VIBRIO CHOLERAE 
V. cholerae is a Gram-negative, motile, facultative anaerobic bacteria that is the causative agent 
of the disease cholera. More than 200 serogroups of V. cholerae have been isolated from the 
environment. However, only two serogroups have been associated with epidemic cholera. The 
O1 serogroup has been shown to be responsible for the 5th, 6th, and 7th pandemics (8). In 1992 a 
new serogroup (O139) was reported as the cause of a cholera outbreak in Bangladesh and India 
leading some to refer to the event as the 8th cholera pandemic (14-17). Despite the emergence of 
the O139 serogroup, the O1 serogroup still remains the dominant cause of present day cholera 
outbreaks. Although the incidents are rare, non-O1/non-O139 strains have been isolated from 
human infections, but were not associated with epidemic disease (18-21). 
The O1 serogroup can further be divided into two biotypes: classical and El Tor. These 
biotypes are determined by physiological differences such as resistance to polymyxin B, 
hemolysin activity, the number of genes encoding cholera toxin (CT), and the presence of 
mannose-sensitive hemagglutinin (MSHA) (22). The classical biotype was associated with the 
5th and 6th pandemics, while the 7th is caused by the El Tor biotype (8). The El Tor biotype is 
associated with a milder form of cholera and appears to have an advantage in survival in the 
aquatic environment (23). The O139 serogroup is believed to have evolved from the O1 
serogroup El Tor biotype via a seroconversion event (24, 25). The El Tor strains are predominant 
in regions where the O1 serogroup is found.  
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1.2.1 V. cholerae in the aquatic environment 
V. cholerae is a facultative human pathogen and a natural inhabitant of aquatic ecosystems (26-
29). V. cholerae can attach to the surfaces of marine species such as plants, copepods, 
crustaceans, and insects (27, 30). The O1 serogroup has been shown to bind to the chitin of these 
marine organisms (31) and form biofilms which contributes to acid tolerance following human 
ingestion of V. cholerae contaminated food or water (32). One key difference between the El Tor 
and classical biotypes is the production of the MSHA (mannose sensitive hemagglutinin) type IV 
pili. The MSHA type IV pili is produced in the El Tor O1 and O139 strains and is involved in the 
adherence to chitin of zooplankton (33). In contrast, the classical strains do not assemble the 
MSHA pili (33). This likely contributes to the increased ability of the El Tor strains to survive in 
the aquatic environment (23). 
 The association of V. cholerae with zooplankton is assumed to provide protection against 
environmental stresses, largely due to formation of biofilms on these surfaces. Reports have 
shown that the El Tor O1 and O139 strains form biofilms on abiotic surfaces in a manner that is 
dependent on the expression of the Vibrio polysaccharide (VPS) exopolysaccharide (34-37). In 
addition to VPS exopolysaccharide, the El Tor O1 serogroup requires MSHA and flagellar 
motility to form normal biofilm (35, 36). The O139 serogroup does not require either MSHA or 
flagellar motility (35, 36). This has been attributed to a high level of expression of the VPS 
polysaccharide in the O139 serogroup. While the expression of VPS polysaccharide is found to 
contribute to environmental survival, its expression was found to inhibit colonization in the 
infant mouse model, suggesting that it decreases virulence (36). 
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1.2.2 Transmission and infection 
Humans acquire V. cholerae through ingestion of contaminated food or water. In areas where V. 
cholerae is endemic, poor sanitation is the primary cause of cholera outbreaks (1). After 
ingestion, the bacteria must survive and pass through the gastric acid barrier of the stomach. The 
infectious dose of V. cholerae reported in human volunteer studies is fairly high (106-1011 colony 
forming units) (38), likely due to the sensitivity of V. cholerae to acidic conditions  (39). After 
passage through the stomach, the bacteria penetrate the mucus lining of the intestinal epithelium, 
where they adhere to and colonize the intestinal epithelia (40). The primary site of V. cholerae 
colonization is the small intestine. During colonization, V. cholerae produces cholera toxin (CT) 
causing the diarrheic symptoms of cholera (discussed below) thereby disseminating the bacteria 
back into the environment (40).  
Human-shed V. cholerae was found to have a greatly increased infectivity compared to in 
vitro grown strains (41). This was found to be transitory as human-shed samples, which were 
further cultured in vitro, no longer display a competitive advantage in vivo. Therefore, passage 
through the host was found to give V. cholerae a hyper-infectious phenotype that is believed to 
contribute to the epidemic spread of cholera.  
In the transition from the aquatic environment to its colonization niche in the small 
intestine, V. cholerae is exposed to several environmental changes such as temperature, acidity, 
and osmolarity. Additionally, the bacteria encounter innate host defenses such as bile salts, 
organic acids, complement secreted by intestinal epithelial cells, and defensins produced by 
Paneth cells (42, 43). V. cholerae has developed mechanisms in order to survive and overcome 
these host defenses, including limiting the uptake and accumulation of antimicrobial compounds. 
This is accomplished by modulating the outer membrane permeability in conjunction with the 
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extrusion of toxic compounds via active efflux transporter (as discussed below) (9, 44-47). 
Further contributing to the ability of  V. cholerae to colonize under these hostile conditions is the 
ability to produce virulence factors, likely in response to these transitional signals (1). 
1.2.3 Major virulence factors 
The disease cholera is characterized by a profuse watery diarrhea, referred to as rice water stool. 
At the apex of infection, an adult can lose >20 L of liquid per day (48). Due to this drastic loss of 
fluids, untreated cholera can lead to dehydration, hypotensive shock, and death within 12h of the 
first symptoms (38). Without intervention cholera has a 60% mortality rate which can be lowered 
to ~1.5% with oral or intravenous rehydration (23). The massive loss of fluid is largely due to the 
action of the CT (49). CT is an AB-type enterotoxin that is secreted across the bacterial outer 
membrane into the extracellular environment (50). It is a hetero-oligomer composed of a single 
active A subunit in association with a ring formed by five B subunits (50-55). The CT-B 
pentamer binds to the GM1 ganglioside receptor on the surface of epithelial cells (56-58). The 
CT-A subunit is enters into the host cytosol, where it is activated by the reduction of a disulfide 
bond releasing CT-A1 subunit (59-61). The active CT-A1 subunit then ADP-ribosylates the G-
protein Gsα, a GTP-binding regulatory protein associated with adenylate cyclase, which leads to 
the constitutive production of cyclic AMP (cAMP) (62-65). cAMP increases chloride and 
bicarbonate secretion while simultaneously inhibiting sodium chloride absorption (49, 66). 
Through osmotic processes, this results in passive water loss from the cell into the lumen, 
resulting in the massive diarrhea that is characteristic of the disease (63, 64).  
The toxin co-regulated pilus (TCP) is the other major virulence factor in V. cholerae. The 
TCP is a type IV pilus that is required for intestinal colonization in both humans and animal 
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models (67, 68). Although TCP does not appear to directly bind to the intestinal epithelium, it 
does cause aggregation of V. cholerae and induces microcolony formation within the intestine 
(69). Additionally, the TCP acts as a receptor for the CTXφ bacteriophage which carries the 
genes that encode for CT (ctxAB) (70). TCP is a polymer composed of the TcpA pilin subunits 
(71). The genes involved in TCP biosynthesis are encoded in the tcpA-F operon. The TCP 
operon is encoded on the Vibrio Pathogenicity Island (VPI) which encodes additional accessory 
colonization factors (acfA-D) (72, 73). 
1.3 THE TOXR REGULON 
1.3.1 ToxT 
The V. cholerae virulence factors CT and TCP are regulated under a complex hierarchical 
regulatory system called the ToxR regulon (Figure 1). The ToxR regulon includes three major 
transcriptional activators: ToxT, ToxR, and TcpP (as reviewed in (23)). Within this hierarchy, 
the primary activator of ctxAB and tcpA-F is ToxT, a member of the AraC/XylS family of 
transcriptional activators. The C-terminal domain of ToxT encodes a conserved AraC DNA 
binding domain, while the N-terminal domain appears to encode dimerization and substrate 
binding domains (74, 75). The N-terminal domain of AraC proteins are thought to be involved in 
effector binding and/or multimerization (74, 75). A number of small effector molecules have 
been shown to negatively affect ToxT activity including virstatin, capsaicin, bile, and fatty acids. 
It is thought that these effector molecules function to inhibit ToxT through a common 
mechanism of binding to the N-terminal domain (76-83). 
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Figure 1. The V. cholerae ToxR regulon.  
The ToxR regulon is a hierarchical regulatory system that controls V. cholerae virulence factor production in 
response to unknown environmental stimuli. Induction of the ToxR regulon begins with AphA and AphB binding to 
the tcpPH promoter to activate TcpP production. TcpP then binds with ToxR at the toxT promoter to activate ToxT 
production. ToxT then directly activates the expression of the tcpA-F operon and the ctxAB genes which result in the 
production of the toxin co-regulated pilus (TCP) and cholera toxin (CT), respectively. 
 
 
ToxT activates the expression of ctxAB and tcpA by binding to a degenerate 13bp DNA 
sequence located in their respective promoters called the Toxbox. A Toxbox sequence is found 
upstream of all known ToxT activated genes (84). While the configuration of the Toxboxes 
differ at the various promoters, it is always located upstream of, but not overlapping, the -35 
promoter element (85). The histone-like protein H-NS is able to counteract the activation of 
ctxAB and tcpA-F transcription by binding to this same DNA region and repressing transcription 
 8 
(86-88). H-NS is further able to reduce the expression of virulence genes by binding to the toxT 
promoter and repressing toxT transcription (87). 
1.3.2 ToxRS and TcpPH 
The expression of toxT is activated by the interaction of two membrane bound transcriptional 
activators: ToxR and TcpP (Figure 1). ToxR is a membrane localized DNA binding protein. 
ToxR is composed of a cytoplasmic DNA binding/transcriptional activation domain, a 
transmembrane domain, and a periplasmic signaling domain (89-92). Wild type ToxR activity 
requires ToxS, another protein that is localized to the inner membrane. ToxS is hypothesized to 
interact with ToxR through its periplasmic domain. The exact role of ToxS is unclear, but it 
likely influences stability and/or enhances dimerization of ToxR, thereby serving as a positive 
effector of ToxR function (93-95). 
Similar to ToxR, TcpP is also a membrane bound transcriptional activator that has a 
cytoplasmic localized DNA binding/transcriptional activation domain, a transmembrane domain, 
and a periplasmic domain. Furthermore, TcpP also requires a membrane bound effector protein, 
TcpH. TcpP and TcpH are thought to interact through their periplasmic domains (96, 97). The 
genes for TcpP and TcpH are encoded in a single operon whose transcription is responsive to 
environmental signals, such as temperature and pH (98). TcpP is regulated post-translationally 
through a regulated proteolytic event that requires at least two proteases that degrade TcpP (99, 
100). Interaction with TcpH prevents proteolytic degradation as demonstrated by the rapid 
degradation of TcpP in cells lacking TcpH (96). TcpP has been shown to be proteolyzed in wild 
type cells grown under virulence repressing conditions (99). The transcriptional and post-
translational regulation of TcpP suggested that control of its activity is important to the cell (23). 
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ToxR and TcpP function together to activate toxT expression in response to unknown 
environmental stimuli. Under virulence inducing conditions ToxR and TcpP  bind directly to the 
toxT promoter (101). ToxR is reported to have a higher affinity for the toxT promoter than TcpP 
(101). The overexpression of TcpP can compensate for loss of ToxR, but ToxR overexpression 
cannot compensate for the loss of TcpP (101-104). This suggested that ToxR provides toxT 
promoter recognition, while TcpP is more directly responsible for transcriptional activation. The 
current hypothesis is that ToxR binds the toxT promoter and interacts with TcpP, which then 
stimulates expression from the toxT promoter (23).  
ToxR also regulates the production of two outer membrane proteins, OmpU and OmpT, 
independent of TcpP (45, 105, 106). ToxR is required for the expression of OmpU, which 
contributes to antimicrobial resistance and functions as an adhesin (107). In contrast, ToxR 
represses the expression of ompT as observed by the induction of ompT expression in cells 
lacking toxR. Expression of toxT is associated with increased susceptibility to bile salts due to its 
large diameter pore. The regulation of these proteins by ToxR has been shown to be important 
for intestinal colonization and antimicrobial resistance (9, 106). 
1.3.3 AphA and AphB 
While toxRS appears to be constitutively active, the expression of tcpPH is regulated by two 
transcriptional activators in a manner similar to ToxR/TcpP activation of toxT (Figure 1). AphA 
and AphB are transcriptional activators that are encoded by unlinked genes. AphA belongs to a 
family of regulators with homology to the PadR repressor (108), while AphB is a LysR-type 
regulator (109). Analogous to ToxR, AphA binds the promoter of tcpPH, but requires interaction 
with AphB to induce transcription (109, 110). AphB binds downstream of AphA and interacts 
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with AphA, which is thought to stabilize AphB and result in activation of tcpPH (109, 110). One 
of the differences between the El Tor and classical biotypes of V. cholerae is due to a point 
mutation in the tcpPH promoters, which affects the ability of AphB to bind to tcpPH (111). This 
variation is attributed for the differential regulation of toxT between the El Tor and classical 
strains of V. cholerae (109, 112).  
1.3.4 LeuO 
Recent work in our laboratory identified a new component to the ToxR regulon (113). LeuO is a 
LysR-family regulator that was found to reduce virulence factor production when induced by 
cyclo(Phe-Pro). Cyclo(Phe-Pro) is a cyclic dipeptide produced by V. cholerae that has been 
reported to repress virulence factor production (114). Overexpression of leuO has been shown to 
repress aphA expression leading to reduced CT and TCP production. Interestingly, induction of 
leuO expression by cyclo(Phe-Pro) was shown to be dependent on ToxR. This suggested a novel 
role for ToxR in environmental sensing of cyclo(Phe-Pro). Thus providing the first example to 
show that ToxR can function to repress virulence factor production in response to environmental 
signals (113). 
1.4 ACTIVE EFFLUX TRANSPORTERS 
In the course of transitioning from the aquatic environment to its colonization niche in the human 
small intestine, V. cholerae must adapt to dramatic environmental changes. The gastrointestinal 
tract contains a number of barriers to colonization by V. cholerae including the acid barrier of the 
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stomach, the production of bile acids in the intestine, competition from the microbiome, 
antimicrobial products produced by the microbiome, and products of the innate immune system 
(115). Resistance to the diffusible antimicrobial compounds is accomplished by reducing the rate 
of influx combined with the expression of active efflux systems (9, 44-47, 116). As discussed 
above, V. cholerae regulates the rate of diffusion across its outer membrane by modulating the 
production of the OmpT and OmpU porins (44, 45, 107). Though outer membrane permeability 
is important in antimicrobial resistance, high level resistance is dependent upon energy-
dependent efflux provided by RND family of transporters (as discussed below) (117-119).  
1.4.1 RND-family efflux systems 
There are five families of efflux systems that have been defined in Gram negative bacteria. The 
five families are differentiated from each other based on sequence similarity, the number of 
pump components, the number of transmembrane-spanning regions in the pump proteins, and the 
energy source used for substrate translocation (120). The five families include: the ATP-binding 
cassette (ABC) superfamily, the major facilitator superfamily (MFS), the multidrug and toxic-
compound extrusion (MATE) family, the small multidrug resistance (SMR) family, and the 
resistance nodulation division (RND) family (120, 121). Most bacteria encode multiple efflux 
systems belonging to several different families. Further, many bacteria encode multiple efflux 
pumps from each individual family. For example, V. cholerae encodes six RND efflux systems 
whereas P. aeruginosa encodes 12 (122, 123).  
The RND family of efflux systems have been a focus in antimicrobial research for more 
than a decade due to their due to their association with multiple antibiotic resistance in Gram 
negative pathogens (as discussed below). There are a number of examples of RND efflux 
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systems exhibiting extremely broad substrate specificity. This includes the V. cholerae VexAB-
TolC (119), Escherichia coli AcrAB-TolC (124), the Neisseria gonorrhoeae MtrCDE, and P. 
aeruginosa MexAB-OprM systems (125); all of which have been shown to efflux chemically 
diverse antimicrobial compounds including dyes, detergents, antibiotics, and antimicrobial 
peptides (126). 
1.4.1.1 Structure of the RND efflux systems 
RND efflux systems are tripartite transporters consisting of an outer membrane pore protein 
(OMP) that is homologous to E. coli tolC, a periplasmic membrane fusion protein (MFP), and an 
integral cytoplasmic membrane RND-family pump protein (127, 128). The energy for transport 
is provided by the proton motive force and the RND pumps function as proton antiporters. These 
three components function together to form a channel for the export of substrates from within the 
cell envelope to the external environment. 
The crystal structure for all three components of the RND efflux systems have been 
solved and used to model the structure of the tripartite transport complex (Figure 2) (127). The 
first structure determined was for TolC from E.coli (shown in red in Figure 2). In 
Enterobacteriaceae (and Vibrio), TolC is a promiscuous protein that also functions as the OMP 
of other transport systems including the MFS and ABC transporters (129). TolC was found to 
assemble into a tightly woven trimer that formed a single 12-stranded beta-barrel that traversed 
the outer membrane with a long alpha-helical bundle extending into the periplasmic space (130, 
131). The second component of the RND efflux systems that was crystalized was the E. coli 
AcrB RND pump protein (shown in blue in Figure 2). AcrB formed a homotrimer with a three-
fold rotational symmetry (128, 132-136). The periplasmic portion of AcrB was found to have 
similar dimensions to the tip of the periplasmic localized TolC alpha-helical bundle and thereby  
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Figure 2. Structural model for tripartite RND efflux systems. 
The tripartite RND efflux system was generated from the crystal structure of E. coli TolC (red), E. coli AcrB 
(green), and P. aeruginosa MexA (blue). A trimer of the TolC outermembrane protein in an open state and is shown 
forming minimal contacts with the AcrB pump which exists as a trimer in the cytoplasmic membrane. Surrounding 
the interface of the two is a ring of nine molecules of the MexA membrane fusion protein, which is a homolog of 
AcrA, the natural partner of AcrB/TolC. The figure was adapted from Eswaran et al., 2004, full reference in 
text(127). 
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was predicted to encode the TolC-binding domain (132). The final component to be solved was 
two different membrane fusion proteins (shown in green in Figure 2); MexA from P. aeruginosa 
and AcrA from E. coli (137, 138). Both proteins were found to be structurally conserved and 
formed elongated structures that had a tendency to be packed side-by-side. Based on this 
observation they were hypothesized to wrap around and stabilize the interaction between TolC to 
the RND pump protein. The MFP is proposed to first bind to the pump protein, after which the 
TolC is recruited and binds to the complex to form the tripartite transporter (139).  
Substrates are thought to be captured by the RND pump protein either from the cytosol or 
from the phospholipid bilayer and then transported through TolC into the extracellular space 
(127, 132). The periplasmic domain of the RND pump determines the substrate specificity of the 
RND efflux system (140-144). In E. coli, chimeric studies with AcrB and AcrD RND pump 
proteins revealed that an exchange of the periplasmic domains caused coinciding changes in 
substrate specificity (145, 146). Genetic and biochemical studies with AcrB revealed that the 
substrate binding pocket was rich in aromatic residues which interacted with the various 
substrates of AcrB (133, 135). The crystal structure of this binding pocket has been solved with 
several substrates bound, including bile, which confirmed the location of the substrate binding 
pocket (141, 147).  
1.4.1.2 Function of the RND efflux systems in antimicrobial resistance 
The RND efflux systems have been shown to be important for antimicrobial resistance in a 
multitude of bacterial genera (reviewed in (129)). Many bacterial genera (e.g. the 
Enterobacteriaceae, Vibrionaceae and Pseudomonads) encode multiple different RND efflux 
systems that contribute to antimicrobial resistance. For example the P. aeruginosa MexAB-
OprM, MexXY-OprM, MexCD-OprJ, and MexEF-OprN RND efflux systems have all been 
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shown to efflux a range of different antibiotics and antimicrobial compounds (148, 149). Further, 
mutational upregulation of these systems have been correlated with clinically significant multiple 
drug resistance in patient isolates and the evolution of multiple drug resistant strains (150-152). 
The RND efflux systems also play an important role in antimicrobial resistance in the 
Enterobacteriaceae. There have been a number of studies showing that the AcrAB-TolC system 
was upregulated in multiple drug resistant clinical isolates (153-155). AcrAB-TolC is the 
principal RND efflux system in E. coli that contributes to resistance against antibiotics, 
acriflavin, ethidium bromide, SDS, triton X-100, bile salts, and short chain fatty acids (156-159). 
Although AcrAB-TolC has been shown to be overexpressed in multidrug resistant clinical 
isolates, it alone is not sufficient to cause clinically relevant increases in drug resistance. Rather, 
it is thought that AcrAB-TolC functions in conjunction with secondary mutations or the 
acquisition of other drug resistance traits. For example, high level ciprofloxacin resistance in E. 
coli has been associated with increased expression of AcrAB-TolC in conjunction with a 
mutation in topoisomerase which is one of the ciprofloxacin target genes (153-155, 160).  
The AcrAB-TolC RND efflux system in Salmonella enterica serovar Typhimurium 
functions in a similar manner as the E. coli AcrAB-TolC. Substrates of this efflux system include 
antibiotics, acriflavin, ethidium bromide, SDS, triton X-100, cetrimide, and bile salts (161-166). 
In both human and veterinary isolates, along with laboratory mutants, the overexpression of 
AcrAB-TolC is associated with multidrug resistance (162, 164, 165). 
The overexpression of the RND efflux systems has been associated with multidrug 
resistance in several species of bacteria. It is interesting to note that overexpression of the RND 
efflux systems in laboratory mutants is often detrimental to the cell. This suggests that there is 
selective pressure to maintain the overexpression phenotype in the clinical setting that is absent 
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in the laboratory. Further, the fact that overexpression of the RND efflux systems is detrimental 
to growth provides an explanation for why the expression of these systems are tightly regulated 
(as discussed below).  
1.4.1.3 Function of the RND efflux systems in other aspects of bacterial biology 
The contribution of RND efflux systems to antibiotic resistance is an easily scored phenotype 
with clinical relevance. Thus it has been the primary focus of those studying these systems. 
However, phylogenetic analysis has shown that the RND efflux systems have evolved 
independent of antibiotic selection (167, 168). Although the native role of the RND efflux 
systems in bacterial physiology is unclear, recent studies have suggested a function for the RND 
efflux systems independent of their role in antimicrobial resistance (reviewed in (169). This is 
exemplified by reports implicating RND efflux systems in diverse phenotypes such as biofilm 
formation (170, 171), iron acquisition (172), plant-bacteria interactions (173), lipid transport 
(174, 175), bacterial virulence (123, 129, 176), extrusion of toxic metal effectors (177), and the 
removal of metabolic byproducts from within the cell (178).  
1.4.1.4 Role of the RND efflux systems in virulence  
The RND efflux systems have been found to be required for virulence in several bacterial 
species, such that loss of RND-mediated efflux caused in vivo attenuation (123, 129, 163, 179-
187). In V. cholerae and in Salmonella, the loss of RND-mediated efflux reduced pathogenicity 
(123, 188, 189). The loss of RND efflux in Salmonella reduced the expression of virulence genes 
encoded on the Salmonella Pathogenicity Islands (188, 189). Similarly, the loss of the V. 
cholerae RND efflux systems caused a decrease in virulence factor production through 
repression of the ToxR regulon (discussed below). In Campylobacter the RND efflux systems 
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have been shown to influence virulence indirectly via effects on motility (190, 191). The RND 
efflux systems have also been linked to pathogenesis due to their ability to efflux quorum 
sensing molecules in Burkholderia (192) and Pseudomonas (129, 193, 194). In addition to the 
linkage of the RND efflux system to the expression of virulence genes, there are numerous 
examples of the RND efflux systems contributing to virulence by providing resistance to 
antimicrobial compounds that are present in the host (124, 147, 187, 195-197). 
1.4.1.5 Metabolic waste disposal 
Studies of metabolic mutants in E. coli revealed upregulation of the acrAB-tolC RND efflux 
system (198). This suggested that AcrAB-TolC RND efflux system may have an innate role in 
removal of excess and potentially toxic metabolic intermediates that accumulated as a result of 
the disruption of the metabolic pathways. Subsequent studies have shown that loss of TolC 
induced the expression of acrAB and the Cpx and BaeSR stress response systems in E. coli (199, 
200). These collective results led to the hypothesis that the native function of the RND efflux 
systems was to remove endogenous metabolites from within the cell that would otherwise prove 
stressful to the cell. Further support for this hypothesis was provided by Ruiz and Levy who 
showed that mutation of certain metabolic genes induced acrAB expression and that the addition 
of the metabolic intermediates to culture media induced acrAB expression in wild type cells 
(178). 
1.4.1.6 V. cholerae RND efflux systems 
The V. cholerae genome encoded six RND efflux systems (VexAB, VexCD, VexEF, VexGH, 
VexIJK, and VexLM) (122, 123). Each RND efflux system was separately encoded in an operon 
structure containing the RND efflux pump protein and at least one associated MFP whose gene  
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Figure 3. V. cholerae gene arrangement of the RND efflux systems. 
Schematic of the genes of the Vibrio cholerae RND efflux systems. The gene for each RND efflux pump (black 
arrows) is encoded in an operon with at least one associated membrane fusion protein (gray arrows). Only the vexAB 
operon has an associated TetR regulator encoded by vexR (open arrow). Listed below each gene is the ORF number 
and gene name. The loci are shown to scale. Figure adapted from Bina et al., 2008, full citation in the text (123). 
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was located upstream of the pump gene (as depicted in Figure 3) (123). All six RND efflux 
systems appear to share the same TolC OMP which was encoded by itself on the chromosome 
(123). The loss of RND-mediated efflux, whether by mutation or by use of chemical inhibitors, 
caused a significant increase in antimicrobial susceptibility, down-regulated the ToxR regulon, 
diminished CT and TCP production, and attenuated colonization. Consistent with the role of the 
RND efflux systems in antimicrobial resistance, and pathogenesis, studies found that vexAB, 
vexGH, and vexIJK were upregulated during human and animal colonization (41, 201, 202). 
Three of the RND efflux systems (VexAB, VexCD, and VexIJK) were shown to contribute to 
the antimicrobial resistance and intestinal colonization phenotypes.  
The VexAB RND efflux system is functionally analogous to the E. coli AcrAB system. 
VexAB exhibited a high basal level of activity and provided V. cholerae with its intrinsic 
antimicrobial resistance (119, 203, 204). The VexAB RND efflux system mediated resistance to 
bile salts, non-ionic detergents, and a variety of antibiotics (e.g. ampicillin, erythromycin, 
novobiocin, and polymyxin B). In contrast, the VexCD and VexIJK RND efflux systems were 
functionally redundant with VexAB and appeared to only efflux bile acids and detergents, 
respectively (119, 123). A mutant lacking the vexBDK genes was found to be attenuated during 
murine colonization. However, vexBDK produced wild type levels of CT and TCP, suggesting 
the contribution of one or more of the remaining RND efflux system (VexEF, VexGH, and 
VexLM) to virulence factor production. Furthermore, the mechanism(s) by which the RND 
efflux systems influence virulence gene expression were unknown. 
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1.5 REGULATION OF RND EFFLUX SYSTEMS 
Bacterial adaptation to environmental cues involves a range of transcriptional responses that are 
triggered and controlled by regulatory proteins. Often these regulatory proteins are able to 
respond to environmental or cellular cues by modulating transcription of target genes. Most 
environmental responsive microbial transcriptional regulators can be classified as one-
component or two-component regulatory systems (205). In one-component systems, the 
regulator is a two-domain protein with a signal receiving domain and a DNA-binding domain 
which transduces the signal to a transcriptional response. In two-component systems the sensing 
and signaling domain are encoded on separate proteins. In this case the environmental stimulus is 
detected by the sensor protein which then activates, by phosphorylation, the DNA-binding 
response protein to effect the expression of target genes.  
1.5.1 TetR family regulators 
The TetR family of transcriptional regulators is one of the largest groups of one-component 
regulatory systems and is widely distributed among bacteria. Members of this family control the 
expression of genes whose products are involved in diverse physiological processes including 
antibiotic resistance, metabolism, stress responses, biofilm formation, quorum sensing, and 
pathogenicity (as reviewed in (206)). TetR proteins are defined by a highly conserved N-terminal 
DNA binding domain and a highly variant C-terminal domain that interacts with small-molecule 
ligands (206). The ligand binding domain is capable of binding to effector molecules which 
modulate the interaction of the DNA binding domain with its target sequences. In the case of 
RND efflux systems, the activity of TetR regulators is often modulated by binding substrates of 
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the linked RND efflux system. In many cases, TetR proteins appear to be capable of binding a 
diverse set of ligands that correspond to the multiple substrates of linked RND efflux systems 
(206).  
 Ahn et al. predicted regulatory targets of TetR-family proteins by genome context and 
concluded that a gene neighboring a tetR regulator was highly probable as the target of a TetR if 
an intergenic region of  <200bp separated the genes (207). The probability that a certain gene 
was the target of TetR was lowered as the intergenic region increased. The vast majority of 
characterized TetR family regulators act as transcriptional repressors and in most cases also 
autoregulate their own expression (206, 208). The majority of studied TetR regulators have been 
reported to regulate the expression of antimicrobial efflux pumps, including the E. coli AcrR 
which regulates the expression of acrAB RND efflux system.  
The TetR family of regulators was named after TetR, a regulator of the tetracycline TetA 
efflux pump in E. coli (206). In the Tet regulatory system, tetR is encoded upstream and 
divergent from tetA (209). The intergenic region encodes two palindromic operator sequences 
that are bound by a TetR homodimer thereby repressing transcription from both promoters. 
Tetracycline, the substrate of TetA, activates expression of tetA by binding to the TetR dimer, 
changes its conformation thereby lowering its affinity for DNA (209). Then, TetA exports 
tetracycline from within the cell which renders the cell resistant to tetracycline.  
1.5.1.1 TetR family proteins in V. cholerae  
 
One of the V. cholerae RND efflux systems has previously been reported to be regulated by a 
regulator belong to the TetR family. Cerda-Maira et al. reported that the expression of the V. 
cholerae VexCD RND efflux system was regulated by BreR (VC1746), a TetR-family protein 
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that was encoded by an unlinked gene (210). BreR was determined to negatively regulate the 
expression of both itself and of vexCD. The expression of both vexCD and breR were found to be 
induced by the presence of the bile salts cholate, deoxycholate, and chenodeoxycholate; all of 
which were shown to be substrates of vexCD (210). They further showed that deoxycholate 
interfered with BreR DNA binding and allowed expression of both breR and vexCD. 
Among the six V. cholerae RND efflux systems only the vexAB system encoded a linked 
TetR-family regulatory gene, which has been named vexR (Figure 3). The vexR gene was 
encoded as the first gene in a three gene operon that included vexA and vexB; a genetic 
organization that is distinct from most RND efflux systems where the TetR regulator is encoded 
in the opposite orientation from the RND efflux system (206). The function of vexR in the 
expression of the vexRAB operon has not been reported. 
1.5.2 Two-component regulatory systems 
Two-component signal transduction systems allow bacteria to respond to environment signals 
through the combined efforts of a sensing component which usually encodes a histidine kinase 
activity and a cytosolic response regulator (211-214). The sensing component is a protein 
embedded in the membrane that responds to specific environmental signals. Once stimulated, the 
protein auto-phosphorylates a histidine residue and transfers this phosphate onto a conserved 
aspartate residue in the cytoplasmic response regulator, thereby activating it (213, 214). The 
cytoplasmic response regulator is a transcription factor whose activity is altered upon 
phosphorylation. Once phosphorylated, the response regulator then effects the expression of its 
target genes, thereby modulating a cellular response to the environmental signal (213, 214). In 
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the absence of the inducing signal the sensing component (the histidine kinase) can also function 
as a phosphatase which maintains the regulatory system in the off state (213, 214).  
1.5.2.1 Cpx two-component regulatory system 
The Cpx two-component system is widely distributed among Gammaproteobacteria including 
the Enterobacteriaceae and Vibrionaceae. This system has been well characterized in E. coli 
where it has been shown to alleviate membrane stress caused by misfolded proteins (254, 255). 
In this regulatory system (Figure 4A) (211), CpxA functions as a membrane associated sensor 
histidine kinase. Upon stimulation, CpxA autophosphorylates itself and then transfers the 
phosphate to a conserved aspartate residue on the cytoplasmic CpxR response regulator 
(reviewed in (254, 255)). Phosphorylated CpxR (CpxR~P) then modulates the expression of its 
target genes by binding to a consensus binding sequence located in their promoter regions (215). 
In the absence of stimuli, CpxA acts as a phosphatase on CpxR and renders it inactive.  
CpxR~P also regulates its own expression (i.e. the cpxRA operon) and the divergently 
transcribed cpxP (Figure 4) (211, 216). CpxP is a periplasmic protein that appears to repress 
CpxR activation by interacting with the periplasmic domain of CpxA and inhibiting its kinase 
activity. CpxP may also exhibit chaperone activity (254, 255). CpxA* mutants lead to 
constitutive activation of the Cpx system and have been useful in analyses of Cpx regulons. The 
cpxA* mutation inactivates CpxA phosphatase activity, resulting in the accumulation of activated 
CpxR (i.e. CpxR~P) (254, 255). The dual activation of both the cpxRA and cpxP is hypothesized 
to function in both amplifying the cellular stress signal and in restoring the cell to basal levels 
upon loss of stimulation (211). 
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1.5.2.2 E. coli Cpx 
The E.coli Cpx system has been proposed to function in alleviating stress resulting from cell 
envelope perturbations that are generally associated with cell envelope stress (254, 255). 
Consistent with this idea, the majority of stimuli that activate the Cpx system have been 
predicted to result in the production of misfolded or damaged cell envelope proteins (reviewed in 
(254, 255)). Activators of the Cpx system in E. coli include alkaline pH, copper, changes in inner 
membrane lipid composition, overproduction of the outermembrane lipoprotein NlpE, 
accumulating misfolded variants of the maltose binding protein, and elevated osmolarity. 
However, the effects of misfolded proteins on Cpx induction are not universal as there are 
examples of misfolded proteins that fail to activate the Cpx system (254, 255).  
Once activated, the Cpx system modulates the expression of genes whose products 
function in alleviating cellular stress. In E. coli CpxR~P activates genes encoding the 
extracytoplasmic protease DegP, chaperones such as the peptidyl prolyl cis/trans isomerase 
PpiA, and the disulfide oxidoreductase DsbA (254, 255). Together, these proteins may be able to 
respond to misfolded proteins either by repairing or eliminating the damaged envelope protein. 
1.5.2.3 Cpx functions beyond responding to misfolded proteins 
While the Cpx system has been shown to function in alleviating cellular stress due to misfolded 
or damaged proteins, there is mounting evidence that the function of the Cpx system extends 
beyond maintaining the cell envelope (217). In E. coli, cell swarming was reduced by the 
CpxR~P mediated repression of motB and aerR (218, 219); and activation of the Cpx system was 
reported to reduce growth in biofilms (220). Furthermore, there are several reports indicating that 
the Cpx system is important for pathogenicity in E. coli and in related pathogens. 
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In enteropathogenic E. coli, the disruption of CpxR was associated with a reduction of 
type IV bundle forming pili production and of adherence to eukaryotic cells (221). The Cpx 
system in uropathogenic E. coli regulates the expression of factors involved in the assembly of 
pili and a cpxR null mutant in uropathogenic E. coli produced fewer and shorter pili than wild 
type (221). In S. enterica serovar Typhimurium, the mutation of cpxA caused attenuation in mice 
(222). Furthermore, the Cpx pathway of Shigella sonnei responds to changes in extracellular pH 
by regulating the expression of the type III secretion system (223). Together these indicated that 
the activation of Cpx pathway functions in pathogenicity through the genes which it regulates. 
1.5.2.4 V. cholerae Cpx system 
In V. cholerae, the cpx locus is organized in a manner similar to E. coli: cpxRA is encoded in an 
apparent operon with cpxP being encoded immediately upstream and divergently from cpxRA 
(211). The intergenic region between the V. cholerae cpxRA and cpxP encodes a CpxR 
conserved binding site, which in E. coli mediated CpxR activation of target genes (211, 219). 
While the genomic arrangement of the Cpx system in V. cholerae is similar to E. coli, the 
predicted amino acid sequences vary between these two systems (Figure 4B) (211). The CpxR 
proteins had the highest identity being 60%, while the CpxP proteins were only 21.6% identical. 
CpxA was 43.6% identical between the two genera, but there was a much high level of 
divergence in the periplasmic sensing domain of the protein. The CpxA periplasmic domain, 
which is thought to interact with CpxP, was found to be 20.7% identical. The cytosolic domain, 
which interacts with CpxR was found to be 54.3% identical. The variance in amino acid 
sequences found in CpxP and the CpxA periplasmic domain suggested that the Cpx systems in 
these two species respond to different stimuli (211). 
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Figure 4. Cpx regulon. 
(A) Schematic of the E. coli Cpx pathway. OM, outer membrane; IM, inner membrane. (B)  Organization of the V. 
cholerae cpxRA operon. The predicted sequence of V. cholerae and E. coli Cpx proteins were aligned using DNA 
strider. SP, signal peptide; PL, periplasmic loop; CD, cytoplasmic domain.” Figure adapted from Slamti et al., full 
citation in the text (204). 
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Although a number of Cpx-inducing stimuli have been described in E. coli, studies 
suggested that these stimuli are not conserved in V. cholerae (211). For example, the E. coli Cpx 
system is activated by increased osmolarity, but not by increased salinity (211, 224). In contrast, 
the V. cholerae Cpx system functions in an opposite manner; it is not responsive to osmolarity, 
but is activated by increased salinity (211). Additionally, the E. coli Cpx system is active under 
standard laboratory growth conditions, whereas the V. cholerae Cpx system is inactive. The 
differences in physiological roles of the Cpx system in E. coli and V. cholerae may be related to 
the distinct environmental niches these organisms occupy and appear to be reflected in amino 
acid sequence variability in the signaling domain of CpxA (211, 225).  
While the physiological roles of the V. cholerae and E. coli Cpx systems appear to differ, 
deletion of tolC activated the Cpx system in both organisms (200, 211). In E. coli, the activation 
of the Cpx system was linked to loss of TolC-dependent efflux (200). TolC functions as the 
outer-membrane pore component of several V. cholerae transport systems including RND family 
transporters (226). Thus, we speculated that the tolC-dependent activation of the V. cholerae Cpx 
system resulted from the loss of RND efflux activity.  
1.6 GOALS OF DISSERTATION 
The RND family efflux systems are well known for their ability to efflux a broad range of 
antimicrobial substrates. However, there is increasing evidence to suggest that the RND efflux 
systems have physiological roles beyond xenobiotic resistance to include pathogenesis and 
cellular stress responses. The Vibrio cholerae genome encodes six RND efflux systems: VexAB, 
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VexCD, VexEF, VexGH, VexIJK, and VexLM. This work sought to characterize the role of 
these systems in antimicrobial resistance, pathogenesis, and environmental stress. 
In the first chapter of these studies, the goal was to elucidate the roles of the VexEF, 
VexGH, and VexLM RND efflux systems in regards to RND-mediated antimicrobial resistance, 
murine colonization, and virulence factor production. Loss of RND efflux activity in the cell 
caused a significant increase in antimicrobial susceptibility, reduced virulence factor production, 
downregulation of the ToxR regulon, and attenuated murine colonization (123). Three of the 
RND efflux systems (VexAB, VexCD, and VexIJK) were found to partially contribute to these 
phenotypes (123). This latter finding suggested additional RND efflux systems may also 
contribute to the observed phenotypes. Therefore, a genetic approach was used to create a panel 
of RND efflux pump mutants which was used to determine the function of the remaining three 
RND efflux systems (i.e. VexEF, VexGH and VexLM) in these phenotypes. The results of these 
studies showed that VexGH contributed to RND-mediated antimicrobial resistance and murine 
colonization in a manner that was redundant with the previously characterized RND efflux 
systems (176). VexEF and VexLM were not found to contribute to antimicrobial resistance 
against any tested substrates nor were they found to contribute to murine colonization. VexAB, 
VexCD, VexGH, and VexIJK were determined to be major contributors to virulence factor 
production (176). Although virulence factor production was reduced in the ∆vexBDHK mutant 
compared to wild type, it was still significantly higher than the RND deficient mutant suggesting 
the contribution of VexEF and/or VexLM.  
The second chapter of this work focused on the characterization of the relationship 
between the RND efflux systems to the Cpx stress response system in V. cholerae. Initial 
characterization of the V. cholerae Cpx system by Slamti and Waldor found that the cpx locus 
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was organized in a similar manner to E. coli (211). However, the environmental cues which 
induced the E. coli Cpx system did not appear to be conserved in V. cholerae. This suggested 
that the Cpx system fulfilled a different physiological role in V. cholerae. While the 
physiological roles of the V. cholerae and E. coli Cpx systems appeared to differ, deletion of 
tolC activated the Cpx system in both organisms (200, 211). TolC functions as the outer-
membrane pore component of several V. cholerae transport systems including RND family 
transporters (227). Thus, we speculated that the tolC-dependent activation of the V. cholerae Cpx 
system resulted from the loss of RND efflux activity. Therefore, we explored the linkage 
between the RND efflux systems and the Cpx system. CpxR was found to function as a positive 
regulator of the VexAB and VexGH RND efflux systems (211). Conversely, mutation of vexRAB 
or vexGH resulted in the activation of the Cpx system, which suggested that the VexAB and 
VexGH RND efflux systems functioned in the regulation of the Cpx system. Activation of the 
Cpx system did not affect virulence factor production in V. cholerae. The induction of the Cpx 
system upon loss of RND-mediated efflux suggested that the accumulation of innate RND efflux 
substrates caused cellular stress. The overall results showed that the Cpx system and the RND 
efflux systems were reciprocally regulated and that the RND efflux systems likely function to 
alleviate cellular stress due to the accumulation of potentially deleterious endogenous 
compounds. 
The final chapter of this work focused on the regulation of the vexAB RND efflux system 
by VexR. The expression of RND efflux systems is often regulated by a linked TetR family 
transcriptional regulator (208). The VexAB system was encoded in a three gene operon that 
included an uncharacterized upstream TetR family regulator (i.e. vexR). Based on this, we 
hypothesized that VexR was a regulator of the VexAB RND efflux system. The results of this 
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work revealed that VexR functioned as a positive regulator of the vexRAB operon, a finding that 
is in contrast to most RND-associated TetR regulators which function as repressors. 
Furthermore, vexRAB was found to be upregulated, in a vexR-dependent manner, in response to 
the efflux status of the cell. This suggested that V.cholerae was able to sense the loss of RND 
efflux activity. We hypothesized that this sensing was the result of the intracellular accumulation 
of an endogenous compound that was likely a substrate of the RND efflux systems. We therefore 
tested whether metabolic intermediates could function as inducers of the RND efflux systems by 
quantifying vexRAB expression in a panel of metabolic mutants. The results of these experiments 
showed that vexRAB was upregulated in several metabolic mutants, including tryptophan 
biosynthetic mutants. Furthermore, indole, an intermediate in tryptophan biosynthesis, was found 
to induce vexRAB expression and be a substrate of VexAB. The collective results indicated that 
VexR positively regulated vexRAB in response to VexAB efflux substrates and that the VexAB 
RND system plays a central role in modulating the intracellular level of potentially toxic 
metabolites. 
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2.0  VIBRIO CHOLERAE VEXH ENCODES A MULTIPLE DRUG EFFLUX PUMP THAT 
CONTRIBUTES TO THE PRODUCTION OF CHOLERA TOXIN AND THE TOXIN CO-
REGULATED PILUS 
Work described in this section was published in PLoS ONE 
(PLoS ONE. 2012. 7(5): e38208. doi:10.1371/journal.pone.0038208) by authors  
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2.1 INTRODUCTION 
Vibrio cholerae is a Gram negative, motile, facultative anaerobic bacterium, and the causative 
agent of cholera, a severe diarrheal disease, which untreated can rapidly lead to dehydration, 
hypotensive shock, and death. V. cholerae is a common inhabitant of aquatic environments 
where it can survive and persist in association with aquatic plants and animals. Humans acquire 
cholera by ingesting V. cholerae contaminated food or water (1). Upon ingestion, V. cholerae 
colonizes the small intestine where a complex regulatory cascade is induced, resulting in the 
production of several important virulence factors including cholera toxin (CT) and the toxin co-
regulated pilus (TCP) (67, 228). CT is an AB-type enterotoxin that is responsible for the 
secretory diarrhea that is characteristic of cholera (229). The TCP is a type IV bundle forming 
pilus that is essential for intestinal colonization of both humans and laboratory animals (67, 68, 
230, 231). CT and TCP production are tightly controlled by a hierarchical regulatory system 
called the ToxR regulon (232, 233). In response to unknown stimuli, ToxR and TcpP, two 
membrane associated transcriptional regulators, activate transcription of toxT (101, 228, 234, 
235). ToxT, an AraC-family transcriptional regulator, directly activates the expression of the 
ctxAB and the tcpA-F operons which encode for the production of CT and the TCP, plus a 
number of accessory virulence genes (89, 236, 237). 
In order to colonize and survive in the host, V. cholerae must protect itself from the toxic 
effects of antimicrobial compounds that are present in the gastrointestinal tract (GI). V. cholerae 
does this by limiting the uptake and intracellular accumulation of toxic antimicrobial molecules 
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that are present in the GI tract. This is accomplished by modulating the outer membrane 
permeability (e.g. through the production of porin proteins and cell envelope modifications) in 
conjunction with efflux of the antimicrobial molecules via active efflux transporters (9, 44-47). 
There are five different active efflux systems described in bacteria: the ATP-binding cassette 
superfamily (ABC), the small multidrug resistance family (SMR), the multi antimicrobial 
extrusion protein family (MATE), the major facilitator superfamily (MFS), and the resistance-
nodulation-cell division superfamily (RND) (120). The RND family is particularly interesting 
because of its broad substrate specificity and its association with multidrug resistance in many 
Gram negative pathogens. Individual RND efflux systems, including the V. cholerae VexAB-
TolC  (119), Escherichia coli AcrAB-TolC (124), and Pseudomonas aeruginosa MexAB-OprM 
systems (125), have been shown to efflux chemically diverse antimicrobial compounds 
including: dyes, detergents, antibiotics, and antimicrobial peptides (126). 
RND efflux systems are tripartite transporters that function as proton-substrate antiporters 
(238, 239). RND efflux systems are composed of an outer membrane pore protein (OMP) that is 
homologous to E. coli tolC, a periplasmic membrane fusion protein (MFP), and an integral 
cytoplasmic membrane pump protein belonging to the RND superfamily of transporters (127, 
131, 132, 137, 238). These three components function to form a channel for the extrusion of 
substrates from within the cell envelope to the external environment. Most Gram negative 
pathogens encode multiple RND efflux systems; V. cholerae encodes six. In V. cholerae, each 
RND system is separately encoded in an operon structure wherein the RND efflux pump protein 
has at least one associated MFP whose gene is located upstream of the pump gene. It appears that 
all six RND efflux systems share the same TolC OMP which is encoded separately on the 
chromosome (123). Previous work in our laboratory showed that three of the RND efflux pumps 
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(VexB, VexD, and VexK) were required for antimicrobial resistance in vitro. The VexB RND 
efflux pump exhibited a very broad substrate specificity and contributed resistance to bile acids, 
detergents, and several antibiotics. In contrast, the VexD and VexK RND pumps appeared to 
only efflux bile acids and detergents, respectively (119, 123). 
Recently, our laboratory reported that the V. cholerae RND efflux systems were not only 
important for antimicrobial resistance and intestinal colonization, but were also important for CT 
and TCP production (123). A mutant that lacked all six RND efflux pumps (i.e. ∆RND) was 
attenuated for CT and TCP production and was hypersensitive to antibiotics. Although the VexB, 
VexD, and VexK efflux pumps contributed to in vitro antimicrobial resistance, a mutant lacking 
the vexBDK genes produced WT levels of CT and TcpA. This finding suggested that one or more 
of the three remaining RND pumps (VexF, VexH, and VexM) must function in virulence factor 
production. In this study we have further characterized these three RND efflux pumps. Using a 
genetic approach to generate mutant strains with the RND efflux pumps deleted in various 
permutations, we found that the VexH RND efflux pump contributed to antimicrobial resistance, 
CT and TCP production, and successful colonization of the infant mouse small intestine. VexF 
and VexM did not appear to function in antimicrobial resistance in vitro, but were required for 
high level production of CT and TCP. 
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Table 1. Bacterial strains, plasmids, and oligonucleotides 
 
Strain Genotype Strain # Source 
 Vibrio cholerae    
 N16961-Sm Spontaneous streptomycin-resistant 01 El Tor strain N16961 
ΔlacZ  
JB58 (119) 
 ΔvexH  N16961-Sm ΔvexH  JB116 (123) 
 ΔvexDH N16961-Sm ΔvexD ΔvexH JB186 (123) 
 ΔvexDHM N16961-Sm ΔvexD ΔvexH ΔvexM JB386 (123) 
 ΔvexDF N16961-Sm ΔvexD ΔvexF JB435 (123) 
 ΔvexDFHM N16961-Sm ΔvexD ΔvexF ΔvexH ΔvexM JB459 (123) 
 ΔvexDFHKM N16961-Sm ΔvexD ΔvexF ΔvexH ΔvexK ΔvexM JB464 (123) 
 ΔRND N16961-Sm ΔvexB ΔvexD ΔvexF ΔvexH ΔvexK ΔvexM JB485 (123) 
 ΔvexB N16961-Sm ΔvexB JB495 (119) 
 ΔvexK N16961-Sm ΔvexK JB528 (123) 
 ΔvexBK N16961-Sm ΔvexB ΔvexK JB531 (123) 
 ΔvexD   N16961-Sm ΔvexD   JB692 (119) 
 ΔvexBD N16961-Sm ΔvexB ΔvexD JB694 (119) 
 ΔvexBDHK N16961-Sm ΔvexB ΔvexD ΔvexH ΔvexK   DT12 This study 
 ΔvexBHK N16961-Sm ΔvexB ΔvexH ΔvexK DT23 This study 
 ΔvexBDH N16961-Sm ΔvexB ΔvexD ΔvexH DT30 This study 
 ΔvexBH N16961-Sm ΔvexB ΔvexH DT60 This study 
 ΔvexHK N16961-Sm ΔvexH ΔvexK DT64 This study 
 ΔvexDK N16961-Sm ΔvexD ΔvexK DT70 This study 
 ΔvexDHK N16961-Sm ΔvexD ΔvexH ΔvexK DT76 This study 
     
Escherichia coli   
 EC100Dpir+ F- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80dlacZΔM15 ΔlacX74 
recA1 endA1 araD139 Δ(ara, leu)7697 galU galK λ- rpsL (StrR) 
nupG pir+ 
 Epicentre 
 SM10λpir       thi-1 thr leu tonA lacY supE recA::RP4-2-4-Tc::Mu Kmr (λ 
pirR6K) 
 (240) 
Plasmids   
 pWM91 Suicide plasmid vector used for allelic exchange  (241) 
 pM132 pWM91::ΔVC0914  (123) 
 pM133 pWM91::ΔVC1673  (123) 
doi:10.1371/journal.pone.0038208.t001   
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2.2 RESULTS 
2.2.1 Function of VexH in Antimicrobial Resistance 
Deletion of vexH alone did not affect V. cholerae susceptibility to any of the tested antimicrobial 
compounds (Table 2). This is consistent with the reported functional redundancy among the V. 
cholerae RND efflux pumps (123). Deletion of vexH in a ∆vexB background resulted in 
increased sensitivity to Triton X-100, ampicillin and novobiocin suggesting that this detergent 
and these antibiotics were substrates for the VexH RND efflux pump. This finding was 
corroborated by the corresponding increase in susceptibility to ampicillin and novobiocin in the 
∆vexBDKH strain relative to the parental ∆vexBDK strain (Table 2). Novobiocin was also found 
to be a substrate for the VexB and VexK RND efflux systems as evidenced by the increased 
susceptibility observed for these mutants. 
VexB and VexD were previously shown to efflux bile salts (119). Therefore vexH was 
deleted in the ∆vexBD background in order to test if vexH contributed to bile salt resistance. The 
resulting ∆vexBDH mutant exhibited an increase in susceptibility to cholate and deoxycholate 
(Table 2). A similar increase in bile salt susceptibility was observed following the introduction of 
the vexH deletion into a ∆vexBDK background. These results support the conclusion that bile 
salts were substrates for the VexH RND efflux pump. The observation that the cholate and 
deoxycholate susceptibility results were identical for the ∆vexBDHK strain and the ∆RND strain 
supported the conclusion that the VexB, VexD, VexH, and VexK RND efflux pumps were 
responsible for V. cholerae resistance to bile acids in vitro. 
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Table 2. Antimicrobial susceptibility of V. cholerae RND mutants 
 
 Mean length of mutant growth relative to WT (s.d.)1 
 Cholate Deoxycholate Triton X-100 Novobiocin Ampicillin 
Strain 5% 0.05% 3% 0.01% 0.01% 0.6µg/mL 10µg/mL 2µg/mL 
N16961-Sm 100(0) 100(0) 100(0) 100(0) 100(0) 100(0) 100(0) 100(0) 
∆vexB 100(0) 100(0) 100(0) 100(0) 34.4(±3.1)A 66.7(±25.5)A 22.9(±7.8)A 100(0) 
∆vexH 100(0) 100(0) 100(0) 100(0) 100(0) 75.7(±29.4) 100(0) 100(0) 
∆vexBD NG 58.9(±14.1)A NG 73.9(±5.5)A 35.6(±1.6)A 58.9(±13.5)A 40.0(±14.6)A 100(0) 
∆vexBH 100(0) 100(0) 100(0) 100(0) 24.0(±4.3)B 19.3(±2.7)B NG 20.6(±3.9)B 
∆vexBK 100(0) 100(0) 100(0) 100(0) 23.9(±4.8)B 23.2(±10.5)B 22.0(±10.2)A 100(0) 
∆vexBDH NG 31.1(±1.6)C,D NG 47.2(±0.1)C,D 26.4(±8.2) 19.3(±2.6) NG 20.7(±1.7)B 
∆vexBDK NG 38.9(±1.6)C,D NG 47.2(±0.1)C,D 23.1(±4.8) 24.6(±9.5) 23.8(±10.4)A 100(0) 
∆vexBHK 100(0) 100(0) 100(0) 100(0) 24.3(±4.6) 8.2(±8.9) NG 22.0(±1.1)B 
∆vexDHK 34.4(±1.6)A 100(0) 100(0) 100(0) 100(0) 62.2(±31.8) 100(0) 100(0) 
∆vexBDHK NG 25.9(±3.32) NG 33.3(±8.9) 23.6(±3.3) 12.8(±5.4) NG 19.2(±2.3)B 
∆RND NG 25.9(±3.32) NG 34.8(±6.8) 23.8(±5.9) 10.2(±8.8) NG 23.0(±2.9)B 
Antimicrobial susceptibility was determined using antibiotic and detergent gradient agar plates. 1The length of the mutant bacterial growth across the 90x90 mm 
gradient plate normalized to 100 mm. Data represents the average of three of more experiments with the standard deviation in parenthesis. Unpaired t-test was used 
to determine significance. Ap<0.001 compared to N16961-Sm; Bp<0.05 compared to ∆vexB; Cp<0.05 compared to ∆vexBD; Dp<0.05 compared to ∆vexBDHK. NG: 
no bacterial growth. doi:10.1371/journal.pone.0038208.t001 
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2.2.2 The VexF and VexM Pumps do not Function in Antimicrobial Resistance in vitro 
The ∆vexBDHK mutant had the same antimicrobial susceptibility profile as the ∆RND mutant 
for all of the tested antimicrobial compounds, including cholate, deoxycholate, Triton X-100, 
SDS, erythromycin, Polymyxin B, novobiocin, ampicillin, and penicillin (Table 2 and data not 
shown). This suggested that neither VexF nor VexM functioned in antimicrobial resistance in 
vitro. 
2.2.3 Multiple RND Efflux Pumps Contribute to Virulence Factor Production  
CT production in the V. cholerae ∆RND mutant was decreased by 70% relative to WT (Figure 
5A) with a corresponding decrease in TCP production (Figure 5B). This is in agreement with 
previously reported work (123) and was used as a RND efflux-negative reference for analysis of 
CT and TCP production by the RND mutant strains generated in this study. CT and TcpA 
production in the ∆vexBH, ∆vexHK, ∆vexDK, ∆vexBDH, ∆vexBDK, ∆vexBHK, ∆vexDHK, 
∆vexDFHM, and ∆vexDFHKM mutants (Figure 5A, 5B, and data not shown) was not statistically 
different from WT. In contrast, CT and TcpA production in the ∆vexBDHK mutant was reduced 
by 45% relative to WT (Figure 5A and 5B), suggesting that these four efflux pumps were 
required for virulence factor production. The observation that the presence of a functional copy 
of any one of these four RND efflux pumps resulted in a WT phenotype suggested that there is 
redundancy among these pumps for their function in CT and TCP production. The finding that 
the ∆vexBDHK mutant produced more CT and TcpA than the ∆RND mutant suggested that 
VexF and/or VexM also contributed to virulence factor production and support the conclusion  
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Figure 5. CT and TCP production by RND mutants.  
CT and TCP production in the indicated strains was determined following growth under AKI conditions. CT (A) and 
TcpA (B) were detected by CT GM1-ELISA and TcpA Western immunoblotting, respectively. Error bars represent 
the standard deviation of the mean from three or more experiments. Statistical analysis was performed by one-way 
ANOVA. *p<0.05 compared to wild type (WT); **p<0.05 compared to all tested 
strains.doi:10.1371/journal.pone.0038208.t001 
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that at least five of six RND efflux pumps are required for high-level production of CT and 
TcpA. 
2.2.4 VexH Contributes to in vivo Colonization 
The competitive index (CI) is a measure of fitness of a test strain relative to the WT strain for 
colonization of the infant mouse small intestine. Mutants that are able to compete equally with 
the WT strain exhibit a CI of ~1, whereas mutants that are outcompeted by the WT (i.e. 
attenuated mutants) will have a CI of <1. Analysis of the mutants constructed in this study 
showed that the ∆vexBH, ∆vexHK, ∆vexDK, ∆vexDHK and ∆vexBHK strains competed equally 
with the WT strain (Figure 6A). Similar results were previously reported for the ∆vexBD strain 
(123). In contrast, the ∆vexBDH and ∆vexBDHK mutants were found to be severely attenuated 
and could not be recovered from the infant mice when inoculated at a 1:1 ratio (data not shown). 
The in vivo attenuation of these mutants did not emanate from an apparent growth defect as all 
of the mutants competed equally with WT during in vitro competitive growth assays and there 
were no differences in the growth kinetics of the strains in minimal media (data not shown). 
There was a possibility that the detection limit of the infant mouse colonization assay hindered 
our ability to recover severely attenuated mutant strains (e.g. ∆vexBDH, ∆vexBDHK, and ∆RND) 
in the intestinal homogenates. To compensate for this the challenge inoculum was biased for the 
mutant strains by 100-fold (i.e. 1:100 ratio of WT to mutant cells) which resulted in an ~2 log 
increase in the detection the limit. To validate that the biased input did not affect the CI, we 
tested the ∆vexDHK strain which competed equally with the WT strain at the 1:1 ratio. The 
results showed that the ∆vexDHK competed equally with the WT strain at the 1:100 input ratio,  
 41 
 
 
Figure 6. Infant mouse colonization assays with the RND efflux mutants. 
Competition assays were performed using the infant mouse colonization assay as described in the Materials and 
Methods. Infant mice were challenged with a ~105 cfu inoculum containing a mixture of wild type and the indicated 
mutant at a ratio of 1:1 (A) of 1:100 (B). The competitive index was calculated as the ratio of mutant to wild type 
recovered from the small intestine, corrected for the ratio of mutant to wild type that was present in the inoculum. 
Each symbol represents one mouse. *The ∆RND mutant was not recovered from mice necessitating the calculation 
of a theoretical CI as described in the Materials and Methods. Mean and standard deviation are indicated by 
horizontal bars. Significance was determined using the Mann-Whitney U t-test. (1) p<0.01. 
doi:10.1371/journal.pone.0038208.t001 
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confirming that the biased input did not affect the CI value (Figure 6B). The modified assay was 
then used to test the ∆vexBDH, ∆vexBDK, ∆vexBDHK, and ∆RND strains. The results of this 
analysis confirmed the severely attenuated phenotype of each strain (Figure 6B). However, the 
∆vexBDH and ∆vexBDHK strains, which could not be recovered from infant mice when 
inoculated at the 1:1 ratio, were recovered in 30% of the challenged mice using the modified 
assay. Using data from the colonized mice, the ∆vexBDH and ∆vexBDHK strains had CI’s that 
were reduced by 3.7 and 4.1 log units (Figure 6B). The ∆RND strain still could not be recovered 
from the mice which is consistent with this mutant having the greatest colonization defect with a 
>4.8 log reduction in its CI. 
Despite the modifications to the colonization competition assay, the ability to quantify 
colonization differences between highly attenuated mutants (e.g. the ∆vexBDH, ∆vexBDHK, and 
∆RND strains) was still limited. Therefore, we assessed the ability of these three highly 
attenuated strains to colonize the infant mouse small intestine in the absence of the WT 
competitor strain (Figure 7). Mice were challenged with the mutants at two inocula: ~106 
cfu/mouse and ~108 cfu/mouse. The 106 cfu/mouse inoculum was equal to the mutant titer used 
in the modified competition assay while the 108 cfu/mouse inoculum was used to determine if 
increasing the challenge dose would facilitate colonization by the mutant strains. 
The WT strain and ∆vexBDK mutant colonized 100% of the challenged infant mice when 
administered at 106 cfu/mouse. However, the ∆vexBDK mutant exhibited an apparent in vivo 
growth defect since the mutant replicated to a final in vivo titer was ~2 log units lower per mouse 
than was observed with the WT (Figure 7A). Inoculation of mice with 106 cfu of the ∆vexBDH 
mutant resulted in colonization of about 50% of the challenged mice. In the successfully 
colonized mice, the ∆vexBDH titers were at least 5-logs lower than was observed in mice  
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Figure 7. Colonization of the infant mouse small intestine by V. cholerae RND efflux mutants. 
Infant mice were challenged with ~6x106 cfu (A) or ~8x107 cfu (B) of the indicated V. cholerae mutant. Bacterial 
loads in the small intestine were assessed after overnight incubation. Means and standard deviation are indicated by 
horizontal bars. The Mann Whitney U t-test was used to determine significance. (1) p<0.05 compared to all tested 
strains; (2) p<0.05 compared to ∆vexBDK; (3) p<0.05 compared to the ~6x106 cfu (A) ∆vexBDH challenge. 
doi:10.1371/journal.pone.0038208.t001 
 
 
challenged with the WT strain and 3-logs lower than the output observed in mice challenged 
with the ∆vexBDK mutant (Figure 7A). This indicates that the in vivo growth defect of the 
∆vexBDH mutant was significantly greater than what was observed for the ∆vexBDK mutant. 
This is also consistent with the severe attenuation of this mutant in the colonization competition 
assays. When the challenge inoculum was increased to 108 cfu/mouse the ∆vexBDH mutant 
successfully colonized 100% of the challenged mice. In addition, the bacterial titer in each 
mouse also increased by 3-logs to a level that was equivalent to what was observed with the 
∆vexBDK mutant (Figure 7B). The increase in the output titer was limited to the ∆vexBDH 
 44 
mutant and was not observed when mice were challenged with 108 cfu of the ∆vexBDK mutant. 
The ∆vexBDHK and ∆RND mutants did not successfully colonize the intestinal tract at either 
inoculum level (Figure 7). This indicates that if either of these strains is able to colonize the 
infant mouse small intestine, the mutants were present at very low levels that were below our 
limits of detection. Since we were unable to distinguish an in vivo difference between these two 
strains, other approaches will be required to assess the function of VexF and VexM in vivo. 
2.3 DISCUSSION 
Deletion of vexH in the WT background did not result in an observable phenotype. There were 
two plausible explanations for this lack of phenotype: either VexH did not contribute to 
antimicrobial resistance, or its contribution was masked due to redundancy with one or more of 
the other five V. cholerae RND efflux pumps. The latter was proven true since the introduction 
of the vexH deletion into V. cholerae lacking the vexBDK RND efflux pumps resulted in 
increased susceptibility to a number of antimicrobial compounds (Table 2). This showed that 
VexH possessed a relatively broad substrate specificity that was second only to VexB (Table 2 
and data not shown). VexH contributed to cholate, deoxycholate, Triton X-100, novobiocin, and 
ampicillin resistance, but not to penicillin or erythromycin resistance (which were VexB 
substrates). Redundant substrate specificity between VexH and VexB is consistent with the 
observation that VexH has the largest amino acid sequence identity in common with VexB 
among the V. cholerae RND efflux pumps (123). The V. cholerae ∆vexBDHK mutant exhibited 
the same antimicrobial susceptibility profile as the ∆RND strain (Table 2). This suggests that 
VexB, VexD, VexK, and VexH are the only RND efflux pumps that contribute to antimicrobial 
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resistance in vitro. Although these four RND efflux pumps were redundant for some substrates, 
they do not have equal activity. All four pumps contributed to bile acid resistance, yet the 
presence of VexB or VexD is sufficient to provide a WT level of resistance in the absence of 
VexH and/or VexK (Table 2) (119). Only in a ∆vexBD mutant background can the contribution 
of VexH and VexK be observed. Together this suggests that VexB and VexD are major 
contributors to bile acid resistance in vitro, while VexH and VexK have minor roles. This 
conclusion is likely only relevant to V. cholerae grown under the conditions used in our assays as 
there are reports to suggest that the expression of the RND efflux systems are responsive to 
environmental cues including those present in vivo in rabbit ileal loops and in humans (119, 202, 
210, 242). 
The antimicrobial susceptibility results also suggested that neither VexF nor VexM 
contributed to antimicrobial resistance in vitro. This was a surprising finding as vexF from a non-
O1 Vibro was reported to produce a functional efflux system when expressed in E. coli in 
conjunction with V. cholerae tolC (243). This discrepancy may reflect strain or functional 
differences of VexF in a heterologous system (243). Alternatively, it is also possible that VexF 
or VexM are expressed under conditions or efflux substrates other than tested in this study (see 
below). The finding that V. cholerae produces redundant RND efflux pumps that function in bile 
acid and detergent resistance seems to be an important adaption to facilitate colonization of the 
small intestine. Redundant bile efflux pumps would provide an obvious benefit since intestinal 
bile is a natural host defense that microorganisms must overcome in order to colonize the small 
intestine (1). Consistent with bile salts being a major substrate of the RND efflux pumps, a 
number of studies have suggested that bile salts and other components of bile function to induce 
the expression of the RND efflux systems. In 2004, Chatterjee et. al. (244) reported that V. 
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cholerae grown in bile accumulated lower amounts of hydrophobic compounds than V. cholerae 
grown without bile, a phenotype they attributed to bile-dependent induction of active efflux. 
More recently, we and others have shown that transcription of the vexAB and vexCD RND efflux 
systems are upregulated in the presence of bile acids (123, 210). These results are consistent with 
the hypothesis that substrates of the individual RND efflux pumps function as effectors to 
upregulate the expression of the respective RND efflux system. While the chemical effectors that 
control the expression of vexH are unknown, a recent study has suggested that vexH expression 
may be responsive to the iron status of the cell (41, 245, 246). This finding, combined with the 
hypothesized iron limiting conditions V. cholerae may encounter late during infection (201), 
could explain the in vivo induction of VexH in humans during infection (242). If vexH 
transcription is up-regulated during in vivo colonization as a response to iron availability, then 
VexH could have a greater role in vivo than indicated by our in vitro analysis. 
The function of the RND efflux systems in mediating resistance to host defenses is 
correlated with the ability of many bacterial pathogens to survive, invade, and colonize their 
hosts (129, 179, 181, 247). We therefore expected that V. cholerae RND efflux mutants with 
similar antimicrobial susceptibility profiles would behave similarly in vivo, but our results 
revealed this to be false. For example, the ∆vexBDK and ∆vexBDH mutants exhibited similar 
susceptibility profiles for bile salts and detergents, but the ∆vexBDH mutant was more attenuated 
in vivo than the ∆vexBDK mutant and less attenuated than the ∆vexBDHK and ∆RND mutants. 
Consistent with this the ∆vexBDH mutant required a two-log higher inoculum than did the 
∆vexBDK mutant to efficiently colonize the small intestine (108 vs. 106 cfu/mouse, respectively; 
Figure 7). This is in contrast to WT which can efficiently colonize when administered at 
inoculums of 103–104 cfu/mouse (248). Even at the higher inoculums, neither mutant was able to 
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reach titers in the intestine equivalent to WT. It was noteworthy that administration of the 
∆vexBDH mutant at 108 cfu/mouse resulted in a three-log increase in the bacterial outputs from 
the colonized mice relative to inoculation at 106 cfu/mouse. This phenomenon was not observed 
with the ∆vexBDK mutant (Figure 7B). Together this suggests that the in vivo roles of the RND 
efflux systems do not completely correlate with their contributions to in vitro antimicrobial 
susceptibility of WT V. cholerae. The fact that the ∆vexBDH mutant can survive to similar titers 
as the ∆vexBDK mutant when given at a high inoculum suggests that the ∆vexBDH mutant may 
be defective in colonization of the intestinal epithelium. The intestinal epithelium is covered by a 
thick mucus layer which provides a diffusion barrier against antimicrobial compounds that are 
present in the lumen (e.g. bile) (249). One implication of this is that the epithelial surface likely 
represents a more amenable environment for the survival of antimicrobial hyper-susceptible 
organisms like the ∆vexBDK and ∆vexBDH efflux mutants. Thus one possible explanation for 
the colonization difference observed between the ∆vexBDK and ∆vexBDH mutants is that they 
exhibit differential susceptibility to antimicrobial compounds that are present in the intestinal 
lumen. 
This idea is supported by the observation that VexH has a broader substrate range than 
VexK (Table 2), which would make VexH more important during colonization than VexK. The 
finding that both VexH and VexK were induced during colonization of the human gut (242) 
corroborates the idea that these two RND efflux pumps are induced in vivo. Alternatively, it is 
possible that the colonization differences are due to unknown in vivo growth defects or 
differential effects on the in vivo induction of the ToxR regulon (see below). The CT and TCP 
bioassays showed that VexB, VexD, VexH, and VexK contributed to virulence factor 
production. However, the ∆vexBDH, ∆vexBDK, ∆vexBHK, and ∆vexDHK mutants were not 
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different from WT for CT and TCP production (Figure 5). This suggests that these four efflux 
systems were functionally redundant for CT and TCP production. Consistent with this result was 
the finding that VexB was able to complement for the loss of the five other RND efflux systems 
(123), which was evidenced by the observation that a vexDFHKM mutant (which is vexB+) was 
phenotypically identical to WT (Figure 6). The function of VexF and/or VexM in CT and TCP 
production was evident as the mutant that lacked vexBDHK was attenuated for CT and TCP 
production, while the mutant that lacked all six RND efflux systems (i.e. ∆RND) produced even 
less CT and TCP. This observation provides the evidence that VexF and/or VexM are required 
for WT CT and TCP production. This also indicates that neither VexF nor VexM are able to fully 
compensate for the loss of the other four RND efflux systems. 
Although much is known about how RND efflux systems contribute to antimicrobial 
resistance, the mechanism of how they affect virulence factor production is not known. We 
previously showed that the V. cholerae RND efflux systems effect on virulence gene expression 
mapped to tcpPH transcription (123), but the connection between RND efflux systems and 
tcpPH transcription has not yet been determined. We hypothesize that the RND efflux systems 
function to modulate the intra- or extracellular concentration of a low molecular weight molecule 
that functions as a negative effector of tcpPH transcription. Efflux-dependent modulation of an 
effector molecule represents a mechanism that could be used to link efflux to gene expression. 
This process could be used to fine-tune the expression of virulence genes in response to the 
growth environment. For example the efflux of any given effector molecule, which would affect 
its cellular distribution, would be dependent upon the presence of competing efflux substrates in 
the bacterium’s growth environment (e.g. components of bile in the GI tract). Consistent with 
this hypothesis, a number of potential low molecular weight effector compounds have been 
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described in the literature that affect virulence factor production including: fatty acids, bile acids, 
quorum sensing molecules, cyclic nucleotides, and cyclic peptides (77, 80, 114, 118, 250, 251). 
Significantly, all of these compounds have been reported to be effluxed in Gram negative 
bacteria  (244, 252, 253) which suggests the possibility that effector efflux could be applicable to 
other bacterial pathogens where the RND efflux systems have also been reported to influence 
virulence factor production (179, 189). In addition to negatively affecting tcpPH transcription, 
efflux could also impact genes downstream of tcpPH in the ToxR regulon. For example, given 
the role of the RND efflux systems in bile resistance, it is possible that the loss of efflux could 
impact intracellular fatty acids pools and thus affect ToxT activity and virulence factor 
production (78, 254). 
In summary, we have shown that VexH contributes to antimicrobial resistance and 
exhibits broad substrate specificity. VexH was found to be important for intestinal colonization 
and virulence factor production; phenotypes consistent with vexH being in vivo induced in 
humans (242). We have also shown that the V. cholerae RND efflux pumps have redundant 
functions, not only in antimicrobial resistance, but also in virulence factor production. 
Collectively these results support the conclusion that the RND efflux system contribute to V. 
cholerae pathogenesis in two ways. First, the RND efflux systems function to provide the 
bacterium with protection against antimicrobial compounds that are present in the host. Second, 
the RND efflux systems are required for efficient production of virulence factors. 
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3.1 INTRODUCTION 
V. cholerae is a facultative human pathogen that causes cholera, a severe acute diarrheal disease 
that is estimated to afflict 3-5 million people annually (255). People acquire cholera by ingestion 
of V. cholerae contaminated food or water (1). Once in the host environment, V. cholerae 
produces a variety of virulence factors that enable the pathogen to colonize the small intestine 
and to cause diarrhea. Two critical virulence factors co-regulated by the virulence activator ToxR 
are the Toxin Coregulated Pilus (TCP), a type IV pilus that is essential for colonization, and 
cholera toxin (CT), an enterotoxin that causes the secretory diarrhea that is the hallmark of 
cholera (67, 68, 228-231). In addition to the expression of TCP, intestinal colonization is also 
dependent upon V. cholerae overcoming host barriers in the human gastrointestinal tract. These 
barriers include antimicrobial compounds such as bile salts, fatty acids and components of the 
innate immune system. V. cholerae resistance to these factors is largely dependent upon the 
production of the Resistance-Nodulation-Division (RND) family of efflux systems (123, 176).  
RND efflux systems are tripartite transporters that are ubiquitous among Gram-negative 
bacteria. Each RND efflux system is made up of three components: an outer membrane porin 
homologous to E. coli tolC; an integral cytoplasmic membrane pump protein belonging to the 
RND superfamily of transporters; and a periplasmic membrane fusion protein that links the outer 
membrane pore to the cytoplasmic membrane pump protein (127, 131, 137, 238, 239). These 
RND systems have garnered much attention in regards to xenobiotic resistance as a number of 
RND systems have been shown to efflux numerous chemically unrelated antimicrobial 
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compounds including dyes, detergents, antibiotics, and antimicrobial peptides (120, 126). As 
such, many of these broad-spectrum RND efflux systems are intricately linked to the 
development of multiple drug resistant organisms. Although antibiotic resistance provides an 
easily scored phenotype for many efflux systems, phylogenetic analysis indicates that the RND 
efflux systems evolved independently of antibiotic selection (167, 168). Thus the native role of 
the RND efflux systems in bacterial physiology remains unclear, but there is accumulating 
evidence to suggest that they influence bacterial physiology independent of their role in 
xenobiotic resistance. This is exemplified by reports implicating RND efflux systems in diverse 
phenotypes such as (reviewed in (169)) biofilm formation (170, 171), iron acquisition (172), 
plant-bacteria interactions (173), lipid transport (174, 175), bacterial virulence (123, 129, 176), 
extrusion of toxic metal effectors (177), and the removal of  metabolic byproducts from within 
the cell (178).  
 V. cholerae encodes six RND efflux systems which are required for antimicrobial 
resistance, virulence factor production, and intestinal colonization (119, 123, 256). Functional 
characterization of the RND systems revealed that four of the six systems (i.e. VexAB, VexCD, 
VexGH, and VexIJK) mediate resistance to antimicrobial compounds in vitro (119, 123, 176). 
The VexAB RND efflux system exhibits a high basal level of activity and provides V. cholerae 
with its intrinsic antimicrobial resistance, a function analogous to E. coli AcrAB. The VexAB 
system is a multiple drug efflux system that mediates resistance to bile salts, non-ionic 
detergents, and a variety of antibiotics (e.g. ampicillin, erythromycin, novobiocin, and 
polymyxin B). The other three RND efflux systems are functionally redundant with VexAB. 
VexCD is a bile specific efflux system; VexGH mediates resistance to bile acids, non-ionic 
detergents, ampicillin and novobiocin; VexIJK effluxes bile acids, non-ionic detergents, and 
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novobiocin. The remaining two RND efflux systems, VexEF and VexLM, do not appear to 
influence resistance to antimicrobials. All six of the RND efflux systems contribute to virulence 
(123, 256) and strains lacking the RND efflux systems are severely attenuated in vivo (123, 256). 
Inactivation of the RND efflux systems results in down-regulation of the ToxR regulon, 
diminished CT and TCP production, and severe attenuation of growth in suckling mice (114, 
123). The mechanism(s) by which the RND efflux systems influence virulence gene expression 
are unknown.  
The Cpx two-component system is widely distributed among Gammaproteobacteria 
including the Enterobacteriaceae and Vibrionaceae. In this regulatory system, CpxA functions 
as a membrane associated sensor histidine kinase. Upon stimulation, CpxA autophosphorylates 
itself and then transfers the phosphate to a conserved aspartate residue on the cytoplasmic CpxR 
response regulator (reviewed in (257, 258)). Phosphorylated CpxR (CpxR~P) then modulates the 
expression of its target genes by binding to a consensus binding sequence located in their 
promoter regions. CpxR~P also regulates its own expression (i.e. the cpxRA operon) and the 
divergently transcribed cpxP. CpxP is a periplasmic protein associated with the cpxRA operon 
that appears to repress CpxR activation by interacting with CpxA and inhibiting its kinase 
activity, and may also exhibit chaperone activity (216). CpxA* mutants lead to constitutive 
activation of the Cpx system and have been useful in analyses of Cpx regulons. The cpxA* 
mutation inactivates CpxA phosphatase activity, resulting in the accumulation of activated CpxR 
(i.e. CpxR~P) (211, 215, 259). The Cpx system has been most extensively studied in E. coli 
where it has been shown to alleviate extracytoplasmic stress resulting from cell envelope 
perturbations that are generally associated with misfolded cell envelope proteins (260, 261). 
Consistent with this idea, the majority of stimuli that activate the Cpx system have been 
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predicted to result in the production of misfolded or damaged cell envelope proteins (reviewed in 
(257, 258)).  
Although a number of Cpx inducing stimuli have been described in E. coli, studies 
suggest that these stimuli are not conserved in V. cholerae (211). For example, the E. coli Cpx 
system is activated by increased osmolarity, but not by increased salinity (211, 224). In contrast, 
the V. cholerae Cpx system functions in an opposite manner; it is not responsive to osmolarity, 
but is activated by increased salinity (211). Additionally, the E. coli Cpx system is active under 
standard laboratory growth conditions, whereas the V. cholerae Cpx system is inactive. The 
differences in physiological roles of the Cpx system in E. coli and V. cholerae may be related to 
the distinct environmental niches these organisms occupy and appear to be reflected in amino 
acid sequence variability in the signaling domain of CpxA (211, 225).  
While the physiological roles of the V. cholerae and E. coli Cpx systems appear to differ, 
deletion of tolC activated the Cpx system in both organisms (200, 211). In E. coli, the activation 
of the Cpx system was linked to loss of TolC-dependent efflux (200). TolC functions as the 
outer-membrane pore component of several V. cholerae transport systems including RND family 
transporters (227). Thus, we speculated that the tolC-dependent activation of the V. cholerae Cpx 
system results from the loss of RND efflux activity. Here, we explored the linkage between RND 
efflux activity and the expression of the Cpx system. We show that CpxR functions as a positive 
regulator of the VexAB and VexGH RND efflux systems. Conversely, we found that mutation of 
vexRAB or vexGH resulted in the activation of the Cpx system, suggesting that the VexAB and 
VexGH RND efflux systems function in the regulation of the Cpx system. While the V. cholerae 
VexAB and VexGH RND efflux systems and the Cpx system were reciprocally regulated, the 
defect in virulence factor production in V. cholerae RND efflux mutants was independent of the 
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Cpx system. Together, our findings revealed a genetic linkage between the V. cholerae Cpx 
system and RND-mediated efflux and suggested that the V. cholerae Cpx system is activated in 
response to the accumulation of RND efflux substrates. 
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Table 3. Strains, plasmids and primers used in this study. 
 
Strains Characteristics Source 
E. coli   
EC100Dpir supE44 ΔlacU169 ( 80 lacZΔM15) hsdR17 recA1 endA1 gyrA96 thi-1 
relA1 (λpirR6K) 
Epicentre 
SM10λpir thi-1 thr leu tonA lacY supE recA::RP4-2-Tc::Mu Kmr (λpirR6K) Lab collection 
BW25113 F-, DE(araD-araB)567, lacZ4787(del)::rrnB-3, LAM-, rph-1, 
DE(rhaD-rhaB)568, hsdR514 
(262) 
JW3883-1  F-, DE(araD-araB)567, lacZ4787(del)::rrnB-3, LAM-, rph-1, 
DE(rhaD-rhaB)568, hsdR514, cpxR::Km 
(262) 
V. cholerae   
JB58 V. cholerae O1 El Tor strain N16961 ∆lacZ, SmR Lab collection 
cpxA* JB58::cpxA* (211) 
∆cpxR JB58∆cpxR (211) 
JB485 JB58∆vexB ∆vexD ∆vexF ∆vexH ∆vexK ∆vexM  (123) 
DT1452 JB485∆cpxR This study 
MKW589 ∆cpxR lacZ::cpxP-lacZEc (211) 
DT1458 JB58 lacZ::cpxP-lacZEc  This study 
DT1572 JB58∆vexB lacZ::cpxP-lacZEc This study 
DT1574 JB58∆vexD lacZ::cpxP-lacZEc This study 
DT1578 JB58∆vexH lacZ::cpxP-lacZEc This study 
DT1687 JB58∆vexK lacZ::cpxP-lacZEc This study 
DT1576 JB58∆vexB ∆vexD lacZ::cpxP-lacZEc This study 
DT1580 JB58∆vexB ∆vexH lacZ::cpxP-lacZEc This study 
DT1689 JB58∆vexB ∆vexK lacZ::cpxP-lacZEc This study 
DT1582 JB58∆vexD ∆vexH lacZ::cpxP-lacZEc This study 
DT1584 JB58∆vexB ∆vexD ∆vexH lacZ::cpxP-lacZEc This study 
DT1691 JB58∆vexB ∆vexD ∆vexK lacZ::cpxP-lacZEc This study 
DT1478 JB58∆vexB ∆vexD ∆vexH ∆vexK lacZ::cpxP-lacZEc This study 
DT1480 JB58∆vexB ∆vexD ∆vexF ∆vexH ∆vexK lacZ::cpxP-lacZEc This study 
DT1482 JB58∆vexB ∆vexD ∆vexH ∆vexK ∆vexM lacZ::cpxP-lacZEc This study 
DT1462 JB58∆vexB ∆vexF ∆vexH ∆vexK ∆vexM lacZ::cpxP-lacZEc This study 
DT1476 JB58∆vexD ∆vexF ∆vexH ∆vexK ∆vexM lacZ::cpxP-lacZEc This study 
DT1586 DT1452 lacZ::cpxP-lacZEc This study 
DT1460 JB485 lacZ::cpxP-lacZEc This study 
Plasmids   
pTL61T lacZ transcriptional reporter plasmid, CbR, oriRK2 (263) 
pXB228 pTL61T containing the vexEF promoter region This study 
pXB229 pTL61T containing the vexGH promoter region This study 
pXB230 pTL61T containing the vexIJK promoter region This study 
pXB231 pTL61T containing the vexCD promoter region (123) 
pXB232 pTL61T containing the vexLM promoter region This study 
pXB233 pTL61T containing the vexRAB promoter region (123) 
pXB265 pTL61T containing the breR promoter region This study 
p∆R cpxR::Km allelic exchange vector (211) 
pJL1P’Z Allelic exchange vector for placing cpxP-lacZ into the V. cholerae 
genome 
(211) 
pBAD33-cpxR pBAD33 expressing cpxR (211) 
pBAD33 Arabinose regulated expression plasmid, CmR, p15A origin of 
replication 
(264) 
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Table 3. (continued) 
 
Strains Characteristics Source 
PCR primers    
cpxR-F   GGTCAAGTGACGTATAGGGAGCG  
cpxR-R  GAGGTAGGGTCAATACCGCGAAC  
lacZ5 CTCTAGAAGCTTCTAGCTAGAGGG  
lacZ6 CCGCCACCTGACGTCTAAGAAACC  
P-166c-F-XhoI TTCTCGAGGGGTCCGGAGACGTACT  
P-166c-R-XbaI CGTCTAGAGGAGCTGTTTATCGCCG  
P-VC0628-F-XhoI GGCTCGAGATATTTGATCGGCGGAGT  
P-VC0628-R-XbaI GGCTCGAGATATTTGATCGGCGGAGT  
P-VC0914-F-XhoI GCCTCGAGCACATCGCTCAAGTGCGC  
P-VC0914-R-XbaI CGTCTAGATCTTTGGCCGATAGCACA  
P-VC1673-F-XhoI GGCTCGAGACCGCAGCCTTGCTGGG  
P-VC1673-R-XbaI AATCTAGACCCACCAGCAAAGTGGA  
P-VC1746-F-SmaI AACCCGGGAATTCGGCTTTTTCTTTCCAAATCGGCAGTG  
P-VC1746-R-BamHI AAGGATCCAATCAGCGCCAACCGTTTTTGCTCACTGAG  
P-VCA638-F-XhoI GGCTCGAGGGGTTTGGTCGGCATCT  
P-VCA638-R-XbaI CGTCTAGAGTGCGATACTCCAACTTA  
doi:10.1128/IAI.00025-14 
 
 
3.2 RESULTS 
3.2.1 Identification of CpxR regulated genes. 
To gain a better understanding of the genetic basis of the V. cholerae Cpx response, we used 
microarrays to identify CpxR regulated genes. This was done by defining the effect of the cpxA* 
mutation on the V. cholerae transcriptome. The cpxA* mutation inactivates the phosphatase 
activity of CpxA, which results in accumulation of CpxR in its activated form (i.e. CpxR~P). 
Analysis of the microarray revealed that the levels of 25 transcripts were changed ≥2 fold in  
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Table 4. CpxR regulated genes 
 
Gene 
categorya ORF # 
Expression ratio (sd) CpxR 
binding 
site? Gene Gene product cpxA* 
Cellular processes 
 vc2691 67.0 (16.8) yes b cpxP periplasmic protein cpxP, putative 
Cell envelope 
 vc1854 0.5 (0.1) no ompT OmpT porin 
Metabolism 
 vca0151 5.2 (2.3) yes  oxidoreductase, putative 
 vca0249 2.3 (0.3) yes  cytochrome b561, putative 
 vca0538 10.4 (3.3) yes c  cytochrome b561 
Regulatory functions 
 vc0166 3.2 (0.7) yes (2x) vexR transcriptional regulator, TetR family 
 vc2692 8.1 (1.7) yesb cpxR transcriptional regulator CpxR 
Transport and binding proteins 
 vc0042 0.5 (0.2) yes trkH potassium uptake protein 
 vc0164 2.4 (0.2) yesd vexB RND efflux pump VexB 
 vc0165 2.2 (0.3) yesd vexA Membrane fusion protein VexA 
 vc0913 14.8 (2.4) yes vexG membrane fusion proteins VexG 
 vc0914 12.4 (2.2) yese vexH RND efflux pump VexH 
 vc2436 2.1 (0.3) yes tolC outer membrane pore protein TolC 
 vca0576 4.2 (2.2) yes hutA heme transport protein HutA 
 vca0603 2.6 (1.4) no  ABC transporter substrate-binding protein 
 vca0782 4.3 (1.9) yes  ABC transporter, ATP-binding protein 
Hypothetical & conserved hypothetical proteins 
 vc0191 2.0 (0.9) yes   
 vc0806 0.5 (0.1) no   
 vc0915 2.4 (1.1) no   
 vc0938 5.5 (1.3) no   
 vca0126 2.0 (0.5) no   
 vca0139 51.1 (25.4) yes (3x)   
 vca0162 3.0 (1.2) no   
 vca0539 11.2 (2.0) yesc   
 vca0781 3.1 (1.2) yesf   
a. Gene categories were derived from Heidelberg et al. (122). 
b. The CpxR consensus binding site was located in the intergenic region between the divergently transcribed cpxP 
and cpxR genes. 
c. vca0538 and vca0539 are in an operon that contains 3 CpxR consensus binding sites located upstream of vca0538 
d. vc0166, vc0165 and vc0164 are in an operon with two CpxR consensus binding site located upstream of vc0166 
e. vc0913 and vc0914 are in an operon with a CpxR consensus binding site located upstream of vc0913  
f. vca0782 and vca0781 are in an operon with a CpxR consensus binding site located upstream of vca0782 
doi:10.1128/IAI.00025-14 
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response to the constitutive activation of CpxR; 22 genes were upregulated and three genes were 
downregulated (Table 4). We hypothesized that if CpxR directly regulated the expression of 
these genes, then their respective promoters would likely contain a CpxR consensus binding 
sequence. We therefore searched the putative promoter regions of the 25 genes for sequence 
similarity to the published CpxR consensus binding site (GTAAN6GTAA) (265). Eighteen of the 
genes (72%) contained a putative CpxR consensus sequence in their respective promoters; all but 
one of these genes was upregulated by CpxR. An analysis of 25 randomly selected promoters 
identified two genes (8%) containing CpxR consensus binding sequences. Seven genes did not 
contain a CpxR binding site and were likely regulated in an indirect manner. The preferential 
location of CpxR consensus binding sites in the promoters of positivity regulated genes suggests 
that CpxR primarily functions as a transcriptional activator in V. cholerae.  
Transcripts for cpxP and cpxR, which are known to be regulated by CpxR, were in the list 
of upregulated genes lending credence to our approach. CpxP is located next to cpxR and is 
expressed from a divergent promoter. A CpxR consensus binding sequence is located in the 
intergenic region separating these two genes, a location that is consistent with CpxR’s known 
regulation of its own expression as well as the divergently transcribed cpxP (261, 266). In 
contrast to E. coli, the V. cholerae Cpx response did not appear to activate genes involved in 
alleviating membrane stress (e.g. dsbA, degP, and fkpA) resulting from misfolded membrane 
proteins (219, 265, 267); a finding that may reflect functional differences in the Cpx response in 
the Vibrionaceae versus the Enterobacteriaceae.  
Notably, 11 of the 25 CpxR regulated genes were involved in maintaining the 
permeability barrier of the cell (Table 4). Five of the upregulated genes encoded for the 
production of two broad-spectrum RND efflux systems: VexAB, VexGH, and their cognate  
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Figure 8. CpxR consensus binding sites in the vexRAB, vexGH, and tolC promoters. 
Putative CpxR consensus binding sequences in the promoter regions of the vexRAB, vexGH and tolC genes are 
indicated by grey boxes. The start codon for each gene is marked by bold font. Numbering is relative to the start 
codon for each respective gene. doi:10.1128/IAI.00025-14 
 
 
outermembrane pore component TolC. Furthermore, a putative CpxR consensus binding 
sequence was found in the promoter regions of vexRAB, vexGH, and tolC, suggesting that CpxR 
regulates their expression (Figure 8). One of the downregulated genes was ompT, which encodes 
a ToxR-regulated porin that possesses a large diameter pore. Repression of ompT is associated 
with decreased susceptibility to low molecular weight antimicrobial compounds such as bile salts 
(9, 268, 269). 
3.2.2 CpxR is a positive regulator of the V. cholerae RND efflux systems.  
The expression of vexRAB and vexGH RND efflux systems increased in the cpxA* 
mutant (Table 4). This finding, combined with the presence of CpxR consensus binding  
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vexRAB and vexGH promoters (Figure 8), suggested that CpxR likely regulated the expression of 
these two RND efflux systems. To test this hypothesis and to validate the microarray results, we 
quantified vexRAB and vexGH expression in WT, in the cpxA* mutant (which constitutively 
activates CpxR) and in a cpxR deletion mutant during growth in LB broth and during growth 
under AKI conditions. These growth conditions were selected as they represent conditions where 
the RND efflux systems have been shown to contribute to both antimicrobial resistance and 
virulence factor production (10). We measured reporter expression at two time points (2 and 4 h 
post inoculation for the LB cultures and 3.5 and 6.5 h post inoculation for the AKI cultures) to 
control for potential growth-dependent effects on expression.  
With activation of CpxR, in the cpxA* background, vexRAB expression was significantly 
increased relative to WT under AKI growth conditions. In contrast, the absence of CpxR, in the 
∆cpxR background, did not influence vexRAB expression under either condition (Figures 9A and 
9B). Thus, CpxR does not regulate the basal-level expression of vexRAB, but can enhance 
vexRAB expression under conditions where the Cpx system is activated. The expression level of 
vexGH was increased during growth in LB broth and under AKI conditions in the cpxA* 
background (Figures 9C and 9D). However, the basal level of vexGH expression under AKI 
conditions appeared to be much lower than was observed in LB broth. In contrast to vexRAB, 
cpxR deletion resulted in a significant reduction in vexGH expression during growth in LB broth 
(Figure 9C), but not during growth under AKI conditions (Figure 9D), implying that CpxR 
positively effects the basal level expression of vexGH during growth in LB broth, but not under 
AKI conditions. Collectively these observations indicate that there are media-dependent 
differences in the activation of the Cpx system and that the Cpx system is likely inactive during 
growth under virulence gene inducing conditions. These findings validate the microarray results  
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Figure 9. Expression of vexRAB and vexGH in V. cholerae cpx mutants. 
The indicated V. cholerae strains bearing either a vexRAB-lacZ (A, B and E) or vexGH-lacZ (C, D and F) reporter 
were grown in LB broth (A and C), or under AKI conditions (B and D), or in LB broth containing KCl at indicated 
concentrations (E and F). Culture aliquots were taken at 2 h and 4 h (A and C), 3.5 and 6.5 h (B and D) or at 4 h (E 
and F) and assayed for β-galactosidase activity. The presented data is the mean +/- SD of three independent 
experiments. Statistical significance was determined by ANOVA with the Tukey-Kramer multiple comparisons test 
(A, B, C, & D). Panels E and F were compared to 0 KCl. * = P<0.001. doi:10.1128/IAI.00025-14 
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and support the conclusion that CpxR is a positive regulator of the vexRAB and vexGH RND 
efflux systems. 
Since vexRAB and vexGH appeared to be positively regulated by CpxR, we predicted that 
their expression should increase with activation of the Cpx system. We therefore quantified 
vexRAB and vexGH expression in WT and a ∆cpxR mutant following growth in LB broth 
containing various concentrations of KCl, a known inducer of the V. cholerae Cpx system (211). 
The results showed a KCl concentration-dependent increase in vexRAB expression. Growth in 
1M KCl resulted in a 1.5-fold increase in vexRAB-lacZ expression, while growth in 2M KCl 
caused a 2-fold increase in vexRAB-lacZ expression relative to growth in LB broth without KCl 
(Figure 9E). This phenotype was found to be dependent on CpxR as deletion of cpxR abolished 
the KCl-dependent induction of vexRAB (Figure 9E). The expression of vexGH was also induced 
by KCl as evidenced by a 2-fold increase in vexGH-lacZ expression during growth in 2M KCl 
relative to the LB control (Figure 9F). The induction of vexGH by KCl was also dependent on 
CpxR as deletion of cpxR abolished KCl-dependent increase in vexGH expression (Figure 9F). 
Together these results confirm that the data obtained with the cpxA* mutant reflects activated 
CpxR and provides additional evidence to support the conclusion that the vexRAB and vexGH 
RND efflux systems are positively regulated by the Cpx system in a CpxR dependent manner.  
3.2.3 Activation of the Cpx response enhances V. cholerae resistance to antimicrobial 
compounds. 
Since both the vexRAB and vexGH RND efflux systems were upregulated in the cpxA* mutant 
(Figure 9), we predicted that the cpxA* mutant should exhibit enhanced resistance to 
antimicrobial compounds that are substrates for these two RND efflux systems (e.g. bile salts and 
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other detergent-like molecules). To test this hypothesis, we calculated the plating efficiency of 
CpxR activated V. cholerae on Thiosulfate-citrate-bile salts-sucrose (TCBS) agar. Growth of V. 
cholerae on TCBS agar is dependent upon the expression of the RND efflux systems which 
provide resistance to bile salts and other detergent-like compounds that are present in this 
medium (119, 123, 256, 270, 271). In these experiments we compared the plating efficiency of 
cpxA* and ∆cpxR strains to WT. We also compared the plating efficiency of WT and the ∆cpxR 
mutant grown in LB broth +/- 2 M KCl. The results showed that there was a 3-fold increase in 
the recovery of the cpxA* mutant relative to WT, while the recovery of the ∆cpxR mutant was 
not significantly different from WT (Figure 10). Activation of the Cpx system by growth in 2M 
KCl resulted in a 3-fold increase in recovery of the KCl grown cells relative to cells grown in LB 
without KCl. Growth of the ∆cpxR mutant in 2M KCl did not have a significant effect on its 
recovery which confirmed  that this phenotype was dependent on cpxR (Figure 10). In 
conjunction with the previous data (Figure 9), these results provide further evidence to support 
the idea that activation of the Cpx system induces vexRAB and vexGH expression in a CpxR-
dependent manner thereby enhancing antimicrobial resistance. 
Next the effect of the Cpx system on V. cholerae antimicrobial susceptibility was 
investigated by examining the resistance of the WT, cpxA* and ∆cpxR strains to antimicrobial 
agents using disk diffusion assays. The results showed that the cpxA* mutant exhibited increased 
resistance to ampicillin, but not to other tested antimicrobial compounds (Table 5). Since VexAB 
and VexGH are the only two RND efflux systems that contribute to ampicillin resistance, this 
finding is consistent with the idea that both of these RND efflux systems are upregulated in the 
cpxA* mutant. It is not surprising that differences in susceptibility were not observed for the 
other RND-dependent antimicrobial substrates as the contributions of VexAB and VexGH to  
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Figure 10. Effect of CpxR activation on the recovery of V. cholerae on TCBS agar. 
V. cholerae WT, cpxA* and ∆cpxR were cultured in LB broth or LB broth containing 2 M KCl before aliquots were 
diluted in PBS and plated in duplicate onto LB agar and TCBS agar plates for enumeration. The plates were 
incubated overnight at 37°C before the resulting colonies were counted. The recovery ratio for each mutant was 
calculated by the following equation: [the number of mutant colonies on TCBS/the number of mutant colonies on 
LB] divided by [the number of WT colonies on TCBS/the number of WT colonies on LB]. The results are the mean 
of three independent experiments +/- SD. Statistical significance relative to WT was determined by ANOVA with 
the Tukey-Kramer multiple comparisons test. * = P < 0.001. doi:10.1128/IAI.00025-14 
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Table 5. Susceptibility of V. cholerae strains to antimicrobial compounds by disk diffusion assays. 
 
 Zone of growth inhibitiona (SD) 
Strain CuCl2 SAR DOC TET GENT PXB ERY AMP 
WT 25.3 
(0.96) 
17.7 (0.58)  8.5 
(1.29) 
26.5 (0.35)  18.8 (0.40) 0 (0) 24.0 (1.63) 10.0 
(0.89) 
∆cpxR 25.5 
(0.71) 
15.0 (0) 8.0 (0) 28.3 (0.50) 18.0 (0) 0 (0) 23.5 (1.0) 9.4 (0.84) 
cpxA* 25.3 
(0.50) 
16.3 (0.50) 8.3 
(0.96) 
26.0 (0.82)  19.2 (0.75)  0 (0) 24.8 (2.75) 0 (0)1 
aZone of growth inhibition (measured in mm) to CuCl2, sarcosyl (SAR), deoxycholate (DOC),  tetracycline (TET), 
gentamicin (GENT), polymixin B (PXB), erythromycin (ERY), and ampicillin (AMP). Student t-test was used to 
determine if differences were significant compared to WT: 1P<0.0001. doi:10.1128/IAI.00025-14 
 
 
resistance to these substrates is masked due to redundancy among the six RND efflux systems 
(119, 123, 256). There was no significant difference in susceptibility to any of the compounds 
tested between the WT and the ∆cpxR mutant strain, suggesting that the tested xenobiotics did 
not function to activate the expression of the Cpx response. This was verified by plating V. 
cholerae containing a cpxP-lacZ reporter on LB agar containing subinhibitory amounts of these 
xenobiotics; no differences in expression of the reporter in the presence or absence of any of the 
compounds were noted (data not shown), confirming that the Cpx system was not activated in 
response to these antimicrobial compounds. Based on these observations, we conclude that the 
Cpx system is not required for V. cholerae’s intrinsic resistance to xenobiotic antimicrobial 
compounds, but its activation could enhance the pathogen’s resistance to antimicrobials through 
increased expression of vexRAB and vexGH. 
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Figure 11. Ectopic expression of cpxR activates vexRAB and vexGH expression in V. cholerae. 
V. cholerae  containing the indicated RND efflux system reporters, and either pBAD33-cpxR or pBAD33, was 
grown in LB broth at 37°C in the presence or absence of arabinose as described in the methods. After 4 h of growth, 
triplicate aliquots were taken and assayed for β-galactosidase activity. The presented data is the mean +/- SD of  
three independent experiments. Statistical significance was determined by ANOVA with the Tukey-Kramer multiple 
comparisons test. * = P < 0.001. doi:10.1128/IAI.00025-14 
 
 
3.2.4 Ectopic expression of cpxR activates vexRAB and vexGH expression. 
The observation that the vexRAB and vexGH promoters contain CpxR consensus binding 
sequences (Figure 8), and were upregulated in a cpxA* background (Figure 9), suggested that 
CpxR was a positive regulator of vexRAB and vexGH. To confirm this hypothesis, we expressed 
cpxR from the arabinose inducible promoter in pBAD33 in V. cholerae harboring either vexRAB-
lacZ or vexGH-lacZ reporters. This resulted in a dramatic arabinose dose-dependent increase in 
both vexRAB and vexGH expression (Figure 11A). In contrast, cpxR expression did not affect the  
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Figure 12. Effect of CpxR on the expression of the indicated RND efflux systems. 
V. cholerae containing the indicated RND efflux system reporter plasmids and pBAD33-cpxR were grown in LB 
broth in the presence or absence of arabinose as described in the methods. Following 4 h growth, triplicate aliquots 
from each culture were collected and assayed for β-galactosidase activity. The results are the mean and SD from 
three independent experiments. doi:10.1128/IAI.00025-14 
 
 
expression of any other RND efflux system (Figure 12); confirming the CpxR was specific for 
vexRAB and vexGH. These results confirmed our hypothesis that CpxR was a positive regulator 
of the vexRAB and vexGH RND efflux systems. Taken together, these observations are consistent 
with the hypothesis that CpxR functions as an activator at the vexRAB and vexGH promoters. 
3.2.5 Mutation of vexB and vexH activate the Cpx system.  
Our collective findings revealed that the VexAB and VexGH RND efflux systems are 
components of the Cpx response. This suggested the possibility that active efflux by the RND 
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efflux systems might function to suppress the Cpx response. To test this hypothesis, we used a 
chromosomal cpxP-lacZ reporter as an indicator of the activation state of the Cpx system; cpxP 
expression is regulated by CpxR (211). We compared cpxP expression in WT vs JB485, a strain 
lacking all six RND efflux systems (123). JB485 produced dark blue colonies on LB-X-gal 
plates whereas the WT and the JB485∆cpxR mutant yielded white colonies (Figure 13A). 
Control cultures grown on agar plates containing 500µM CuCl2 (a Cpx inducer) showed 
induction of cpxP in WT, but not the cpxR mutants validating that the cpxP-lacZ construct is 
faithfully reporting on the activation state of the Cpx system in each strain. Thus, the absence of 
RND efflux activity induces the Cpx system, a finding consistent with the idea that the RND 
efflux systems normally suppress the activity of the Cpx system in V. cholerae.  
Previous studies have shown that four of the six RND systems (vexB, vexD, vexH and 
vexK) contribute to in vitro resistance of V. cholerae to antimicrobial compounds with both 
distinct and redundant roles (119, 123, 256). We therefore sought to determine which of the 
RND efflux systems contributes to Cpx suppression by examining cpxP expression in a panel of 
strains that included both single and multiple RND efflux mutants. For these experiments, the 
cpxP-lacZ reporter was introduced into the chromosome of each of the RND mutants. Expression 
of cpxP was then examined on LB-X-gal plates and LB-X-gal plates containing CuCl2 (as a 
positive control). LB agar was used to screen for cpxP expression because previous studies have 
shown that the Cpx system was poorly expressed in LB broth (211). Among the four single RND 
efflux mutants (vexB, vexD, vexH and vexK) only the vexB mutant produced light blue colonies 
on LB-X-gal (Figure 13A); the vexH mutant produced colonies that appeared white to the naked 
eye but were discernable as faint blue in color under magnification, while the vexD and vexK 
mutant colonies were white in color. These observations suggest that cpxP expression is  
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Figure 13. Induction of the Cpx system in V. cholerae RND efflux mutants. 
Expression of a chromosomal cpxP-lacZ reporter in the indicated V. cholerae strains. (A) The indicated strains were 
inoculated onto the surface of LB-X-gal plates +/- 500 µM CuCl2 before the plates were incubated overnight at 37°C 
and photographed. (B) The same V. cholerae cpxP-lacZ fusion strains were cultured under AKI conditions for 5 h 
when culture aliquots were collected and their β-galactosidase activity assayed. The fold change was calculated as 
the β-galactosidase activity (measured in Miller Units) in the mutant divided by the WT. The bars represent the 
mean +/- SD of three independent experiments. Statistical relevance as compared to WT was calculated using a one-
way ANOVA with Dunnet’s post-hoc test. * = P < 0.001. doi:10.1128/IAI.00025-14 
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activated in the absence of either vexB or vexH, (albeit to a very low level in the absence of 
vexH), but that the absence of either vexD or vexK does not induce cpxP expression. 
Furthermore, a vexBDK triple mutant produced colonies that were similar in color to the vexB 
single mutant, supporting the idea that vexD and vexK do not influence cpxP expression under 
these conditions. When the vexB and vexH deletions were combined, the resulting strain 
produced dark blue colonies similar in color to JB485 (Figure 13A), consistent with the 
hypothesis that these two RND efflux systems are functionally redundant for this phenotype. We 
hypothesized that if Cpx activation was a result of efflux activity provided by vexGH and/or 
vexRAB, then a strain lacking all five RND efflux systems except vexRAB should suppress 
expression of the Cpx system relative to JB485. Indeed, this was what we observed with the 
∆vexDFHKM(vexB+) strain which produced faint blue colored colonies that were similar in 
color to the ∆vexH mutant (Figure 13A). We conclude that efflux activity provided by the 
VexAB and VexGH RND efflux systems maintains the Cpx system in a suppressed state during 
growth of V. cholerae on LB agar.  
We also examined whether the RND efflux systems influence the expression of the Cpx 
system during growth under virulence inducing conditions. For these experiments, each RND 
mutant was grown under AKI conditions before assaying for cpxP expression. There was no 
difference in cpxP expression among any of the single deletion mutants (Figure 13B). However, 
when a vexB mutant was combined with a vexH deletion, we observed an approximately 2-fold 
increase in cpxP expression. The vexBK and vexDH mutants did not appear to affect cpxP 
expression. This suggested that during growth under AKI conditions, vexB and vexH function in 
a redundant manner to limit activation of the Cpx system. There was an increase in cpxP 
 72 
expression in the vexBDHK mutant relative to the vexBDH mutant, suggesting that the VexIJK 
RND efflux system contributed to the suppression of the Cpx system. The expression of cpxP in 
the vexBDHKM(vexF+), and vexBDFHK(vexM+) mutants was similar to the vexBDHK mutant. 
Expression of cpxP was similar to WT in the vexDFHKM(vexB+) mutant, confirming that the 
VexAB RND efflux system is sufficient to complement for the absence of the other five RND 
efflux systems. The increase in cpxP expression in JB485 relative to the vexBFHKM(vexD+) 
mutant suggests that the VexCD RND efflux system contributes to the suppression of the Cpx 
system during growth under AKI conditions. These findings are reminiscent of our previous 
observations regarding CT and TCP production in RND efflux deficient V. cholerae: where all 
six RND systems were required for high-level CT and TCP production (256). The concordance 
of these observations raises the intriguing possibility that the factor responsible for activation of 
the Cpx system during AKI growth may also contribute, by a Cpx-independent mechanism, to 
the virulence attenuation observed in JB485 (123). 
3.2.6 CpxR contributes to vexRAB and vexGH expression in RND efflux negative V. 
cholerae. 
The above data suggested that the Cpx system was activated by loss of the RND efflux systems 
(Figure 13). Based on this, and the finding that CpxR activated vexRAB and vexGH expression 
(Figures 9 and 11), we hypothesized that the expression of vexRAB and vexGH in JB485 would 
be upregulated in a CpxR-dependent manner. To test this we quantified vexRAB and vexGH 
expression in WT, JB485, and JB485 ∆cpxR during growth under AKI conditions. AKI 
conditions were selected as they showed the most dramatic effect on the expression of vexRAB 
and vexGH (Figure 9). The results showed a significant increase in the expression of both  
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Figure 14. CpxR activates vexRAB and vexGH expression in the absence of RND efflux activity. 
The indicated V. cholerae strains containing a vexRAB (A) or  vexGH  (B) reporter plasmid were grown under AKI 
growth conditions. Aliquots were taken at 3.5 and 6.5 hours and assayed for β-galactosidase activity. The presented 
data is the mean +/- SD of three independent experiments. Statistical significance was determined by ANOVA with 
the Tukey-Kramer multiple comparisons test. *=P<0.001. doi:10.1128/IAI.00025-14 
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vexRAB and vexGH in strain JB485 relative to WT at 3.5 and 6.5 hours (Figures 14A and 14B). 
The level of vexRAB expression in JB485 ∆cpxR was reduced relative to JB485, but was still 
greater than in WT (Figure 14A). This suggests that CpxR contributes to the induction of 
vexRAB in JB485, but that additional factors are also contributing to vexRAB upregulation. In 
contrast to vexRAB, the expression level of vexGH returned to WT levels in the JB485 ∆cpxR 
mutant, indicating that CpxR was responsible for the upregulation of vexGH in JB485 (Figure 
14B). Together these results provide additional evidence supporting the conclusion that the loss 
of RND efflux activity results in CpxR activation and that CpxR functions as a positive regulator 
of vexRAB and vexGH. 
3.2.7 The Cpx system does not affect CT or TCP production. 
The RND efflux systems were shown to contribute to the production of both CT and TCP in V. 
cholerae (123). While still unknown, the mechanism by which the RND systems repressed CT 
and TCP production was linked to repression of the ToxR regulon (123). The upregulation of the 
Cpx system in the RND deficient mutant suggested the possibility that CpxR could function to 
repress CT TCP production was linked to repression of the ToxR regulon (123). The 
upregulation of the Cpx system in the RND deficient mutant suggested the possibility that CpxR 
could function to repress CT and TCP production. We investigated this hypothesis by 
quantifying CT and TCP production in WT, cpxA*, ∆cpxR, JB485, and JB485∆cpxR strains. If 
cpxR was responsible for attenuated CT and TCP production, then its deletion in the RND 
negative background should result in increased CT and TCP production. Likewise, CT and TCP 
production should be decreased in WT by the cpxA* mutation due to constitutive activation of  
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Figure 15. Quantification of CT and TcpA production in V. cholerae strains. 
The indicated strains were grown under AKI growth conditions. Culture aliquots were collected following overnight 
growth and assayed for (A) CT production using a GM1 ELISA and (B) TcpA production by Western blot using 
polyclonal antibody that was generated against TcpA. doi:10.1128/IAI.00025-14 
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the Cpx system. Our results showed that there was no significant difference in CT or TCP 
production between WT, cpxA*, and ∆cpxR or between JB485 and JB485∆cpxR (Figure 15). 
This indicated that the defect in virulence factor production in JB485 was not a result of the 
activation of the Cpx system. These results also suggested that the Cpx system does not function 
to regulate virulence factor production in V. cholerae; a result that is consistent with previous 
findings showing that the Cpx system was dispensable for V. cholerae colonization of the infant 
mouse small intestine (211). 
3.3 DISCUSSION 
Bacteria have evolved overlapping mechanisms to sense and respond to stress that can result 
from exposure to toxic molecules, adhesion to abiotic surfaces, or from misfolded proteins. The 
Cpx two-component system represents one such system that in E. coli mitigates envelope stress 
resulting from protein misfolding (258). V. cholerae also encodes a Cpx two-component system 
that shares a conserved genetic organization with the E. coli Cpx system (211). However, there 
are differences in the amino acid sequences of the sensor domains of the V. cholerae and E. coli 
CpxA and CpxP proteins and the V. cholerae Cpx system does not respond to stimuli that 
activate the E. coli Cpx system (211). Thus, the Cpx systems may play different roles in the 
physiology of these two related Gammaproteobacteria. 
Our characterization of the V. cholerae CpxR transcriptome supports the idea that there 
are differences between the V. cholerae and E. coli Cpx regulons. One key difference we found 
is that genes involved in protein fate (e.g. degP and dsbA) were either not detected as being 
regulated or were found to be repressed by CpxR in V. cholerae (Table 4). This finding is similar 
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to Haemophilus ducreyi, where degP was also noted to be absent from the Cpx regulon (272). 
Together these observations suggest that the physiological role for Cpx systems may not be 
universally conserved among Gram-negative bacteria. Although degP and dsbA appear to be 
regulated independently of CpxR in V. cholerae, the activation of the Cpx system in V. cholerae 
dsbC and dsbD mutants (211), which likely results in misfolded cell envelope proteins, suggests 
that the Cpx system can respond to misfolded proteins. The mechanism by which this occurs 
remains to be determined, but could involve alternate sigma factor sigma (E) (rpoE) which has 
been shown to functionally overlap with the Cpx system in responding to extracytoplasmic stress 
in E. coli (219, 273). 
The list of V. cholerae CpxR regulated genes included a number of genes that mediate 
uptake and efflux of low molecular weight antimicrobial compounds. This included the ompT 
porin (which was repressed) and the vexRAB, vexGH, tolC genes (which were upregulated). The 
latter loci encode for the production of two broad-spectrum RND efflux systems that contribute 
to V. cholerae resistance to multiple antimicrobial compounds and pathogenesis (119, 123, 176). 
Several lines of evidence suggest that the vexRAB and vexGH operons are regulated by CpxR: 
the promoters of both operons contain CpxR consensus binding sequences (Figure 8); both 
operons were upregulated in the cpxA* mutant (Figure 9); ectopic cpxR expression activated 
their expression in V. cholerae (Figure 11); and KCl (a Cpx system activator) induced their 
expression in WT, but not in a ∆cpxR mutant (Figure 9). This conclusion is buttressed by the 
observation that the cpxA* mutant exhibited increased resistance to ampicillin (an antibiotic 
substrate of the VexAB and VexGH RND systems) and exhibited a growth advantage on TCBS 
agar (Table 5 and Figure 10), and that induction of the Cpx system with 2M KCl provided a 
growth advantage for WT on TCBS, but not for a ∆cpxR mutant (Figure 10). While our data 
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strongly support the conclusion that CpxR is an activator of these two RND efflux systems, 
CpxR was not required for V. cholerae intrinsic resistance to antimicrobial compounds (Figure 
10 and Table 5). This suggests that the Cpx system could contribute to xenobiotic resistance 
under Cpx-inducing conditions by further increasing the expression of vexRAB and vexGH; 
however, the Cpx system is not required for V. cholerae intrinsic resistance to xenobiotics.  
Besides finding that the V. cholerae Cpx response promotes expression of RND efflux 
systems, we also found that inactivation of RND efflux stimulates the Cpx response. Mutation of 
vexB and/or vexH resulted in activation of the V. cholerae Cpx system. It is interesting to note 
that this phenotype was also observed with deletion of RND efflux systems in H. ducreyi and 
Klebsiella pneumoniae (274, 275) which suggests that the genetic linkage between the Cpx 
system and the efflux systems is not unique to V. cholerae. The mechanism(s) by which the RND 
efflux systems modulate the activity of the Cpx system are not known. However, since RND 
efflux systems function in small molecule export, we speculate that this phenotype is the result of 
the intracellular accumulation of an endogenously produced small molecule in the RND efflux 
mutants. Consistent with this hypothesis, recent studies suggest that a natural function of RND 
efflux systems may be to remove metabolic waste from within the cell (198). In E. coli, there is 
evidence to suggest that in the absence of RND-mediated efflux, metabolites accumulate in the 
cell and activate the expression of the MAR, Bae and Cpx stress response systems (178, 197-
200, 276). These regulatory systems then activate the expression of the acrAB, acrD and 
mdtABCD RND efflux systems and other stress mitigating genes. Although V. cholerae appears 
to lack the MAR and Bae systems, we propose that a similar mechanism occurs in V. cholerae. 
We speculate that an as yet unidentified cellular metabolite accumulates in the absence of the 
RND efflux and activates the Cpx system. Our observation that different RND efflux pumps 
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were required to suppress the Cpx system during growth on LB agar versus growth under AKI 
conditions suggests that the Cpx system may respond to the accumulation of multiple different 
endogenous molecules. Determining the identity of such effector molecules is a key challenge 
for future studies.  
We previously proposed that a small molecule accumulated in V. cholerae in the absence 
of RND-mediated efflux and repressed CT and TCP production during growth under AKI 
conditions (256). This proposal was supported by the fact that V. cholerae virulence factor 
production was dependent upon all six RND efflux systems and there was functional redundancy 
among the RND systems for this phenotype (114, 123, 256). The similarity of these results to the 
Cpx data, along with the inclusion of the ToxR-regulated ompT in the list of CpxR-responsive 
genes, suggest that attenuation of CT and TCP production in the RND deficient strain may be 
due to the activation of the Cpx system. Although the Cpx system has been linked to virulence in 
other pathogens (222, 277-281), our data indicate that the Cpx system does not affect V. cholerae 
virulence factor production. This was evidence by the fact that cpxR deletion, constitutive 
activation of the Cpx system (i.e. cpxA*), or chemical activation of the Cpx system (i.e. with 
CuCl2), did not affect CT or TCP production. This conclusion is further supported by a previous 
study which showed that the Cpx system was dispensable for V. cholerae intestinal colonization 
(211). 
While our findings strongly suggest that the Cpx system does not exert a significant 
influence over the expression of the ToxR regulated virulence factors CT and TCP, we cannot 
exclude the possibility that the Cpx system plays a role in the regulation of other genes in vivo. 
Late in infection, V. cholerae is thought to encounter growth conditions conducive to the 
induction of the Cpx system including high cell density, nutrient limitation, and the likely 
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accumulation of metabolic waste/byproducts (41, 201). The finding that both the vexAB and 
vexGH RND efflux systems are upregulated late during infection in humans and animals (41, 
201, 202, 242) are consistent with the hypothesis that Cpx system is also induced late in 
infection. Thus, it is tempting to speculate that the Cpx system may contribute to late gene 
expression during infection. Late induced genes contribute to important phenotypes. This 
includes genes that contribute to V. cholerae survival in the environment and genes that 
contribute to the hyper-infectious phenotype associated with human shed vibrios and thought to 
be a key factor responsible for the epidemic spread of cholera (41, 282). 
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4.0  VEXR IS A POSITIVE REGULATOR OF THE VEXAB RESISTANCE-NODULATION-
DIVISION EFFLUX SYSTEM AND MEDIATES RELIEF FROM METABOLIC STRESS.  
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4.1 INTRODUCTION 
Vibrio cholerae is a noninvasive Gram negative bacterial pathogen that causes the disease 
cholera. Cholera is a severe acute diarrheal disease that affects an estimated 3-5 million people 
per year (1). Untreated cholera can rapidly lead to dehydration, hypotensive shock, and death. 
Cholera is contracted by ingesting V. cholerae contaminated food or water (1). Following 
ingestion, V. cholerae colonizes the small intestine via a process that is dependent upon the 
induction of genes which are required for intestinal colonization and disease development. These 
in vivo expressed genes contribute to V. cholerae pathogenesis in diverse ways and range from 
traditional virulence factors (i.e. toxins and adhesins) to genes that facilitate V. cholerae survival 
in the gastrointestinal (GI) tract. V. cholerae persistence in the intestine is dependent upon its 
ability to overcome antibacterial barriers that are intrinsic to the GI tract, including the presence 
of high concentrations of toxic small molecules (such as bile acids and other detergent-like 
molecules), antimicrobial products generated by resident flora, and products of the innate 
immune system. In response to these toxic elements, V. cholerae activates genes which function 
to protect the cell by modulating its outer membrane (OM) permeability barrier and activating 
efflux transporters (123, 211, 283, 284). For example, in response to bile acids V. cholerae alters 
the porin composition of the OM to effectively reduce the rate of bile salt diffusion, and 
presumably the diffusion of other soluble toxic molecules, across the OM (284). In conjunction 
with reduced OM permeability, V. cholerae expresses RND-family transport systems that 
function to efflux bile salts, and multiple other antimicrobial compounds, from within the cell 
envelope to the external environment (123, 211). Together, the activated RND efflux systems 
and reduced OM permeability function synergistically to provide V. cholerae with high-level 
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resistance to lethal antimicrobial compounds present in the host. The importance of these 
responses in the pathobiology of this organism is highlighted by the fact that V. cholerae exhibits 
a greatly diminished ability to colonize the intestinal tract in the absence of these adaptive 
responses (123). 
The RND efflux systems have been a focal point in bacterial antimicrobial resistance 
research due to the ability of individual RND systems to provide resistance to a broad range of 
chemically unrelated substrates that include antibiotics, detergents, dyes, and antimicrobial 
peptides. The RND efflux systems are found in most gram negative bacteria and function as 
proton-substrate antiporters (226, 238, 239, 265). Individual RND efflux systems are composed 
of three components: an outer membrane pore protein that is homologous to Escherichia coli 
TolC, an integral cytoplasmic membrane pump protein belonging to the RND superfamily, and a 
periplasmic membrane fusion protein that links the outer membrane pore protein to the RND 
pump protein (127, 131, 132, 137). Together these three components form a transport apparatus 
that spans the cell envelope and functions to efflux substrates from within the cell envelope into 
the external environment. Although the RND transport apparatus is responsible for the efflux of 
antimicrobials, phylogenetic analysis suggests that the RND efflux systems evolved independent 
of antibiotic selection (167, 168). Indeed, there is mounting evidence that the RND efflux 
systems are involved in diverse functions (reviewed in (169)) such as biofilm formation, iron 
acquisition, plant-bacteria interactions, lipid transport, bacterial virulence, divalent cation 
resistance, and the removal of metabolic byproducts from within the cell. 
The V. cholerae genome encodes six RND efflux systems (123). Inhibition of the RND 
efflux systems renders V. cholerae hypersensitive to multiple antimicrobial compounds and 
attenuates the expression of virulence factors including cholera toxin (CT) and the toxin co-
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regulated pilus (TCP) (119, 123, 176, 267, 285). Among the six RND efflux systems, the VexAB 
system was shown to be the primary system that contributes to intrinsic antimicrobial resistance 
in vitro (119, 123, 267). There have been several studies that suggest that the VexAB RND 
efflux system is important to V. cholerae pathogenesis. This includes finding that vexAB was 
induced in vivo in humans and animals, that vexAB expression was enhanced by the Cpx system, 
and that VexAB was required for high-level virulence factor production (35-37, 50). While there 
is ample evidence to suggest that VexAB is important in pathogenesis, the regulatory 
mechanisms controlling its expression are unknown. 
In many bacteria regulation of the RND efflux systems is mediated by a linked TetR 
family regulator (208). The TetR family is a large family of regulatory proteins that function in 
diverse phenotypes including antibiotic resistance, metabolism, stress responses, and 
pathogenicity (206). TetR proteins contain two functional domains: a conserved N-terminal 
DNA-binding domain and a variant C-terminal ligand binding domain (206). The ligand binding 
domain is capable of binding to effector molecules that modulate the interaction of the DNA 
binding domain with its target sequences. In the case of RND efflux systems, the activity of their 
TetR regulators is often modulated by the binding of efflux substrates of the linked RND system. 
In many cases, TetR proteins appear to be capable of binding a diverse set of ligands that 
correspond to the multiple substrates of linked RND efflux systems (206). The vast majority of 
reported TetR family regulators function as repressors that bind the promoter region and repress 
transcription in the absence of bound ligands. In addition to regulating their specific target genes, 
many TetR regulators are also capable of regulating their own expression (206, 208). 
In this work we tested the hypothesis that a TetR family protein regulated the expression 
of the vexAB efflux system. The vexAB locus encoded a linked gene, named vexR, which had 
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homology to TetR-family regulators. The uncharacterized vexR gene was the first gene in a three 
gene operon that included vexA and vexB; a genetic organization that was distinct from most 
RND efflux systems (206, 207). Our results confirmed that VexR functioned in the regulation of 
the vexRAB operon, but in a manner that was opposite to most TetR regulators associated with 
other RND efflux systems. Our results showed that VexR functioned as an activator of the 
vexRAB operon, whereas most RND-linked TetR regulators function as repressors. We further 
found that the vexRAB operon was upregulated, in a vexR-dependent manner, in response to the 
efflux status of the cell. This suggested that endogenous metabolic compounds may be native 
substrates for VexAB and can serve as activators of the vexRAB efflux operon. Consistent with 
this hypothesis, vexRAB was upregulated in several metabolic mutants, including tryptophan 
biosynthetic mutants. Further the indole, an intermediate in tryptophan biosynthesis, was found 
to induce vexRAB expression. Taken together our results suggested that VexR functions as a 
positive regulator of the vexRAB operon. We further posit that a native role of the VexAB RND 
efflux system is to remove excess cellular metabolites from within the cell that would otherwise 
accumulate to toxic levels. 
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Table 6. Strains, plasmids and oligonucleotides. 
 
Strain: Genotype: Source: 
 Vibrio cholerae   
 JB804 01 El Tor strain C6706, SmR (231) 
 JB3 01 El Tor strain N16961, SmR (119) 
 JB58 01 El Tor strain N16961 ΔlacZ, SmR (119) 
 JB114 JB58 ΔvexM (123) 
 JB116 JB58 ΔvexH (123) 
 JB432 JB58 ΔvexF (123) 
 JB464 JB58 ΔvexD ΔvexF ΔvexH ΔvexK ΔvexM (123) 
 JB485 JB58 ΔvexB ΔvexD ΔvexF ΔvexH ΔvexK ΔvexM (123) 
 JB495 JB58 ΔvexB (119) 
 JB528 JB58 ΔvexK (123) 
 JB692 JB58 ΔvexD   (119) 
 JB694 JB58 ΔvexB ΔvexD  (119) 
 JB718 JB58 ΔvexR ΔvexD This study 
 XBV218 JB58 ΔvexR This study 
 XBV220 JB58 ΔvexR ΔvexB ΔvexD ΔvexF ΔvexH ΔvexK ΔvexM This study 
Escherichia coli 
 EC100Dpir+ F- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80dlacZΔM15 ΔlacX74 recA1 
endA1 araD139 Δ(ara, leu)7697 galU galK λ- rpsL (SmR) nupG pir+ 
Epicentre 
 SM10λpir   thi-1 thr leu tonA lacY supE recA::RP4-2-4-Tc::Mu KmR (λ pirR6K) (240) 
 ER2566 F- glnV44(AS) galK2(Oc) rpsL704(strR) xylA5 mtl-1 argE3(Oc) thiE1 
tfr-3 λ DE3 = λ sBamHIo ∆EcoRI-B int::(lacI::PlacUV5::T7 gene1) 
i21 ∆nin5 
New 
England 
BioLabs 
Plasmids: Description:  
 pBAD18 Expression plasmid, CbR, pBR322 origin of  replication (264) 
 pCM10 Vector for construction of luxCDABE transcriptional fusions, KmR, 
ori101 
(286) 
 pDT1076 pCM10 containing the vexR promoter region from N16961 This study 
 pDT1146 pMMB66EH::vexR This study 
 pDT1777 pDT1076 with Cm-mark cassette inserted into the vector, CmR This study 
 pJB703 pBAD18::vexR This study 
 pMAL-c2 Expression plasmid for fusion of proteins to MBP and cytoplasmic 
expression, CbR, pBR322 origin of replication          
New 
England 
BioLabs 
 pMMB66EH Expression plasmid, CbR, oriV/T (287) 
 pSC137 Vector for transposon mutagenesis of bacteria, CmR,oriR6K  
 pSS35 pMAL-c2::vexR This study 
 pTL61T Vector for construction of lacZ transcriptional fusions, CbR, oriRK2 (9) 
 pWM91 Suicide plasmid vector used for allelic exchange, CbR, oriR6K/fl  (282) 
 pWM91:: ∆vexR pWM91::∆vexR This study 
 pXB233 pTL61T containing the vexR promoter region from N16961 This study 
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Table 7. (continued) 
 
 
 
4.2 RESULTS 
4.2.1 Genetic organization of the vexRAB operon. 
In many Gram negative bacteria the RND efflux systems encode a linked TetR family regulatory 
protein that functions as a repressor of the linked RND efflux system. The V. cholerae genome 
encodes six RND efflux systems; among these six, only the VexAB RND system contained a 
linked gene vexR (VC0166) which encoded a putative TetR-family regulator. The vexR gene was  
Strain: Genotype: Source: 
Oligonucleotides: DNA sequence (5’ – 3’)::  
 166b-F-XhoI AACTCGAGGCAGAGAAATGTGATGT 
 166b-R-XbaI AATCTAGAGCCAAACAGCAGGATCG 
 166c-F-XhoI TTCTCGAGGGGTCCGGAGACGTACT 
 166c-R-XbaI CGTCTAGAGGAGCTGTTTATCGCCG 
 Biotin GCGGGAGTCGGCAGCG 
 MCS4.VexA.R CCGGATCCCATTCTGGTGCGAACTCCAAATTAGTGTTG 
 VC0166-SacI-F CTGAGCTCAAGGGTTCATATGCA 
 VC0166-XbaI-R TTTCTAGATTAGTGTTGAGTAATTGCA 
 VC0166-F1 AAAGAGCTCATTTGCAGAGAAATGTG 
 VC0166-F2 TTATCGCGGCGGGATGCAATTACTCA 
 VC0166-R1 AATCTAGACACTTTTTCATTCTGGTG 
 VC0166-R2 ATTGCATCCCGCCGCGATAAGGATTT 
 VC0166-F-pMAL-
SmaI 
GGCCCGGGTTGCAGAGAAATGTGATGTCTGAAATAGTG 
 
VC0166-R-pMal-
EcoR1 GGAATTCTTAGTGTTGAGTAATTGCATCC 
 vexR-F1 GCGGGAGTCGGCAGCGATAATAATCCGCTCACCGAG 
 vexR-R1 GCGGGAGTCGGCAGCGCCCCTGTTTTGCAATACACTTG 
 vexR-F2 GCGGGAGTCGGCAGCGTGCAAAACAGGGGGTATTAG 
 vexR-R2 GCGGGAGTCGGCAGCGGCCGTACACTATTTCAGACA 
 XWL-BRL-F CGCAGGGTTTTCCCAGTCACGAC 
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Figure 16. Genetic organization of RND efflux operons.  
(A) Schematic of the V. lerae vexRAB operon. (B) Schematic of the E. coli acrR-acrAB locus. Genes encoding a 
TetR-family (white), membrane fusion family (grey), and RND-family (black) proteins are shown. Putative 
promoters for each respective operon are indicated by the thin black arrows. 
 
 
present as the first gene in the vexRAB operon (Figure 16A). Relative to most other RND efflux 
systems, the genetic arrangement of vexR within the vexRAB operon is unusual. In most RND 
efflux systems that encode a linked TetR regulator, the regulatory gene is expressed from a 
divergently expressed promoter that is upstream of and overlaps with the RND efflux system 
promoter. This arrangement is demonstrated by the archetypical acrAB RND efflux system in E. 
coli where acrR is encoded upstream and divergently from the acrAB efflux system (Figure 
16B). The AcrR protein functions to regulate the expression of the acrAB RND system in 
response to its antimicrobial substrates while also regulating its own expression (288). 
4.2.2 Expression of vexRAB is induced in response to VexAB efflux substrates. 
The role of the RND efflux pumps is to extrude their substrates out of the cell. As such, their 
expression is typically regulated by a feedback loop in response to the presence of their efflux  
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Figure 17. Effect of VexAB efflux substrates on vexRAB expression. 
V. cholerae strain N16961 containing pXB233 (vexRAB-lacZ) was grown under AKI conditions for 5 h with the 
indicated concentrations of (A) erythromycin or (B) deoxycholate. Data is the mean ± SD of three independent 
experiments. Statistical significance was determined relative to the media control by one-way ANOVA with 
Dunnet’s post-hoc test. *=P<0.05. 
 
 
substrates. Since bile salts were shown to be major substrates of VexAB (119, 123), we 
hypothesized that vexRAB expression may be regulated in response to bile salts. To test this 
hypothesis we cultured V. cholerae under virulence gene inducing conditions in AKI broth 
containing sub-lethal concentrations of deoxycholate and measured vexRAB expression using a 
vexRAB-lacZ reporter. We also included erythromycin, an antibiotic that is a substrate of 
VexAB. The results of these experiments showed a concentration-dependent induction of 
vexRAB expression in response to both erythromycin (Figure 17A) and deoxycholate (Figure 
17B). Deoxycholate at 0.2% resulted in a 2-fold increase in vexRAB expression while the 
presence of erythromycin at 0.2 µg/mL resulted in a nearly 3-fold increase in vexRAB 
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expression. Based on these results we concluded that the vexRAB operon was regulated in 
response to its efflux substrates. 
4.2.3 VexR is required for expression of the vexRAB operon. 
The finding that vexRAB expression was induced in response to VexAB efflux substrates 
indicated the possibility that the vexRAB system was regulated in a fashion that was similar to 
other RND efflux systems. Given that most TetR-family regulators function as repressors in the 
absence of their efflux substrates, we hypothesized that VexR would function to repress vexRAB 
expression. If this was true, then deletion of vexR should result in increased vexRAB expression. 
We therefore compared vexRAB-lacZ expression in WT and an isogenic ∆vexR mutant strain. 
The strains were grown in LB broth to an OD600 of 0.8 when vexRAB-lacZ expression was 
quantified. The results showed that vexRAB expression was significantly decreased in the ∆vexR 
strain relative to WT (Figure 18A). This finding was opposite to what was expected if VexR 
functioned as a repressor and suggested that VexR is a positive regulator of the vexRAB operon.  
Since vexRAB expression was induced in response to VexAB substrates, we examined whether 
the substrate-dependent induction of vexRAB was contingent on the presence of vexR. We chose 
to focus on deoxycholate as an inducer because it is a major substrate of VexAB and the most 
biologically relevant compound to V. cholerae pathogenesis. Growth of WT in the presence of 
0.2% deoxycholate resulted in a ~5.5-fold increase in vexRAB-lacZ expression (Figure 18A); 
which was greater than the 2-fold increase that was observed under AKI growth conditions 
(Figure 17A). Deletion of vexR largely abolished the deoxycholate-dependent induction of 
vexRAB expression. This result further supported the conclusion that vexR is required for vexRAB 
expression. While VexR appears to be required for robust vexRAB expression, we observed that 
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the presence of deoxycholate still induced vexRAB expression by ~2-fold in the ∆vexR strain 
relative to growth in LB broth, although it was still greatly reduced compared to WT grown in 
LB broth (Figure 18A). This suggests that there may be other factors involved in regulating 
vexRAB expression. Taken together these findings strongly suggested that VexR functioned as a 
positive regulator of the vexRAB operon. 
The above results were surprising since most TetR family regulators function as 
repressors. We therefore sought to further confirm that VexR was an activator of the vexRAB 
operon. If VexR was an activator, we hypothesized that recombinant vexR expression should 
activate expression of the vexRAB promoter in E. coli. We therefore co-transformed pDT1076 
(vexRAB-lux) into E. coli with pBAD18 (empty vector control) or pBAD18::vexR. The resulting 
E. coli strains were then grown in LB broth plus or minus 0.2% arabinose (to induce vexR 
expression from the arabinose inducible promoter in pBAD18) and luminescence production was 
measured at zero, one and two hours. The results showed that the empty vector control (i.e. 
pBAD18) did not affect vexRAB expression (Figure 18B). This indicated that neither pBAD18, 
nor arabinose, affected the expression of the vexRAB-lux reporter. In contrast, there was a 
marked increase in luminescence production in the strain containing pBAD18::vexR. The 
presence of pBAD18::vexR, even in the absence of arabinose, was sufficient to induce vexRAB 
expression as evidenced by the increase in luminescence production at one and two hours (Figure 
18B). This result indicated that the vexRAB promoter is very sensitive to VexR levels. The 
addition of arabinose to the AKI broth further increased vexRAB expression. This result 
suggested that VexR can activate expression of the vexRAB promoter in the absence of additional 
V. cholerae proteins. Based on these results, plus the results presented in Figure 18A, we 
concluded that VexR functioned as a positive regulator of the vexRAB operon. 
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Figure 18. VexR is required for vexRAB expression. 
(A) N16961 WT and ∆vexR containing pXB233 (vexRAB-lacZ) were grown in LB broth. At 3.5h deoxycholate 
(DOC) was added to a final concentration of 0.2% and the cultures were incubated for an additional 30 min before 
vexRAB expression was determined as described in the methods. Data is the mean of three independent experiments 
± SD. Significance was determine by one-way ANOVA with Tukey-Kramer multiple comparison test. Unless 
otherwise indicated, asterisks are significance relative to WT (*p<0.05; **p<0.001). (B) E. coli containing 
pDT1076(vexRAB-lux) and either  pJB703(pBAD18::vexR) or pBAD18 was grown in LB broth with or without 
0.2% arabinose and bioluminescence was assayed at 0h,1h, and 2h. Error bars indicate the mean ± SD of three 
replicates. The results are representative of three independent experiments. (C) Gel mobility shift assay showing the 
binding of VexR to the vexRAB promoter. The promoter was split into two fragments (vexR1) -129 to -46 and 
(vexR2) -59 to +21 relative to the ATG start site. Biotin labeled DNA (2.5nM) from vexR1 (lane 1-4) or vexR2 (lane 
5-12) fragments was incubated with either purified VexR-MBP or MBP as indicated at 0 nM (lane 1), 25 nM (lane 
2), 100 nM (lane 3), or 250 nM (lane 4) prior to electrophoresis. Specific binding reaction, detection, and 
visualization are discussed in the Material and Methods. 
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4.2.4 VexR binds to the vexRAB promoter directly. 
The above experiments suggested that VexR may act directly at the vexRAB promoter. To 
investigate whether this was true we performed gel mobility shift assays using VexR-MBP with 
the vexRAB promoter. The vexRAB promoter was split into two fragments that covered from -129 
to -46 (vexR1) and -59 to +21 (vexR2) relative to the ATG start site (Figure 18C). The results of 
the gel shift assays show that purified VexR-MBP was able to shift the vexR2 promoter 
fragment, but not the vexR1 promoter fragment. Incubation of the vexR2 fragment with MBP did 
not result in a shift confirming that the results were due to VexR (Figure 18C). These results 
validated that VexR directly binds to the vexRAB promoter and supports the conclusion that 
VexR directly regulates the expression of the vexRAB operon. 
4.2.5 VexR contributes to antimicrobial resistance. 
If VexR was a positive regulator of the vexRAB operon, we hypothesized that the deletion of 
vexR should increase V. cholerae susceptibility to antimicrobial compounds that are substrates of 
VexAB. To test this we determined the MIC of deoxycholate, erythromycin, and Triton X-100 
for WT and the ∆vexR mutant. While deoxycholate, erythromycin, and Triton X-100 are all 
substrates of VexAB, other RND efflux systems possess redundant activity for efflux of 
deoxycholate and Triton X-100. The results showed a 2.7-fold decrease in the erythromycin MIC 
in the ∆vexR mutant (Table 7). In contrast, there was no change in the susceptibility of the ∆vexR 
mutant to deoxycholate or Triton X-100. These results contrast the resistance profile of a ∆vexB 
mutant. For example, the erythromycin MIC for the vexR mutant was 1.65 µg/mL compared to 
0.07 µg/mL for the vexB mutant. Likewise, the Triton X-100 MIC for the vexR mutant was >3% 
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while the vexB mutant MIC was 0.0017%. This indicated that the vexR mutant exhibited a 
phenotype that was intermediate between WT and the ∆vexB strain. Since VexB is the only RND 
efflux pump that contributes to erythromycin resistance (119), these results indicate that vexAB is 
still expressed in the ∆vexR mutant, albeit at a lower level than in WT. This residual expression 
is consistent with the data above that deoxycholate still activated vexRAB expression, albeit to a 
low level, in the vexR deletion mutant (Figure 18A). 
The fact that vexR deletion did not affect deoxycholate resistance was expected as 
previous studies have shown that the VexCD RND efflux system was redundant with VexAB for 
bile salt resistance (119, 267). Because of overlapping specificity for deoxycholate, mutation of 
both vexB and vexD are required to produce a bile salt hypersensitive phenotype. Therefore, to 
address whether vexR contributed to deoxycholate resistance we examined the effect of vexR 
deletion in a ∆vexD background. The results showed that deletion of vexR in a ∆vexD 
background reduced the deoxycholate MIC to 0.019%; a MIC that was 2.7-fold greater than the  
 
 
Table 7. Antimicrobial susceptibility of vexR mutants. 
 
  MIC  (s.d.)1 
Strain Genotype Ery (µg/mL) Doc (%) TX-100 (%) 
JB58 WT 4.40 (2.1) >3 (0) >3 (0) 
XBV218 ∆vexR 1.65 (0.9)2,3 >3 (0) >3 (0) 
JB495 ∆vexB 0.07 (0.005)2 >3 (0) 0.0017 (0.0011)2 
JB692 ∆vexD ND >3 (0) ND 
JB718 ∆vexR∆vexD ND 0.020 (0.001)2,4 ND 
JB694 ∆vexB∆vexD ND 0.007 (0.003)2 ND 
(1)Minimum Inhibitory Concentration (MIC) for erythromycin (Ery), deoxycholate (Doc), and Triton X-100 (TX-
100) for the indicated N16961 strains with standard deviations in parenthesis. (2) P< 0.05 relative to WT. (3) P<0.05 
relative to ∆vexB. (4) P<0.05 relative to ∆vexBD. ND=not determined. 
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deoxycholate MIC observed with the ∆vexB∆vexD mutant (Table 7). The intermediate resistance 
phenotype of the ∆vexR∆vexD mutant (relative to the ∆vexB∆vexD mutant) was similar to the 
erythromycin results and further supported the conclusion that the vexRAB efflux system is 
expressed at a reduced level in the vexR mutant.  
 VexAB is the primary RND efflux system involved in Triton X-100 resistance (119). 
Consistent with this, a >1,700-fold increase in Triton X-100 susceptibility was observed in a 
∆vexB mutant (Table 7). However, deletion of vexR did not affect Triton X-100 susceptibility 
(Table 7). This suggests that the low-level vexAB expression in the vexR mutant was sufficient to 
provide WT-level Triton X-100 resistance. Alternatively, it is possible that deletion of vexR 
resulted in the induction of other resistance traits that contributed to Triton X-100 resistance and 
thus compensated for the reduction in vexRAB expression in the vexR mutant. 
 The collective MIC data indicated that VexR was required for high-level resistance to 
erythromycin and deoxycholate, presumably by activating transcription of the vexRAB operon. 
When vexR was deleted, the contribution of VexAB to antimicrobial resistance was significantly 
reduced, but not to a level that was equal to a vexB mutant. This latter finding suggested that 
vexAB expression was not solely dependent on VexR. 
4.2.6 Overexpression of vexR enhances resistance to deoxycholate. 
We hypothesized that if vexR was required for vexRAB upregulation and antimicrobial resistance, 
then vexR overexpression should complement a ∆vexR mutant for growth in the presence of 
deoxycholate and erythromycin. We tested this hypothesis by determining the deoxycholate and 
erythromycin MIC for WT, ∆vexR and ∆vexR∆vexD strains that expressed vexR from the 
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arabinose promoter in pBAD18. In these experiments the respective strains containing pBAD18 
or pBAD18::vexR were grown on antimicrobial gradient agar plates that contained a range of 
different arabinose concentrations. However, we were unable to identify conditions where 
ectopic vexR expression complemented the tested mutants for deoxycholate or erythromycin 
resistance (data not shown). We considered that this result could have been an artifact of the 
pBAD18 expression system, and therefore we cloned vexR into the IPTG-inducible pMMB66EH 
expression vector and repeated the complementation experiments and obtained identical results. 
The reason that we were unable to transcomplement the vexR mutant is not clear. The inability to 
complement the vexR deletion likely did not result from the introduction of a secondary mutation 
during the construction of the vexR mutant since DNA sequencing confirmed the integrity of the 
vexR deletion construct (i.e. pWM91::∆vexR) and the vexRAB locus in the vexR deletion strain. 
Also, the finding that the vexR mutant did not exhibit a defect in Triton X-100 resistance 
confirms that the vexR mutant produced a functional VexAB efflux system. Further, the ∆vexR 
and ∆vexR∆vexD mutants were independently created from different parental strains, making it 
unlikely that the complementation defect was due to an unlinked spontaneous mutation. The lack 
of complementation was also not due to mutations introduced into the complementing plasmids 
as we also confirmed the DNA sequence of both complementing plasmids. This latter conclusion 
is further supported by the observation that the presence of pBAD18::vexR activated vexRAB-
lacZ expression in E. coli (Figure 18B). Based on these results, we speculated that the vexRAB 
activation via vexR may be dependent upon specific physiological conditions or alternatively it is 
possible that activation could be dependent on DNA sequences that are internal to vexR.  
Since the vexR deletion mutant could not be complemented by ectopic vexR expression, 
we sought another method to confirm that VexR contributed to antimicrobial resistance. We  
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Figure 19. VexR contributes to V. cholerae survival under inhibitory antimicrobial conditions. 
V. cholerae N16961 WT (A & B) and ∆vexB (C & D) containing pJB703(pBAD18::vexR) or pBAD18 were grown 
in triplicate wells of microtiter plates containing LB broth (A & C) or LB broth plus 0.015% deoxycholate (B & D). 
Expression of vexR was induced by adding 0.1% arabinose to the growth media as indicated. Cell growth was 
monitored as the change in the optical density at 600 nm and plotted versus time as the mean ±SEM. The results are 
representative of three independent experiments. 
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hypothesized that if vexR was indeed an activator of the vexRAB operon, then ectopic expression 
of vexR in WT should result in enhanced growth in the presence of sub-lethal concentrations of 
VexAB substrates. To test this hypothesis we performed growth curves for WT(pBAD18::vexR) 
and WT(pBAD18) in LB broth containing a sub-lethal concentration of deoxycholate. The 
results of this analysis showed that in the absence of deoxycholate, WT(pBAD18::vexR) 
replicated at a rate that was similar to WT(pBAD18) through six hours (Figure 19A). Thereafter 
WT(pBAD18) growth continued to increase whereas the strain bearing pBAD18::vexR plateaued 
and the cell density slightly decline through 12 hours. This indicated that overexpression of vexR 
during growth in LB broth was detrimental. We speculate that this is a result of increased vexAB 
expression which has been suggested to be growth inhibitory under non-selective conditions 
(208, 289). When the same strains were cultured in LB broth containing deoxycholate, the 
growth pattern reversed. In the presence of deoxycholate WT(pBAD18::vexR) exhibited a 
significant growth advantage over the empty vector control even in the absence of arabinose 
(Figure 19B). The addition of arabinose further enhanced growth of WT(pBAD18::vexR) relative 
to the same culture grown in the absence of arabinose (Figure 19C). The ectopic expression 
results were reminiscent of the findings observed for vexR activation of vexRAB in E. coli 
(Figure 18B) where vexR enhanced vexRAB-lux expression even in the absence of arabinose, and 
further enhanced vexRAB-lux expression with the addition of arabinose. These results provide 
additional support for the hypothesis that VexR is a positive activator of the vexRAB operon.  
 The above results suggested that ectopic vexR expression enhanced deoxycholate 
resistance, but did not allow us to discriminate if the resistance phenotype was mediated by 
VexAB or some other factor. If enhanced growth was due to VexR activation of VexAB 
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production, then deletion of vexB should alleviate the vexR-dependent growth enhancement in 
the presence of deoxycholate. We therefore repeated the above growth experiments in a vexB 
deletion strain. The results showed that the growth of the ∆vexB(pBAD18) control strain was 
slightly attenuated relative to ∆vexB(pBAD18::vexR) during growth in LB (Figure 19C). This 
suggests that vexR may regulate the expression of other genes, in addition to vexAB, that impart a 
growth advantage in LB broth. The growth of the ∆vexB strains was significantly inhibited in the 
presence of deoxycholate (Figure 19D). Unlike the WT strains, vexR expression did not 
significantly affect cell growth (Figure 19D). This confirmed that the enhanced growth observed 
with vexR overexpression in WT grown in the presence of deoxycholate resulted from vexR-
dependent activation of the vexRAB operon (Figure 19B). Taken together the collective results 
strongly support the idea that the overexpression of vexR provided a growth advantage to V. 
cholerae in the presence of deoxycholate via activating production of the VexAB RND efflux 
system.  
4.2.7 VexR contribution to CT production and murine colonization. 
VexAB has been shown to contribute to virulence factor production and to murine colonization 
(123, 176). Our work here demonstrated that VexR was a positive regulator of vexRAB (Figure 
18) and was induced by deoxycholate (Figure 17B). This suggested the possibility that bile acids 
could induce VexR production in vivo and thus affect virulence factor production and intestinal 
colonization. To test if vexR affected virulence, we quantified CT production in WT and ∆vexR. 
We also tested JB485 (which lacks all six RND efflux pumps) and its isogenic vexR deletion 
mutant for alterations in CT production. The rationale for testing JB485 is based on studies  
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Figure 20. Effect of vexR on CT production and murine colonization. 
(A) The indicated N16961 strains were grown under AKI growth conditions. Culture aliquots were collected 
following overnight growth and CT production was quantified using a GM1 ELISA. One-way ANOVA with Tukey-
Kramer multiple comparisons was used to determine significance. *P=<0.01. (B & C) Competition assays to assess 
the role of vexR in intestinal colonization. (B) Infant mouse colonization competition assay. The competitive index 
was calculated as the ratio of ∆vexR to WT recovered from the small intestine, corrected for the ratio of ∆vexR to 
WT that was present in the inoculum. Each symbol represents one mouse. Mean and standard deviation are indicated 
by horizontal bars. (C) In vitro growth competition assay. The in vitro growth competitive index was calculated as 
described for the in vitro assay using cultures grown in LB broth. 
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showing that JB485 was attenuated for CT and TCP production and overexpressed vexR (123, 
176); this suggested a possible link between VexR and virulence factor production (204). The 
results of the analysis showed that JB485 had a 65% reduction in CT production compared to 
WT, which corresponded to previous studies (123, 176). CT production in JB485∆vexR was not 
significantly different from JB485 (Figure 20A). WT and ∆vexR were examined in the infant 
mouse colonization competition model to determine if vexR affected colonization. The results 
showed that the ∆vexR mutant competed equally with WT (Figure 20B). Taken together these 
results indicate that vexR does not significantly affect V. cholerae virulence factor production or 
intestinal colonization. 
4.2.8 Deletion of the RND efflux systems induces vexRAB expression. 
Recent studies have suggested that the RND systems have evolved to remove toxic metabolic 
byproducts from within the cell (178, 198, 199). If this was true, we hypothesized that the 
accumulation of metabolites in RND negative cells would activate the expression of vexRAB. 
The observation that vexRAB was upregulated in an efflux negative strain (JB485) was consistent 
with this hypothesis (204). To further expand upon this idea and to determine whether VexR 
functioned in response to the efflux status of the cell we introduced a vexRAB-lacZ reporter in 
WT, JB485 and JB485∆vexR. The resulting strains were then cultured under AKI conditions for 
5 h when vexRAB expression was assessed (Figure 19). The results showed a ~4.5-fold increase 
in vexRAB expression in JB485 confirming previous results (204). Deletion of vexR in JB485 
reduced vexRAB expression to near background levels which suggested that the increase in 
vexRAB expression in JB485 was dependent upon vexR (Figure 19). 
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Figure 21. Expression of vexRAB in V. cholerae RND efflux mutants. 
The indicated N16961 strains containing pXB233 (vexRAB-lacZ) were grown for 5 h under AKI conditions when 
vexRAB expression was quantified as described in the methods. Error bars indicate ± SD of three independent 
experiments. One-way ANOVA with Dunnet’s post-hoc test was used to determine significant differences relative to 
WT. *=P<0.05; **=P<0.01; ***P=<0.0001. 
 
 
We next tested whether increased vexRAB expression in JB485 was due to loss of vexB or 
a result of the deletion of all six RND efflux systems. We first quantified vexRAB expression in a 
∆vexB mutant. The results showed that vexRAB expression increased in the vexB mutant (~3-
fold), but to a level that was less than observed in JB485 (Figure 19). This suggested that at least 
one of the other RND systems can partially compensate for the loss of vexB. The expression of 
vexRAB in a ∆vexDFHKM (vexB+) was not significantly different from WT. This latter finding 
was consistent with previous work showing that vexB, due to its broad substrate specificity, was 
able to complement for the loss of the other five RND efflux systems (123, 176). Taken together 
these results indicate that vexRAB expression was responsive to the RND efflux status of the cell 
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and that deletion of vexB resulted in vexRAB expression being elevated, likely due to 
accumulation of one of its intracellular substrates. The higher level of vexRAB expression in 
JB485 relative to the vexB mutant indicates that one or more of the other RND efflux systems are 
able to efflux the inducting factor(s). Based on these results we concluded that V. cholerae 
compensates for reductions in RND efflux activity by upregulating vexRAB expression. Exactly 
how V. cholerae senses efflux activity was unclear, but we speculated this resulted from the 
intracellular accumulation of natural substrates of the RND efflux systems in the absence of 
RND efflux activity. Such compounds then presumably function as positive effectors of VexR. 
4.2.9 The expression of vexRAB is altered in metabolic mutants. 
We tested whether V. cholerae upregulated vexRAB expression in response to accumulation of 
metabolic byproducts. Our approach for these experiments was based on the assumption that the 
mutation of metabolic genes would disrupt biosynthetic pathways and result in the intracellular 
accumulation of chemical intermediates of the targeted biochemical pathway which would then 
activate vexRAB expression. To conduct these studies we obtained a number of metabolic 
mutants from a defined transposon mutant library that was constructed in V. cholerae El Tor 
strain C6706 (290). We selected mutants that targeted a number of different metabolic pathways 
including some that have been shown to affect  E. coli acrAB expression (178). This included 
mutants that affected purine metabolism, cysteine metabolism, sulfur metabolism, vibriobactin 
biosynthesis, glycolysis, gluconeogenesis, pyruvate metabolism, amino acid metabolism, and the 
citric acid cycle (Table 8). 
The metabolic mutants were transformed with pDT1777 (vexRAB-lux) and cultured under 
AKI conditions for five hours when vexRAB expression was quantified. While we were most  
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Table 8. V. cholerae C6706 mutants used in this study. 
 
ORF # (gene) Mutant ID1 NR well1 
VC0027(ilvA) EC8508 13-C5 
VC0051(purK) EC20412 29-B12 
VC0052(purE) EC1769 4-D2 
VC0164(vexB) EC23411 32-G3 
VC0374(pgi) EC24273 33-B8 
VC0384(cysJ) EC14462 21-E9 
VC0385(cysI) EC5082 9-D4 
VC0386(cysH) EC9587 14-C9 
VC0537(cysM) EC19978 34-C1 
VC0767(guaB) EC11960 18-E4 
VC0774 EC4709 8-B6 
VC0819(aldA-1) EC11507 17-H6 
VC0923 EC8862 14-B2 
VC0968(cysK) EC11848 18-B2 
VC1061 EC10232 15-B8 
VC1169(trpA) EC5818 10-F1 
VC1170(trpB) EC24412 33-H10 
VC1171(trpC/F) EC12331 19-A2 
VC1172(trpD) EC11883 17-E12 
VC1173(trpG) EC11883 16-G12 
VC1174(trpE) EC11131 34-C5 
VC1579 EC1872 4-G4 
VC1732(aroA) EC389 01-G8 
VC1819(aldA-2) EC14803 22-H2 
VC2013(ptsG) EC12803 19-D7 
VC2092(gltA) EC7541 11-A10 
VC2209(vibF) EC18511 27-D7 
VC2348(deoB) EC10553 16-A4 
VC2362(thrC) EC24541 33-G6 
VC2363(thrB) EC19558 28-H7 
VC2364(thrA) EC13310 20-B1 
VC2558(cysC) EC1335 03-G4 
VC2559(cysN) EC13560 20-H6 
VC2560(cysD) EC21282 30-C10 
VC2649(cysE) EC9914 15-C5 
VCA0013(malP) EC20144 29-G9 
VCA0014(malQ) EC2460 05-C2 
VCA0765(ybjU) EC4499 08-B3 
VCA0886(kbl) EC9834 15-H4 
VCA0896(zwf) EC3123 6-H3 
VCA0987(ppsA) EC14445 21-D11 
VCA1046(mtlD) EC21873 31-C6 
1. The C6706 mutants were obtained from: Cameron DE, Urbach JM, 
Mekalanos JJ. 2008. A defined transposon mutant library and its use in 
identifying motility genes in Vibrio cholerae. PNAS 105:8736-8741. 
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Table 9. Expression of vexRAB in C6706 metabolic mutants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mutated ORF 
(Gene Name): Gene Product: 
RLU/OD600 
(±SD)*10-5 
Fold 
change1 
C6706 (WT) Wild type parental strain 16.8(3.8) ----- 
VC0027(ilvA) threonine dehydratase 26.9(6.7)*** 1.6 
VC0051(purK) phosphoribosylaminoimidazole carboxylase 
ATPase subunit 
21.0(2.7) 1.3 
VC0052(purE) phosphoribosylaminoimidazole carboxylase 
catalytic subunit 
14.4(2.3) 0.9 
VC0164(vexB) RND multidrug efflux pump 35.2(6.6)*** 2.1 
VC0374(pgi) glucose-6-phosphate isomerase 18.4(0.6) 1.1 
VC0384(cysJ) sulfite reductase 19.5(6.4) 1.2 
VC0385(cysI) sulfite reductase subunit beta 10.0(0.2)*** 0.6 
VC0386(cysH) phosphoadenosine phosphosulfate reductase 17.4(2.0) 1.0 
VC0537(cysM) cysteine synthase B 12.7(5.1) 0.8 
VC0767(guaB) inosine 5'-monophosphate dehydrogenase 13.0(2.0) 0.8 
VC0774 2,3-dihydroxybenzoate-2,3-dehydrogenase 10.4(1.7)*** 0.6 
VC0819(aldA-1) aldehyde dehydrogenase 9.6(1.3)*** 0.6 
VC0923 serine acetyltransferase-related protein 9.8(0.9)*** 0.6 
VC0968(cysK) cysteine synthase A 9.4(0.5)*** 0.6 
VC1061 cysteine synthase 5.6(0.8)*** 0.3 
VC1172(trpD) anthranilate phosphoribosyltransferase 37.3(0.9)*** 2.2 
VC1579(almE) enterobactin synthetase component F-related 
protein 
34.6(1.3)*** 2.1 
VC1732(aroA) 3-phosphoshikimate 1-
carboxyvinyltransferase 
10.3(0.5)*** 0.6 
VC1819(aldA-2) aldehyde dehydrogenase 3.3(1.3)*** 0.2 
VC2013(ptsG) PTS system glucose-specific transporter 
subunits IIBC 
12.0(0.7)* 0.7 
VC2092(gltA) citrate synthase 5.9(0.3)*** 0.4 
VC2209(vibF) nonribosomal peptide synthetase VibF 24.6(1.8)*** 1.5 
VC2348(deoB) phosphopentomutase 7.7(3.0)*** 0. 5 
VC2362(thrC) threonine synthase 4.1(0.5)*** 0.3 
VC2363(thrB) homoserine kinase 6.3(3.9)*** 0.4 
VC2364(thrA) aspartokinase I/homoserine dehydrogenase 3.6(0.2)*** 0.2 
VC2558(cysC) adenylylsulfate kinase 11.5(9.2)*** 0.7 
VC2559(cysN) sulfate adenylate transferase, subunit 1 2.8(0.5)*** 0.2 
VC2560(cysD) sulfate adenylyltransferase subunit 2 15.5(2.9) 0.9 
VC2649(cysE) serine acetyltransferase 10.1(0.1)** 0.6 
VCA0013(malP) maltodextrin phosphorylase 23.9(0.6)** 1.42 
VCA0014(malQ) 4-alpha-glucanotransferase 20.5(1.7) 1.2 
VCA0765(ybjU) L-allo-threonine aldolase 3.7(0.3)*** 0. 2 
VCA0886(kbl) 2-amino-3-ketobutyrate coenzyme A ligase 5.3(4.0)*** 0.3 
VCA0896(zwf) glucose-6-phosphate 1-dehydrogenase 11.7(0.6) 0.7 
VCA0987(ppsA) phosphoenolpyruvate synthase 8.1(4.0)*** 0.5 
VCA1046(mtlD) mannitol-1-phosphate 5-dehydrogenase 36.4(0.7)*** 2.2 
Indicated C6706 strains bearing a vexRAB-lux reporter were grown in 96-well plates under AKI 
conditions for 5h before luminescence (RLU) and OD600 were measured. 1Fold change=(mutant 
RLU/OD600)/(WT RLU/OD600). Two-way ANOVA with Dunnet’s post-hoc test to determine 
statistical significance relative to WT. *=P<0.01; **=P<0.001; ***=P<0.0001. 
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interested in the mutants that activated vexRAB expression, we noted several mutations reduced 
vexRAB expression. Based on our hypothesis that vexRAB expression is modulated by 
accumulation of metabolites, this would suggest that reduced vexRAB expression is due to loss of 
down-stream activators. However, we cannot exclude that the observed reduction of vexRAB 
expression was an artifact resulting from cellular byproducts inhibiting the luciferase activity of 
the reporter and not a true representation of the vexRAB promoter (291). The analysis identified 
three mutants (VC1172, VC1579, and VCA1046) which resulted in a >2-fold increase in vexRAB 
expression (Table 9). VC1172 encodes TrpD which functions in tryptophan biosynthesis; 
VC1579 encodes AlmE which is a lipid A modification enzyme (292); and VCA1046 encodes 
mannitol-1-phosphate 5-dehydrogenase and is involved in mannitol metabolism. These results 
confirmed that vexRAB expression was upregulated in response to interruption of at least three 
metabolic pathways. To further investigate this phenomenon we focused on the tryptophan 
biosynthesis due to the availability of mutants and two chemical intermediates in the tryptophan 
biosynthetic pathway. 
4.2.10 Disruption of the tryptophan biosynthetic pathway affects vexRAB expression. 
Mutation of trpD (VC1172) resulted in the strongest induction of vexRAB expression suggesting 
that metabolic intermediates of tryptophan biosynthesis may function as inducers of the vexRAB 
operon. To investigate this we examined vexRAB expression in six different tryptophan 
biosynthetic mutants (Figure 22A). The results showed that vexRAB expression increased 3-fold 
in the trpB mutant, and ~2-fold in the trpA and trpD mutants (Figure 22B). Mutation of trpB 
(VC1170) is predicted to result in indole accumulation while mutation of trpA (VC1169) and 
trpD (VC1172) would result in indole-3-glycerol phosphate and anthranilate accumulation,  
 107 
 
 
Figure 22. Indole activates vexRAB expression.  
(A) Schematic of the V. cholerae tryptophan biosynthetic pathway. (B) The indicated C6706 strains bearing 
pDT1777 (vexRAB-lux) were grown in 96-well plates under AKI conditions for 5 h when luminescence (RLU) and 
OD600 were measured. Data is the mean +/- SEM of three independent assays. Two-way Anova with Dunnet’s post-
hoc test compared to WT was used to determine significance. *=P<0.01; **=P<0.0001. (C) V. cholerae N16961 
containing pXB233 (vexRAB-lacZ) was grown with or without indole, L-tryptophan, or anthranillic acid at the 
indicated concentrations under AKI conditions for 5 h before vexRAB expression was determined as described in the 
methods. Bars indicate the mean +/- SD of three independent experiments. One-way ANOVA with Dunnet’s post-
hoc test was used to determine significant changes relative to growth in media alone. *=P<0.001. 
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respectively. This suggested that indole, indole-3-glycerol phosphate and anthranilate could be 
vexRAB inducers.  
If intermediates from tryptophan biosynthesis were functioning as vexRAB inducers, we 
hypothesized that adding these compounds to the growth media would activate vexRAB 
expression. As anthranilate and indole were available from commercial sources, we tested if the 
addition of these compounds affected vexRAB-lacZ expression in WT. The results showed that  
 indole at 1.5 mM increased vexRAB expression by ~1.5 fold (Figure 22C). This finding, 
combined with the observation that vexRAB was induced in the trpB mutant (Figure 22B), 
suggested that indole was a vexRAB activator. The addition of anthranilate or tryptophan did not 
have a significant effect on vexRAB expression (Figure 22C). The significance of this finding is 
unclear, but suggests that exogenous anthranilate does not induce vexRAB expression; we note 
that trpD mutation may have pleiotropic effects on other metabolic pathways which could have 
influenced vexRAB expression. 
4.2.11 Indole is a substrate of the VexAB RND efflux system. 
Indole is an intermediate in the biosynthesis of tryptophan. Indole is also produced by V. 
cholerae as a byproduct of tryptophan degradation and has been shown to function as a signaling 
molecule in biofilm formation (293, 294). At high concentrations indole is toxic, which 
suggested that it may be a substrate for the V. cholerae RND efflux systems. We therefore tested 
if the RND efflux systems contributed to indole resistance by comparing the growth of WT and 
JB485 on indole gradient agar plates. The results showed that the WT MIC was 2.1 mM while 
the JB485 MIC was 1.6 mM (Table 10). This suggested that the V. cholerae RND efflux systems 
contributed to indole resistance. In an effort to determine which RND efflux system contributed  
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Table 10. Minimum inhibitory concentration of indole for RND mutants. 
 
 
 
 
 
 
 
 
 
 
to indole resistance we examined mutants lacking each of the six RND efflux systems pumps 
(i.e. vexB, vexD, vexF, vexH, vexK, vexM). Only the vexB mutant had a small but significant 
decrease in the indole MIC (1.8 mM), which was lower than the MIC exhibited by JB485 (Table 
10). Although small, the change in the vexB MIC was consistent with the idea that indole is a 
substrate of the VexAB RND efflux system. The discrepancy between the vexB and JB485 MICs 
suggest that at least one of the other RND efflux systems function in indole resistance. All 
together this data indicates that indole is a substrate of the RND efflux systems and that indole 
functions as an inducer of the vexRAB operon. 
4.3 DISCUSSION 
VexR is a positive regulator of the vexRAB operon.  
Strain Genotype Indole MIC (s.d)1 
JB58 WT 2.1 (0.1) 
XBV218 ∆vexR 2.0 (0.2) 
JB495 ∆vexB 1.8 (0.2)2 
JB692 ∆vexD 2.0 (0.2) 
JB432 ∆vexF 2.0 (0.1) 
JB116 ∆vexH 2.1 (0.1) 
JB528 ∆vexK 2.1 (0.1) 
JB114 ∆vexM 2.0 (0.1) 
JB485 ∆vexBDFHKM 1.6 (0.1)3 
(1)Minimum Inhibitory Concentration (MIC) of Indole 
(mM) for the indicated N16961 strains. One-way 
ANOVA with Dunnet’s post-hoc test was used to 
determine statistical difference relative to WT. (2) P< 
0.05 relative to WT; (3) P<0.001 relative to WT. 
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The VexAB RND efflux system is the only V. cholerae RND system that is associated with a 
linked TetR family regulator (Figure 16). In contrast to what is observed with most RND loci, 
VexR was encoded as the first gene in the vexRAB operon. Expression of vexRAB was largely 
dependent on VexR as evidenced by the finding that vexR deletion decreased vexRAB expression 
and abolished the substrate-dependent induction of vexRAB expression (Figure 18A). Deletion of 
vexR also resulted in increased susceptibility to antimicrobial compounds that were substrates of 
VexAB (Table 7). These results indicated that VexR functioned as a positive regulator of the 
vexRAB operon. This conclusion was confirmed in subsequent experiments showing that VexR 
bound directly to the vexRAB promoter (Figure 18C), that VexR was able to activate vexRAB 
expression in E. coli (Figure 18B), and that vexR overexpression in V. cholerae resulted in a 
vexB-dependent growth advantage in the presence of sub-lethal concentrations of deoxycholate 
(Figure 19).  
The finding that VexR was a positive regulator was unexpected; to the best of our 
knowledge VexR is the first example of a RND-associated TetR-family regulator that functions 
as an activator. The vast majority of TetR-family regulators behave as transcriptional repressors. 
This finding highlights differences in the regulation of vexRAB relative to its orthologous 
Enterobacteriaceae system (i.e. acrR-acrAB). In E. coli acrR functions as a negative regulator of 
acrAB while global regulatory systems such as the Mar operon function to positively regulate 
acrAB expression in response to antimicrobial exposure (Figure 16) (206, 207). Although V. 
cholerae lacks the Mar operon, VexR appears to function in a similar role as the Mar operon by 
activating vexRAB expression in response to antimicrobial exposure. It is worth noting that the 
vexRAB and vexGH RND efflux systems are also positively regulated by the Cpx system in 
response to membrane stress (204). However, the Cpx system did not affect the expression of the 
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RND efflux systems in response to antimicrobial compounds that were substrates of the RND 
efflux systems (204). This suggests that vexRAB expression is under the influence of multiple 
regulatory systems that respond to distinct stimuli. 
 
Metabolites activate the expression of the vexRAB operon.  
The expression of vexRAB was highly elevated upon loss of RND-mediated efflux in the mutant 
JB485 (Figure 21). This upregulation was abolished when vexR was deleted (Figure 21), 
indicating that VexR positively regulates vexRAB expression in response to the efflux status of 
the cell. These data suggested that in the absence of RND-mediated efflux, a cellular product 
accumulates within the cell thereby inducing vexRAB expression. As we have demonstrated that 
vexRAB is induced by substrates of VexAB (Figure 17), this indicated that induction of vexRAB 
in JB485 was due to the accumulation of an endogenous substrate of the VexAB RND efflux 
system. Based on recent reports in E. coli (178, 198-200), we hypothesized that the accumulating 
compound would be a byproduct of cellular metabolism. The finding that vexRAB expression 
was upregulated in three of the 36 tested metabolic mutants provided evidence to support this 
hypothesis (Table 9). Altogether, this indicates the VexAB RND efflux system plays a role in 
removing excess metabolites from the cell. While vexRAB was induced in three of the metabolic 
mutants, it is also possible that other efflux systems may function in a similar or redundant role 
to remove metabolites from the cell. For example, the E. coli acrEF, yfiK and aaeAB efflux 
systems have been shown to be important for indole, cysteine-cystine, and p-hydroxybenzoate 
export, respectively (295-297). The fact that vexRAB expression in the ∆vexB was lower than 
what was observed in JB485 supports this conclusion that other RND efflux systems function in 
a similar manner (Figure 21). 
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The mutations that activated vexRAB expression disrupted three different metabolic 
pathways. This suggested that multiple metabolites can activate vexRAB expression (Table 9 and 
Figure 22B). The mutation of trpB resulted in the greatest increase in vexRAB expression. Since 
TrpB catalyzes the conversion of indole to tryptophan (Figure 22A), this suggested that indole 
was likely responsible for induction of vexRAB in the trpB mutant (Figure 22). Activation of 
vexRAB expression by exogenous indole supported this conclusion (Figure 22C). In addition, 
both JB485 and the ∆vexB mutant exhibited increased susceptibility to indole. This suggested 
that indole was a substrate for VexAB and likely additional RND efflux systems (Table 10). 
Based on the fact that indole was both an inducer and substrate of vexRAB, we conclude that the 
VexAB efflux system functions to remove indole from within the cell before it reaches 
concentrations that are detrimental to cell growth. Given the broad substrate specificity of the 
VexAB system, combined with the observation that vexRAB was induced in two other metabolic 
mutants; we propose that the function of VexAB in metabolic relief extends beyond indole.  
 
Role of VexR in virulence factor production and colonization. 
Inhibition of RND efflux activity was shown to attenuate virulence factor production in V. 
cholerae by an unknown mechanism (123), but was hypothesized to result from the 
accumulation of small molecules in the RND mutants that inhibited virulence factor production. 
Although our data shows that the RND-associated virulence defect is independent of vexR, we 
speculate that specific metabolites also function to negatively affect V. cholerae virulence factor 
production. Precedence for small molecule inhibition of virulence factor production includes 
virstatin, bile, and fatty acids (reviewed in (77)). Additional work will be required to identify the 
existence of endogenous molecules that modulate virulence factor production.  
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Conclusions. 
 Herein, we have shown that VexR functions as a positive regulator of the vexRAB operon. VexR 
appears to activate expression of the vexRAB operon in response to efflux substrates of the 
VexAB RND efflux system. The finding that VexR functions as a positive regulator was 
unusual. Although more than 20,000 distinct sequences in the genomic database putatively code 
for TetR family regulators, only a fraction have been characterized, the majority of which 
function as repressors (207, 298). To the best of our knowledge only ten members of the TetR 
family of regulators have been characterized as activators, none of which were associated with 
an RND efflux system (299-308).  
We have established a novel role for VexAB in exporting cellular metabolites. We 
suggest that VexAB relieves cellular stress by preventing the accumulation of metabolic 
byproducts to toxic levels. This is supported by our data which indicates that indole was a 
substrate and inducer of the V. cholerae vexRAB RND efflux system. Our results further suggest 
that the substrates induce the production of VexAB via its cognate regulator (i.e. VexR). It is 
noteworthy that similar processes were documented in E. coli where metabolic mutants and 
metabolic byproducts were found to activate the acrAB RND system (178, 198-200). Therefore, 
the ability of the RND efflux systems to alleviate cellular stress due to excess metabolic 
intermediates appears to be an evolutionarily conserved mechanism. 
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5.0  CONCLUSION 
The endemic and epidemic potential of the disease cholera has had a great historical impact and 
continues to be a public health concern in various communities throughout the world. The 
recurrent problem of cholera is largely due to the success of V. cholerae in overcoming 
challenges in both aquatic and in vivo environments in order to survive, colonize, and further 
disseminate. Essential to the survival of V. cholerae is its ability to adapt to rapid environmental 
changes by responding to environmental cues, to overcome antimicrobial challenge, and to 
produce virulence factors. In order to understand the mechanisms by which V. cholerae adapts 
and survives stringent environmental conditions, we focused on the RND family of multidrug 
transporters. The RND family of efflux systems is known for their ability to efflux a broad range 
of antimicrobial substrates and their contribution to multidrug resistance in several Gram-
negative pathogens.  
In this work, we sought to characterize the function of the RND efflux systems in V. 
cholerae. While the RND efflux systems are known for their ability to efflux a broad range of 
antimicrobial substrates, phylogenetic analysis suggests that they evolved independent of 
xenobiotic selection (167). This suggests that the RND efflux systems may have an innate role 
that is independent of antimicrobial challenge. We hypothesize that the innate function of the V. 
cholerae RND efflux systems is to efflux metabolic waste, which in the absence of RND-
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mediate efflux accumulates, causes cellular stress which then affects virulence factor production. 
Our data herein supports this hypothesis. 
The RND efflux systems in V. cholerae are redundant in contributing to antimicrobial 
resistance due to overlapping substrate specificities. Previously, the RND efflux systems were 
found to contribute to V. cholerae antimicrobial resistance against a broad range of substrates 
(123). Yet the contribution of individual pumps was difficult to elucidate as several RND efflux 
systems were able to compensate for the deletion of other pumps (as discussed in section 2.3). As 
such, a panel of RND mutants was created with various deletion permutations in order to 
distinguish the contribution of individual pumps to antimicrobial resistance. The functional 
redundancy of the V. cholerae RND efflux systems was not restricted to their involvement in 
antimicrobial resistance. Similar patterns of redundancy were observed for virulence factor 
production, murine colonization, and alleviating cellular stress (Sections 2.2.3, 2.2.4, and 3.2.5). 
Therefore, a similar approach was used to discern the roles of the RND efflux systems in 
contributing to each of these phenotypes. 
 It was interesting to note that the characterization of the RND efflux systems in regards 
to antimicrobial resistance provided insight into their roles in other functions. The VexAB RND 
efflux system was considered the major contributor to antimicrobial resistance as it had the 
broadest range of substrates and its presence could compensate for the deletion of all the other 
RND efflux systems. The supremacy of the VexAB RND efflux system was a phenotype that 
was echoed in other functions of the RND efflux systems. The presence of VexAB alone 
produced a wild type phenotype in regards to virulence factor production and murine 
colonization (Section 2.2.3 and (123)). Furthermore, VexAB was sufficient to alleviate cellular 
stress (Section 3.2.5); a phenotype that was likely due to the positive regulation of vexAB by 
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VexR and CpxR. The fact that the VexAB was able to compensate for loss of any or all of the 
other RND systems reinforces the idea that VexAB is the primary RND efflux system in V. 
cholerae and the other RND systems function in response to specific environmental stimuli. This 
is exemplified by finding that the vexCD system in induced only in the presence of bile ((210) 
and data not shown). 
In this work, we have shown that VexR positively regulates the vexRAB operon; thereby 
contributing to VexAB mediated antimicrobial resistance (Section 4.2.3 and 4.2.5). Furthermore, 
we have shown that vexRAB is regulated in response to substrates of VexAB in a manner that is 
dependent on vexR (Section 4.2.2 and 4.2.8). Together this provides a likely mechanism by 
which the VexAB system can respond to antimicrobial compounds, contribute to virulence factor 
production, and compensate of the deletion of the other RND efflux systems. The accumulation 
of VexAB substrates would induce vexRAB expression. The production of VexR would be 
expected to further contribute to the activation of vexRAB expression, which would enhance the 
cell’s response to the stimulus. The observation that the cell is highly sensitive to the production 
of VexR (Section 4.2.3 and 4.2.6) supports the hypothesis that VexR functions as a positive 
regulator to increase the production of the VexAB RND efflux system. The ability of VexR to 
function as a positive regulator is distinct compared to other members of the TetR family of 
regulators (as discussed in Section 4.3). This in conjunction with the observation that vexAB is 
the only V. cholerae RND efflux system with a linked regulator suggests that VexAB plays an 
important role in V. cholerae survival, as is supported by the diverse phenotypes to which 
VexAB contributes and the induction of vexRAB expression during human and animal in vivo 
colonization. 
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VexAB is similar to the E. coli AcrAB RND efflux system. Both RND efflux systems 
have a broad range of substrates and therefore are the major contributors to antimicrobial 
resistance in their respective species. However, the regulation of these two systems differs. 
Herein, we have presented evidence that the VexAB RND efflux system is positively regulated 
by both VexR and the Cpx system (Section 3.2 and 4.2). Contrarily, the AcrAB RND efflux 
system is repressed by its cognate TetR regulator (i.e. AcrR), but activated by the global 
regulatory system referred to as the MAR (multiple antibiotic resistance) regulon. However, in V. 
cholerae there is no known MAR regulon. Therefore we suggest that the V. cholerae VexR 
functions in a similar role to the E. coli MAR regulon. Together this would suggest the ability to 
elicit a rapid and robust response to accumulating substrates by induction of the RND efflux 
systems is a conserved mechanism in these organisms. This would be of obvious benefit to the 
ability of these species to survive in the presence of intestinal bile and other antimicrobial 
compounds. However, as both of these RND efflux systems are implicit in the extrusion of 
cellular metabolites, it may also indicate a common requirement for the disposal of metabolic 
waste. 
As VexAB is a major RND efflux system in V. cholerae, it was used to determine which 
metabolic pathways produce endogenous substrates of the RND efflux systems. The expression 
of vexRAB was observed to be highly induced by mutants from three distinct metabolic pathways 
(Section 4.2.9). Mutants in the tryptophan biosynthetic pathway induced the expression of 
vexRAB due to the accumulation of indole, which was determined to be a substrate of the RND 
efflux systems (Sections 4.2.10 and 4.2.11). Together these results supported our hypothesis that 
the innate role of RND efflux systems is to extrude cellular byproducts. The accumulation of 
certain metabolites induced the expression of vexRAB in accordance with the observed feedback 
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mechanism of the RND efflux systems and their substrates (as discussed in Section 4.3). 
Furthermore, the deletion of all six RND efflux systems induced vexRAB expression higher than 
the deletion of vexB alone (Section 4.2.8). This suggested that the RND efflux systems have a 
redundant role in extruding cellular waste, such that one or more of the innate substrates is also a 
substrate for another RND efflux system. The loss of RND-mediate efflux causes cellular stress 
presumably due to the accumulation of the metabolic waste (as discussed below and in Section 
3.3). Therefore, understanding which metabolites causes cellular stress and identifying the 
corresponding RND efflux systems that contribute to the expulsion of said metabolite could 
prove to useful to developing therapeutic targets. 
 It was interesting to note that the expression of vexRAB was induced by the disruption of 
three distinct metabolic pathways (Section 4.2.9). The sensitivity of vexRAB to structurally 
diverse metabolic substrates is in accordance with the ability of VexAB to provide resistance 
against a broad range of antimicrobial substrates (Section 2.2 and (119, 123)). Similar to 
vexRAB, the expression of the acrAB RND efflux system in E. coli was reported to be induced by 
mutants in four distinct metabolic pathways (309). These data indicate an evolutionary conserved 
mechanism of enteric bacteria to utilize the RND efflux systems in the extrusion of diverse 
metabolic byproducts.  
The finding that the RND efflux systems have an innate role that is unrelated to 
xenobiotic resistance is further supported by the observation that loss of RND-mediated efflux 
causes cellular stress in the absence of antimicrobial challenge. Induction of the V. cholerae Cpx 
system activated the expression of both vexRAB and vexGH RND efflux systems, which 
suggested that the cell was dependent on active efflux to relieve stress. While it would be easy to 
assume that the antimicrobial resistance capability of the RND efflux systems is the target of the 
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Cpx stress response, our data did not support a link between antimicrobial challenge and 
induction of the Cpx system (as discussed in Section 3.3). This suggested that the role of the 
RND efflux systems in relieving cellular stress was not restricted to providing antimicrobial 
resistance, but rather that there was an innate role for the RND efflux systems in the absence of 
xenobiotic challenge. In support of this, our data clearly indicates that loss of RND-mediated 
efflux activates the Cpx system (Section 3.2.6). This was in agreement with previous reports that 
loss of TolC-mediated efflux induced the Cpx stress response system in both V. cholerae and E. 
coli (200, 211). As both of our tested conditions including rich media and no exogenous RND 
substrates, we concluded that the induction of the Cpx stress response was not due to a starvation 
stress response, nor to antimicrobial challenge, but rather due to the accumulation of an innate 
compound (as discussed in Section 3.3). In light of the ability of the V. cholerae RND efflux 
systems to extrude metabolic byproducts, this suggests that the loss of RND-mediated efflux 
allows an accumulation of metabolic waste that causes cellular stress and therefore induces the 
Cpx stress response. Furthermore, it suggests a role for the Cpx system to alleviate cellular stress 
from accumulating metabolites by inducing the vexRAB and vexGH RND efflux systems.  
The RND efflux systems were determined to repress the Cpx system during growth in LB 
broth and under AKI conditions (Section 3.2.5). The VexAB and VexGH RND efflux systems 
were required for Cpx repression under both growth conditions, which corresponds to their 
regulation by the Cpx system and suggested a reciprocal regulation (as discussed in Section 3.3). 
The other RND efflux systems contributed to repression of the Cpx system during growth under 
AKI growth conditions but not in LB broth. These data implied that different metabolites 
accumulated under various growth conditions and require the different RND efflux systems for 
extrusion from the cell. It is possible that a different metabolite is accumulating under each 
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growth condition and requires a different set of RND efflux systems for extrusion from the cell. 
It is also possible that under both conditions there is a metabolite accumulating which is a 
substrate of VexAB and VexGH and that a different metabolite is accumulating under AKI 
conditions that require the function of the other RND efflux systems. While for the sake of 
reductionism only one or two substrates are suggested to be accumulating, we cannot exclude 
that there are multiple substrates accumulating under each growth condition that are effluxed by 
multiple pumps. All of these possibilities are supported by the ability of the V. cholerae RND 
efflux systems to efflux multiple substrates, to have overlapping substrate specificity, and to 
have a redundancy in function that allows some pumps to compensate for the loss of others.  
The contribution of all six RND efflux systems to repression of the Cpx system during 
growth under AKI conditions had an interesting correlation with the ability of the RND efflux 
systems to contribute to virulence factor production. As the reduction in virulence factor 
production upon loss of RND-mediated efflux was attributed to the accumulation of a small 
molecule (as discussed in Section 2.3), this introduced the possibility that the accumulation of 
said small molecule coordinately induced the Cpx system. This also suggested the possibility that 
the Cpx system was responsible for repression of virulence factor production. However this 
hypothesis was proven to be incorrect as ∆cpxR and cpxA* mutants were found to have no effect 
on CT or TcpA production compared to WT, nor did they significantly affect colonization 
(Section 3.2.7 and (211)).  
The clinically relevant symptoms and epidemic potential of cholera is due to the ability of 
V. cholerae to colonize the intestine and elicit the secretory diarrhea that is characteristic of the 
disease. Therefore, understanding the regulation and action of the virulence factors TCP and CT 
is important to controlling morbidity and spread of this disease. The reduction of virulence factor 
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production upon loss of RND-mediated efflux has been a phenotype of interest. The RND efflux 
systems are not in themselves capable of binding to and regulating the expression of genes. Nor 
are they part of the cellular machinery required for assembly and/or extrusion of the TCP and 
CT. Together this suggested that the capability of the RND efflux systems to modulate virulence 
factor production was likely related to their innate ability to extrude molecular compounds (as 
discussed in Section 2.3). Our revelation that the innate role of the RND efflux systems is to 
expel metabolic waste suggests that the accumulating small molecules that affect virulence factor 
production are likely endogenous metabolites. Understanding the linkage between metabolism 
and virulence could potentially elucidate therapeutic approaches for V. cholerae and other gram 
negative pathogens where the RND efflux systems have been shown to be important for 
virulence.  
The RND efflux systems that were major contributors to virulence factor production 
(VexAB, VexCD, VexGH, and VexIJK) also contributed to resistance against the bile salts 
cholate and deoxycholate (Sections 2.2.1 and 2.2.3). The overlapping substrate specificity 
indicates that the repression of virulence factors may be due the accumulation of a common 
substrate. While VexEF and/or VexLM also contributed to virulence factor production, 
antimicrobial susceptibility assays did not indicate redundant substrate specificity with VexAB, 
VexCD, VexGH, or VexIJK (Sections 2.2.1-2.2.3). Together, this suggests that there are multiple 
effector molecules extruded by the RND efflux systems that affect virulence factor production. 
However, we cannot exclude that it is a single un-identified molecule that is a substrate of all six 
RND efflux systems. 
The metabolic intermediate indole was determined to be a substrate and inducer of the 
vexRAB operon (as discussed in Section 4.3). Previous work has shown that indole is a cellular 
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cue that can regulate bacterial gene expression in a number of bacteria. In V. cholerae indole has 
been shown to regulate genes involved in quorum sensing and biofilm formation (293). 
Therefore, we hypothesized that the accumulation of indole in an RND-deficient mutant caused 
reduced virulence factor production. Preliminary findings support this hypothesis; indole 
inhibited the production of CT and TcpA in a dose-dependent manner (Appendix C). The 
addition of 0.5 mM indole caused a reduction in virulence factor production that was similar the 
RND deficient mutant. As V. cholerae strains have been reported to produce up to 0.5mM of 
indole in culture supernatant (293, 310), this data indicates that biological levels of indole are 
sufficient to repress the production of CT and TCP. While further work is needed to determine 
the mechanism by which indole represses virulence factor production, we can conclude that loss 
of RND-mediated efflux can cause an accumulation of indole which is sufficient to repress 
production of CT and TCP.  
V. cholerae modulates gene expression late during infection, downregulating virulence 
genes and upregulating genes involved in exiting the host and disseminating back into to the 
environment (41, 282). Passage through a host has been shown to induce a hyper-infectious 
phenotype which is suggested to be a large contributor to the epidemic spread of V. cholerae 
(41). Indole is a cellular cue that could be involved in the transition of V. cholerae from the host 
to the environment. Preliminary results indicate that indole can repress CT and TCP in a dose 
dependent manner (Appendix). As indole is cellular signal that is expected to increase with cell 
density, this is likely a signal during late infection that could repress virulence factor production. 
Coordinately, indole has been shown to induce biofilm in V. cholerae (293). Biofilm formation 
contributes to the hyper-infectious phenotype, protection of V. cholerae in the environment, and 
surviving that gastric barrier. Therefore, if true, the use of indole as a cellular signal is of crucial 
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importance to V. cholerae and suggests an innate role of the RND efflux systems during 
pathogenesis.  
 
Conclusion 
In this work, we have shown that the V. cholerae RND efflux systems contribute to V. cholerae 
survival and pathogenesis due to their ability to efflux a broad range of substrates. The diversity 
of substrates and the redundancy of these pumps were most easily categorized by their 
contribution to antimicrobial resistance. In addition to antimicrobial resistance, our work has 
established an intrinsic role of the RND efflux systems in extruding metabolic waste. In the 
absence of RND-mediated efflux, metabolic substrates accumulate and prove stressful to the cell 
and induce the Cpx system. In a wild type cell, the Cpx system would respond to the 
accumulation of metabolic waste by activating the vexRAB and vexGH RND efflux systems to 
reduce the intracellular levels of the stressful metabolites. Furthermore, the innate role of the 
RND efflux systems in expelling metabolic waste provides a mechanism by which the RND 
efflux systems repress virulence factor production. Upon loss of RND-mediated efflux, one or 
more cellular metabolites, such as indole, accumulates and represses the transcription of ctxAB 
and tcpA, likely through the ToxR regulon. Together these data indicate the V. cholerae RND 
efflux systems play an important role in V. cholerae survival and pathogenesis by regulating and 
responding to the accumulation of small molecules. 
 124 
 
 
Figure 23. Model of the function of the RND efflux systems in V. cholerae. 
The RND efflux systems extrude a broad range of substrates:  (1) exogenous compounds such as antibiotics 
and bile salts; and (2) endogenous metabolic by-products such as indole. (A) In a WT cell, the accumulation of 
metabolic waste activates (3) the Cpx system. (4) Phosphorylated CpxR then induces expression of (5) cpxRA/cpxP 
and the (6) vexRAB and (7) vexGH RND efflux systems. This induction increases (8) VexAB and (9) VexGH 
production, thereby alleviating cellular stress.  Furthermore, exogenous and endogenous substrates of VexAB induce 
the expression of (6) vexRAB in a (10) vexR-dependent manner, resulting in increased (8) VexAB production to 
extrude the compounds. (B) The loss of RND mediated efflux causes the accumulation of (11) metabolic substrates. 
This proves stressful to the cell and (12) induces the Cpx system, thereby constitutive activating (13) CpxR and 
causing the induction of (14) cpxP, (15) vexRAB and (16) vexGH expression. (11)The accumulation of one or more 
cellular metabolites represses (17) ctxAB and (18) tcpA, likely through the ToxR regulon. 
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APPENDIX A 
MATERIALS AND METHODS 
A.1 BACTERIAL STRAINS AND CULTURE CONDITIONS 
The bacterial strains used in this study are listed in the Tables 1, 3, and 6 in each respective 
chapter. Escherichia coli EC100Dpir+, SM10λpir, and ER2566 were used for cloning, plasmid 
mobilization, and protein purification, respectively. Vibrio cholerae strains used in this study 
were derivatives of O1 El Tor strains N16961 and C6706 (122, 231, 290). V. cholerae strains 
JB3 (N16961-lacZ+ SmR),  JB58 (N16961-∆lacZ SmR), or JB804 (C6706-lacZ+ SmR) were used 
as the wild type (WT) control strain for all experiments as indicated. Bacterial strains were 
grown at 37°C in Luria-Bertani (LB) broth or on LB agar. V. cholerae was grown in AKI broth 
under AKI growth conditions for virulence inducing conditions (311). AKI growth conditions 
were as follows: a fresh saturated overnight LB broth culture of the indicated strain was 
inoculated 1:10,000 into 10 mL of AKI broth in a 18x175 mm test tube. The test tube was then 
incubated statically at 37°C for 4 h when the broth culture was transferred into a sterile 125 mL 
Erlenmeyer flask. The Erlenmeyer flask was then incubated with shaking overnight at 37°C 
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before CT and TCP production was assessed. Bacterial stocks were maintained at -80°C in LB 
broth containing 25% glycerol. Growth media was supplemented with carbenicillin (Cb) and 
streptomycin (Sm) at 100 µg/mL, kanamycin (Km) at 50 µg/mL, or chloramphenicol (Cm) at 1 
µg/mL (for V. cholerae) or at 20 µg/mL (for E.coli) as required. 5-bromo-4-chloro-3-indolyl-β-
D-galactopyranoside (X-gal) was added to LB agar plates at 40µg/mL unless otherwise 
indicated. Bacterial growth media was purchased from Difco (Lawrence, KS) and chemicals 
were purchased from Sigma-Aldrich (St Louis, MO). 
A.2 PLASMID CONSTRUCTION 
Plasmids and oligonucleotides used in this study are listed in the appropriate Tables associated 
with each chapter (Tables 1, 3, and 6). Enzymes for cloning experiments were purchased from 
New England Biolabs (Beverly, MA). β-galactosidase reporter constructs for vexRAB, vexEF, 
vexGH, vexIJK, and vexLM were constructed as follows. Briefly, the gene-specific PCR primer 
pairs (i.e. 166c-F-XhoI/166c-R-XbaI, P-VC0628-F-XhoI/R-XbaI, P-VC0914-F-XhoI/R-XbaI, P-
VC1673-F-XhoI/R-XbaI, and P-VCA0638-F-XhoI/R-XbaI) were used to amplify the promoter 
region for each operon from the V. cholerae N16961 genome. The resulting PCR amplicons were 
then digested with XhoI and XbaI restriction endonucleases before being ligated into similarly 
digested pTL61T to generate pXB233(vexRAB-lacZ), pXB228 (vexEF-lacZ), pXB229 (vexGH-
lacZ), pXB230 (vexIJK-lacZ), and pXB232 (vexLM-lacZ). The breR-lacZ reporter (pXB265) 
was similarly created using the PCR primer pair P-VC1746-F-SmaI/R-BamHI and the indicated 
restriction endonucleases. The DNA sequence of the reporter constructs were subsequently 
verified by DNA sequencing. pDT1076 (vexRAB-lux) was generated by cloning the vexRAB 
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promoter from pXB233 into pCM10 as follows. The vexRAB promoter was PCR amplified from 
pXB233 using the BRL-F and166c-F-XhoI PCR primers. The resulting PCR amplicon was then 
made blunt ended before being restricted with BamHI. The resulting fragment was then cloned 
into pCM10 that had been linearized with EcoRI, made blunt-ended, before being restricted with 
BamHI. A Cm-marked version of pDT1076 was created by transposing the Cm-marked mariner 
transposon from pSC137 into pDT1076 to generate pDT1777. The reporter plasmids were 
verified by DNA sequencing 
The vexR expression plasmids were constructed as follows. pJB703 was generated by 
amplifying vexR from N16961 using the VC0166F-SacI and VC0166-XbaI-R PCR primers. The 
resulting amplicon was restricted with SacI and XbaI endonucleases before being ligated with 
similarly digested pBAD18 generate. pDT1146 (pMMB66EH::vexR) was generated by 
amplifying the vexR gene from N16961 using the VC0166F-SacI and MCS4.VexA.R primers. 
The resulting amplicon was blunt ended, digested with BamHI, and then ligated with similarly 
treated pMMB66EH (kindly provided by Dr. Robert Shanks, University of Pittsburgh) to 
generate pDT1146. The sequence of vexR in both plasmids was confirmed by DNA sequencing. 
pSS35 was constructed by amplifying the vexR gene from N16961 using the VC0166-F-pMAL-
SmaI and VC0166-R-pMal-EcoRI PCR primers. The resulting PCR amplicon was then digested 
with EcoRI and SmaI endonucleases to make and cloned into the same sites of pMAL-c2 (NEB). 
The DNA sequence of the protein purification construct was subsequently verified by 
sequencing. 
The allelic exchange vector pWM91::∆vexR was generated by crossover PCR as 
previously described (118, 119, 123, 312). Briefly, vexR-specific VC0166-F1-R2 and VC0166-
F2-R1 PCR primer pairs (Table 6) were used in separate PCR reactions with N16961 genomic 
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DNA as a template. The resulting ~1kb PCR products were gel purified, pooled, and then used as 
the template for a second PCR reaction using the flanking F1-R1 PCR primers to generate the ~2 
kb vexR deletion construct. The resulting ~2kb PCR amplicon was then purified, restricted with 
XbaI and SacI endonucleases before being ligated with similarly digested pWM91 to generate 
pWM91::∆vexR. The resulting plasmid was then used to delete vexR. Briefly, pWM91::∆vexR 
was conjugated into the V. cholerae and cointegrants were selected for Cb/Sm resistance. Several 
Cb/Sm resistant colonies were then streaked for single colonies onto LB agar (without NaCl) 
containing 5% sucrose to select for the resolution of the integrated plasmid. Several sucrose-
resistant colonies were screened for Cb sensitivity to verify plasmid loss before the vexR deletion 
was confirmed by PCR using flanking primers. 
A.3 MUTANT CONSTRUCTION 
Unmarked in-frame deletions of the RND efflux pump protein gene in each respective strain was 
constructed by allelic exchange using genetic constructs and methods previously reported and as 
described above (118, 119, 123, 312). The ∆vexBDHK, ∆vexBHK, ∆vexBDH, and ∆vexBH 
mutants were derived by deletion of vexH in strains JB740, JB531, JB694, and JB495, 
respectively. The ∆vexHK, ∆vexDK, and ∆vexDHK mutants were derived by deletion of vexK 
deletion in strains JB116, JB692, and JB186, respectively. The deletion of vexR is described 
above. 
Deletion of V. cholerae cpxR was performed as previously described (211). Briefly, p∆R 
was conjugated into V. cholerae and co-integrants were selected for Sm/Km resistance. Several 
Sm/Km resistant colonies were streaked onto LB (without NaCl) containing 5% sucrose to select 
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for resolution of the integrated plasmid. Several resistant colonies were screened for Cb 
sensitivity to verify the loss of the plasmid, and for Km resistance to verify the presence of the 
Km cassette inserted in the cpxR gene. PCR using cpxR-F and cpxR-R primers was then used to 
confirm the presence of the cpxR::Km insert. 
Introduction of the chromosomal cpxP-lacZ reporter into V. cholerae was performed as 
previously described (225). Briefly, the pJL1P’Z reporter construct was conjugated into V. 
cholerae strains and co-integrants were selected for Sm/Cb resistance. Several Sm/Cb resistant 
colonies were then streaked onto LB (without NaCl) containing 5% sucrose to select for 
resolution of the integrated plasmid. Sucrose resistant colonies were then screened for Cb 
sensitivity to verify plasmid loss before the cpxP-lacZ insertion was confirmed by PCR using the 
lacZ5 and lacZ6 primers. Construction of the V. cholerae RND efflux mutant strains was 
previously reported (119, 123, 256, 313). 
A.4 TRANSCRIPTIONAL REPORTER ASSAYS 
Strains were grown under the indicated growth conditions and culture aliquots were taken in 
triplicate at various time points post-inoculation to quantify β-galactosidase activity as 
previously described (9, 314). All reporter experiments were performed independently at least 
three. The V. cholerae lacZ::cpxP-lacZ reporter strains were cultured under AKI conditions as 
follows. Overnight cultures were diluted 1:10,000 into 73 mL of AKI broth in a 30 mm diameter 
glass cylinder. The cultures were then incubated statically at 37°C for 4 h when 10 mL aliquots 
were transferred into 125 mL Erlenmeyer flasks and grown at 37°C with shaking. Aliquots were 
then collected at the indicated times for the β-galactosidase assay. The two plasmid reporter 
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system utilized overnight cultures of V. cholerae containing pBAD33-cpxR or pBAD33 
(negative control) and the indicated lacZ reporter (i.e. vexRAB-lacZ or vexGH-lacZ). The 
cultures were diluted 1:100 in LB broth plus or minus arabinose to achieve the indicated final 
concentration and the cultures were incubated with shaking at 37°C. Aliquots were then collected 
at the indicated times to measure gene expression using the β-galactosidase assay. 
A.5 LUCIFERASE REPORTER ASSAYS 
E. coli EC100Dpir+ containing pDT1041 and pDT1124 (or pBAD18) were grown overnight in 
LB broth before being diluted 1:200 into fresh LB broth with or without 0.2% arabinose. 
Aliquots (100µL) of the diluted cultures were then distributed in triplicate into the wells of white 
96-well microtiter plates with clear bottoms and incubated with shaking at 37°C for the duration 
of the assay. Luminescence production and the OD600 at indicated time points were determined 
using a BioTek Synergy HT plate reader. The reported results are the average relative light units 
(RLU) for each test sample divided by the optical density. Two-Way ANOVA with Tukey’s 
multiple comparison post-test was used to determine significance. 
C6706 transposon mutants containing pDT1777 were grown overnight in LB broth 
before being diluted into LB or AKI broth. Strains grown in LB broth were diluted 1:200 from 
the overnight culture into fresh LB broth with Cm and grown under the same conditions as listed 
above. Strains grown under AKI conditions were diluted 1:10,000 into AKI broth with Cm. 
Aliquots (370µL) of the diluted cultures were then distributed in triplicate as described above. 
Plates were incubated statically at 37°C for 4h, at which point 215µL of culture was removed 
from each well for a final volume of 155µL/well. Plates were then grown with shaking at 37°C 
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for the remainder of the assay. Luminescence production and the OD600 at indicated time points 
were determined using a BioTek Synergy HT plate reader. The reported results are the average 
relative light units (RLU) for each test sample divided by the optical density. Two-way ANOVA 
with Dunnet’s post-hoc test was used to determine significance relative to WT. 
A.6 IDENTIFICATION OF CPXR BINDING SITES 
Putative CpxR binding sites were identified in the promoter regions of the differentially 
regulated genes using CloneManager Professional Software (SciEd Software). The search was 
limited to 300 bp preceding the ATG start codon for each gene and used the published CpxR 
consensus binding site (i.e. GTAAN6GTAA) with an allowance for limited mismatches without 
gap insertion (265). To estimate the frequency of CpxR binding sites in the V. cholerae genome, 
we randomly selected 25 genes (15 from the large chromosome and 10 from the small 
chromosome) using the random number generator function in Microsoft Excel. The promoters of 
these genes were then searched as described above for the presence of CpxR consensus binding 
site. 
A.7 ANALYSIS OF CPX EXPRESSION ON AGAR PLATES 
A chromosomal cpxP-lacZ reporter was used to examine the expression the Cpx system in a 
panel of various RND efflux mutants. Overnight cultures of the reporter strains were diluted 100-
fold into LB broth and grown at 37°C with shaking for 1 h. The cultures were then normalized to 
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an OD600 of 0.1 and equal volumes of the cultures were spun down and the pellet resuspended in 
an equal volume of PBS. The resuspended cultures were then diluted 1000-fold before 2 µL was 
inoculated onto LB agar plates containing 160 µg/mL X-gal. As a positive control the same 
cultures were also inoculated onto LB agar plates containing 160 µg/mL X-gal and 500 µM 
CuCl2. The inoculated plates were incubated overnight at 37°C before being photographed using 
a digital camera. 
A.8 ANTIMICROBIAL SUSCEPTIBILITY TESTS 
Antimicrobial susceptibility tests were performed using antibiotic and detergent gradient agar 
plates or by antibiotic disk diffusion. Antimicrobial susceptibility tests using gradient agar plates 
were performed as previously described (123, 269, 285, 315). Each 9 cm x 9 cm gradient plate 
was inoculated with six V. cholerae strains, including WT which served as an internal control, 
before being incubated at 37°C. The following day the length of bacterial growth along the 
antimicrobial gradient was recorded for each strain. Reported values represent the average from a 
minimum of three independent experiments. The minimum inhibitory concentration (MIC) of 
each strain was calculated by the percent growth across the plate multiplied by the antimicrobial 
concentration used in the plate. Statistical significance was calculated as indicated. 
Antimicrobial susceptibility tests using disk diffusion were performed as previously 
reported (119) using the following antibiotic disks purchased from Becton Dickenson (Franklin 
Lakes, NJ, USA): ampicillin (10 µg/mL), tetracycline (10 µg/mL), gentamicin (10 µg/mL), 
erythromycin (15 µg/mL), and polymyxin B (300 µg/mL). Test compounds that were not 
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commercially available were prepared by spotting 20 µL of concentrated stock onto blank 6 mm 
disks from Becton Dickenson (i.e. 1M CuCl2, 10% sarcosyl, and 10% deoxycholate). LB agar 
plates were inoculated with a lawn of the test strains using overnight cultures before the disks 
were aseptically placed on the surface of the agar plates. The plates were then inoculated 
overnight at 37°C before the zones of growth inhibition were measured in mm using a ruler. The 
student t-test was used to determine statistical significance in the zones of growth inhibition. 
A.9 GROWTH ANALYSIS 
Strains were grown overnight in LB broth and normalized to an OD600 of 1.0. The cultures were 
then diluted 1:20,000 into LB broth with or without arabinose and/or deoxycholate as indicated. 
Aliquots of 100µL of each strain were then distributed in triplicate into the wells of a flat bottom 
96-well microtiter plate. The 96-well plate was then incubated in a BioTek ELx808 plate reader 
at 37°C with intermittent shaking and growth was monitored by measuring the absorbance at 600 
nm every 20 min for 14h. The presented data is the average of triplicate samples for each time 
point. 
A.10  PLATING EFFICIENCY 
Overnight cultures of the tested V. cholerae strains were diluted 100-fold into LB broth or LB 
broth containing 2M KCl before being incubated at 37°C with shaking for 1 h. The cultures were 
then normalized to an OD600 of 0.25 when equal aliquots of each strain were spun down in a 
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microfuge and the resulting cell pellet resuspended in PBS. Serial dilutions of the cultures were 
then inoculated onto LB agar and Thiosulfate-Citrate-Bile Salts-Sucrose (TCBS) agar plates 
using an EDDY JET 2 Spiral Plater (IUL instruments). The agar plates were then incubated 
overnight at 37°C before the viable cells were enumerated using a Flash & Go automatic colony 
counter (IUL Instruments).  
A.11  CT AND TCP QUANTIFICATION 
CT and TCP production were assayed as previously described (123) from cultures grown under 
AKI growth conditions. CT production was determined by GM1 enzyme-linked immunosorbent 
assay (ELISA) as previously described using purified CT (Sigma) as a standard. TCP production 
was quantified by Western immunoblotting using a polyclonal antibody that was directed 
towards TcpA, the pilin subunit of the TCP (285). The polyclonal antisera against CT and TcpA 
were kindly provided by Dr. John Mekalanos (Harvard Medical School, Boston, MA) and Dr. 
Jun Zhu (University of Pennsylvania). Immunoreactive proteins on the Western blots were 
visualized using the SuperSignal West Pico Chemiluminescent Detection Kit (Pierce 
Biotechnology). 
A.12 GROWTH ANALYSIS IN THE INFANT MOUSE MODEL 
The colonization phenotype of the RND efflux mutants were assessed using the infant mouse 
competition assay as previously described (123, 283, 285). Briefly, 5–7 day old mice were 
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separated from their mothers 2 h prior to inoculation. The infant mice were then anaesthetized 
with isoflurane (Aceto Pharm, NY) and inoculated by gavage using a 30 cm length of 0.011” x 
0.024” polyethylene tubing that was attached via a 30.5 GA needle to a 1 cc syringe containing 
the inoculum. The inoculum consisted of a mixture of the wild type strain (lacZ+) and the RND 
mutant strain (lacZ-) at a 1:1 or 1:100 ratio (WT:mutant) and administered in a 50 mL volume 
that contained ~2.5x104 cfu of each strain; for the 1:100 inoculum the mutant titer was increased 
to ~2.5x106 cfu. An aliquot of the inoculum was also serially diluted and spread onto LB plates 
containing Sm and X-gal to verify the input ratio. Following inoculation the mice were kept in a 
humidified incubator at 30°C. The following day, the infected mice were sacrificed and the small 
intestine was removed from above the cecum and homogenized in 5 mL of sterile PBS. Serial 
dilutions of the homogenates were then spread onto LB agar plates containing Sm and X-gal. 
The agar plates were then incubated at 37°C overnight when the resulting bacterial colonies were 
quantified as WT (lacZ+) or mutant (lacZ-) based on colony color. A competitive index (CI) was 
calculated for each mutant strain as the ratio of the mutant to the WT in the input inoculum 
divided by the ratio of the mutant to WT in the output from the mouse intestinal homogenates. 
To determine the in vitro competitive index, an inoculum consisting of a 1:1 ratio of the test and 
control strain was inoculated into fresh LB or media and cultured with shaking overnight at 37°C 
before being serially diluted and spread onto LB plates containing Sm and X-gal to determine the 
output ratio. Standard bacteria growth assays in M9-glycerol minimal media were also 
performed to control for potential unknown metabolic differences that could affect growth of the 
mutants in vivo. A theoretical CI was calculated for mutant strains that could not be recovered 
from the mouse challenge experiments by using an artificial value of 1 recovered cfu for each 
strain. 
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 The infant mouse colonization assay was performed identical to the competition assay 
with the exception that the inoculum consisted of a single strain of V. cholerae with the mice 
receiving either 2x106 or 2x108 cfu. Following overnight incubation, the intestinal homogenates 
were serially diluted before being spread onto LB-Sm agar plates to enumerate the bacterial 
loads in the small intestine of each mouse. 
A.13 MICROARRAY ANALYSIS 
RNA was isolated for the cpxA* microarrays from WT and the cpxA* mutant strain that were 
grown in LB broth at 37°C with shaking to an OD600 ~1.0. The subsequent steps of cDNA 
preparation and labeling, microarray hybridization, and data collection, were carried out as 
previously described (316). The experiment was repeated independently three times with two 
technical replicates for each individual experiment. The resulting data was processed as follows. 
The background subtracted spot intensities for each gene were subjected to global normalization 
before being averaged across all experimental samples. Genes exhibiting a change in expression 
of ≥2-fold with a coefficient of variation ≤ 0.6 across all experiments were defined as being 
differentially regulated. The microarray data has been deposited in NCBI’s Gene Expression 
Omnibus and is available through accession number GSE55037. 
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A.14 PURIFICATION OF VEXR 
VexR was purified as follows. E. coli ER2566 carrying pMAL-c2 or pSS35 were grown 
overnight at 37°C with aeration. The cultures were then diluted 100-fold into LB broth with Cb 
and incubated at 37°C with shaking until reaching an OD600 of ~0.5 when isopropyl β-D-1-
thiogalactopyranoside (IPTG) was added to a final concentration of 0.3 mM and the cultures 
were incubated for an additional 2 h. The cells were then harvested by centrifugation, the 
supernatant removed, and the pellet resuspended in column buffer (20 mM Tris-HCl, 200 mM 
NaCl, 1 mM EDTA) plus 1 mM phenylmethylsulfonyl fluoride (PMSF). The cells were then 
lysed using a M-11P Microfluidizer processor according to the manufacturer’s instructions 
(Microfluidics). The resulting lysates were cleared of particulate matter by centrifugation at 
15,000 x g for 20 min at 4°C. The clarified supernatants (i.e. VexR-MBP or MBP) were diluted 
1:6 with column buffer and loaded onto a 0.8 x 7 cm column containing 1 mL of amylose resin 
(New England Biolabs). The column was washed with 12 column volumes of column buffer 
before the bound proteins were eluted with elution buffer (20 mM Tris-HCl, 200 mM NaCl, 1 
mM EDTA, 10 mM maltose). Protein concentrations were determined using the Coomassie Plus 
(Bradford) Assay kit according to manufacturer’s instructions (Thermo Scientific).The purity of 
the eluted proteins were assessed by SDS–PAGE with Coomassie Brilliant Blue R-250 staining.  
A.15 ELECTROPHORETIC MOBILITY SHIFT ASSAY (EMSA) 
DNA fragments designated vexR1 (the nucleotide sequence between -129 and -46 of the vexR 
promoter region) and vexR2 (-59 to +21 of the vexR promoter region) were amplified from the 
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N16961 genome using the primers vexR-F1/vexR-R1 and vexR-F2/vexR-R2, respectively. The 
fragments were then used as a template for a PCR amplified using the biotin primer resulting in 
biotin end labeled fragments. The biotin labeled probes (2.5 nM) were incubated with purified 
VexR-MBP or MBP in amounts ranging from 0 to 250 nM in 10 μl of binding buffer containing 
10 mM Tris (pH 7.4), 150 mM KCl, 0.1 mM DTT, 0.1 mM EDTA (pH 8), and 200 μg/mL 
sheared salmon sperm DNA. The binding reactions were incubated at room temperature for 20 
min before being subjected to electrophoresis on a nondenaturing 5% polyacrylamide gel in 
0.25x TBE buffer at 200V for 45 min. The DNA in the gel was transferred to a nylon membrane 
in 0.5x TBE buffer at 380 mA for 1 h. The nylon membrane was then UV crosslinked at 120,000 
microjoules using Stratalinker 1800. The biotin labeled DNA probes were then detected using 
the Chemiluminescent Nucleic Acid Detection Module (Thermo Scientific) and documented 
using a FluorChem E imaging system (Protein Simple). 
 
. 
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APPENDIX B 
ABBREVIATIONS 
# : number 
% : percent 
:: : insertion 
~ : approximately 
± : plus/minus 
°C : degree centigrade 
ANOVA : analysis of variance 
β : beta 
bp : base pair 
Cb : carbenicillin 
cc : cubic centimeter 
cDNA : complementary DNA 
cfu : colony forming units 
CI : competitive index 
cm : centimeter 
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Cm : chloramphenicol 
cpxA* : cpxA mutant 
CpxR~P : phosphorylated CpxR 
CT : cholera toxin 
CuCl2 : copper chloride 
∆ : deletion 
DNA : deoxyribonucleic acid 
DTT : Dithiothreitol 
e.g. : exemplī grātiā ; latin for “for example” 
E. coli : Escherichia coli 
EDTA : Ethylenediaminetetraacetic acid 
ELISA : enzyme-linked immunosorbent assay 
g(centrifuge) : gravitational acceleration 
GA : gauge 
GI : gastrointestinal  
GM1 : monosialotetrahexosyl ganglioside 
h : hour 
H.drucreyi : Haemophilus ducreyi 
HCl : hydrochloric acid 
i.e. : id est; latin for “that is” 
IPTG : Isopropyl β-D-1-thiogalactopyranoside 
kb : kilo bases 
KCl : potassium chloride 
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Km : kanamycin 
lacZ : in reference to the b-galactosidase gene 
LB : luria bertani 
lux : in reference to the luciferase operon  
M : molar 
mA : milli Amps 
MAR : multiple antibiotic resistance 
MATE : multi antimicrobial extrusion protein family 
MBP : maltose binding protein 
MFP : membrane fusion protein 
MFS : major facilitator superfamily 
µg : micro gram 
MIC : minimum inhibitory concentration 
mL : milli liter 
µL : micro liter 
mm : milli meter 
µm : micro meter 
MU : Miller Units 
NaCl : sodium chloride 
NCBI : National Center for Biotechnology Information 
ng : nano gram 
NG : No bacterial growth 
nm : nano meter 
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nM : nano Molar 
number" : inch 
OD : optical density  
OD600 : optical density at 600 nano meters 
OMP : outer membrane protein 
P : P value 
PAGE : Polyacrylamide gel electrophoresis 
PBS : phosphate buffered saline 
PCR : polymerase chain reaction 
pH : measurement of acidity/basicity of an aqueous solution 
PMSF : phenylmethylsulfonyl fluoride 
RLU : relative light units 
R : resistance 
RNA : ribonucleic acid 
RND : Resistance-Nodulation-Cell Division family 
s.d. : standard deviation 
SDS : sodium dodecyl sulfate 
Sm : streptomycin 
SMR : small multidrug resistance family 
TBE : Tris/Borate/EDTA 
TCBS : Thiosulfate-citrate-bile salts-sucrose 
TCP : Toxin co-regulated pilus 
Tris : tris(hydroxymethyl)aminomethane 
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UV : ultra violet 
V : volts 
V. cholerae : Vibrio cholerae 
WT : wild type 
X-gal : 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
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APPENDIX C 
PRELIMINARY DATA: INDOLE REPRESSES VIRULENCE FACTOR PRODUCTION 
C.1 INTRODUCTION 
The toxin co-regulated pilus (TCP) and cholera toxin (CT) are two virulence factors important 
for the colonization and pathogenicity of V. cholerae. They are encoded by the genes tcpA-F and 
ctxAB, respectively, whose expressions are coordinately regulated under a complex hierarchy 
called the ToxR regulon (as reviewed in Section 1.3). The production of these two virulence 
factors was significantly reduced upon the loss of RND-mediated efflux, whether by chemical 
inhibitors or genetic manipulation (Section 2.2.3 and (123, 285)). The reduction of CT and TCP 
production corresponded with the downregulation of the ToxR regulon. 
The RND efflux systems are a family of multidrug transporters which have not been 
implicated in the direct binding and regulation of genes (as reviewed in Section 1.4). Nor are the 
V. cholerae RND efflux systems required for the assembly and/or extrusion of TCP and CT. 
Therefore this indicated that the RND efflux systems contributed to virulence factor production 
through their cognate ability of transporting small molecules (as discussed in Section 2.3). 
Indeed, as the expression and activity of the ToxR regulon has been shown to be modulated by 
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various small molecules (76-83, 113), it was suggested an endogenous substrate of the RND 
efflux systems accumulates in their absence and can repress ctxAB and tcpA. 
V. cholerae has six RND efflux systems, all of which have been implicated in 
contributing to virulence factor production (Section 2.2.3). The four RND efflux systems which 
were major contributors to CT and TCP production (VexAB, VexCD, VexGH, and VexIJK) 
were also characterized as providing intrinsic antimicrobial resistance against common substrates 
(i.e. the bile salts cholate and deoxycholate) (Sections 2.2.1 and 2.2.3). Together, this suggested 
that the RND efflux systems have overlapping substrate specificities and that a common 
substrate of these accumulates upon loss of RND efflux to repress CT and TCP.  
Characterization of the V. cholerae RND efflux systems has revealed an intrinsic role in 
extruding metabolic waste (as discussed in Section 4.3). The tryptophan biosynthetic 
intermediate indole was found to be a substrate of the RND efflux systems (Sections 4.2.9-
4.2.11). Indole has also been reported to be a cellular cue which can regulate the expression of 
genes in various bacteria species, including V. cholerae (293, 317-319). Therefore, indole was a 
possible candidate for the inhibition of CT and TCP. 
C.2 RESULTS 
As indole was a substrate of the RND efflux systems, it was hypothesized that indole would 
accumulate upon the loss of RND-mediate efflux and repress the production of CT and TCP. In 
order to test this hypothesis, we assayed the ability of V. cholerae N16961 to produce virulence 
factors in the presence of various concentration of indole. The results showed a concentration  
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Figure 24.  Indole repression of V. cholerae CT and TCP production.  
V. cholerae N16961 strains were grown under AKI conditions with or without the indicated concentrations of 
indole. (A) The CT production of JB58 was detected by CT GM1-ELISA. Error bars represent the standard deviation 
of the mean from three or more experiments. (B) TCP of JB58 and JB485 was detected by TcpA Western 
immunoblotting. 
 
 
 
 
 
 147 
dependent inhibition of CT and TCP production in the presence of indole. The addition of 0.5 
mM indole caused a 57.4% reduction in CT relative to WT, while 1.5 mM of indole reduced CT 
production 98.8% (Figure 24A). The production of TCP was similarly reduced in a dose 
dependent manner (Figure 24B). As V. cholerae strains have been reported to produce up to 0.6 
mM of indole in culture supernatants (293, 310), this data indicates that biological levels of 
indole can repress the production of CT and TCP. The reduction of CT and TCP in WT treated 
with 0.5 mM indole is reminiscent of the RND deficient strain, which exhibited an  ~70% 
reduction in CT/TCP compared to WT (Section 2.2.3 and (123)). These results support our 
hypothesis that the reduction of virulence factor production in the RND deficient strain is due to 
the accumulation of metabolic intermediates that are normally efflux by the RND efflux systems.  
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